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1. Riassunto dell’attivita’ svolta 
I mitocondri sono organelli fondamentali nella vita e nella morte cellulare. I 
mitocondri sono complessi organelli a doppia membrana che formano un network 
subcellulare molto dinamico. La loro struttura e’ fondamentale per la loro funzione e 
per questo la morfologia di questi organelli continua a cambiare, passando da un 
network molto interconnesso fino alla divisione in singole unita’. Componenti chiave 
che regolano la forma dinamica dei mitocondri sono le proteine mitocondriali pro-
fissione Drp1 e Fis1 e le proteine mitocondriali pro-fusione Mfn1/2 e Opa1. 
Non solo i mitocondri sono la sede della catena respiratoria, in cui avviene la 
conversione dell’energia, ma sono anche fondamentali per la regolazione di apoptosi e 
autofagia. Inoltre, sono responsabili della regolazione dell’omeostasi del Calcio e dello 
stress ossidativo, della differenziazione e crescita cellulare, e dell’amplificazione di 
cascate di segnale. Recentemente, disfunzioni nel funzionamento dei mitocondri sono 
state legate all’insorgenza di varie malattie; in particolare, in malattie 
neurodegenerative, come il morbo di Parkinson, e’ stato riscontrato l’accumulo di 
mitocondri non funzionali. 
Il morbo di Parkinson e’ la seconda malattia neurodegenerativa piu’ comune, 
dopo il morbo di Alzheimer. Questa malattia e’ caratterizzata dalla degenerazione 
selettiva dei neuroni dopaminergici della Substantia Nigra (SN) del sistema nervoso 
centrale. I pazienti affetti da tale malattia, sviluppano dal punto di vista clinico 
bradicinesia, tremore e rigidita’, mentre dal punto di vista neurologico e’ possibile 
notare la perdita dei neuroni dopaminergici nella SN e, nella maggior parte dei casi, la 
presenza di incursioni intraneuronali chiamate Lewy bodies. 
Nella maggior parte dei casi, questa malattia insorge sporadicamente, 
rendendo difficile trovare un’eziologia comune per questo disturbo, ed individuare 
quindi una possibile terapia. Tuttavia, il 10% dei casi di morbo di Parkinson risultano 
avere un’origine genetica, e lo studio di mutazioni geniche relazionate all’insorgenza di 
forme familiari di Parkinson ha aiutato a comprendere meglio le cause e i meccanismi 
molecolari alla base di questa malattia. Ad esempio, mutazioni nel gene PARK2, che 
codifica per Parkin, sono la causa piu’ comune di una forma Autosomica Recessiva 
Precoce di Parkinson. Parkin codifica per un’E3-ubiquitin ligasi, con un ruolo 
fondamentale nel riconoscimento ed eliminazione dei mitocondri non funzionali 
tramite autofagia. La sua funzione e’ strettamente legata ad un’altra proteina le cui 
mutazioni sono legate all’insorgenza di forme precoci di Parkinson, PINK1. 
La struttura di Parkin e’ caratterizzata da un dominio Ubiquitin-like nella 
regione N-terminale e quattro domini zinc-finger RING-like: RING0, RING1, IBR e 
RING2. Inoltre, la struttura di Parkin contiene una regione chiamata linker, che non 
presenta alcuna similitudine con altri domini noti, unisce i due domini IBR e RING2. 
Questa regione e’ anche chiamata Motivo Unico di Parkin. La funzione principale di 
Parkin e’ trasferire molecole di ubiquitina da un’E2-ubiquitin ligasi alle proteine target. 
E’ stato dimostrato che Parkin, la cui localizzazione subcellulare e’ prevalentemente 
citoplasmatica, e’ selettivamente recrutato ai mitocondri danneggiati e ne promuove 
l’eliminazione tramite mitofagia (una forma selettiva di autofagia). Come accennato, la 
traslocazione di Parkin dipende dalla Serina/Treonina protiein chinasi PINK1. Tuttavia il 
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meccanismo tramite cui PINK1 attiva Parkin rimane poco chiaro. Una volta ai 
mitocondri, Parkin ubiquitina vari target, tra cui la proteina pro-fusione Mitofusina, 
portando alla fissione dei mitocondri. Tuttavia, ancora non e’ noto quali modificazioni 
post-trascrizionali avvengano su Parkin, regolandone il reclutamento, o da che 
condizioni cellulari sia influenzata la sua traslocazione. In questa tesi dimostriamo 
come il Calcio e la Calcineurina abbiano un ruolo fondamentale nel reclutamento di 
Parkin e nella mitofagia. 
La concentrazione di Calcio nel citoplasma e’ fondamentale per la regolazione 
di molti processi metabolici e per la trasduzione di segnale. Infatti, il pool 
citoplasmatico di Calcio e’ molto limitato e finemente regolato dai mitocondri e 
dall’ER. Tra i vari processi regolati da Calcio, e’ importante ricordare che l’attivazione di 
fosfatasi e di chinasi dipendenti da Calcio modifica non solo lo stato di fosforilazione di 
varie proteine, ma anche la loro localizzazione subcellulare, la conformazione e le 
interazioni con altre proteine. Ad esempio, la fosforilazione e defosforilazione della 
proteina pro-fissione mitocondriale Drp1, regola la sua traslocazione ai mitocondri, 
evento fondamentale per l’attivita’ pro-fissione di Drp1. In particolare, la traslocazione 
di Drp1 a mitocondri a seguito di depolarizzazione indotta da CCCP e’ regolata dalla 
defosforilazione del residuo Serina 637 da parte della Calcio-Calmodulina dipendente 
fosfatasi Calcineurina (CaN). Al contrario, la fosforilazione di Drp1 dipendende dalla 
protein chinasi A (PKA), che blocca Drp1 nel citoplasma nel caso di starvation della 
cellula e porta ad un allungamento dei mitocondri, che in questo caso non potranno 
essere eliminati tramite mitofagia. E’ chiaro come la fosforilazione e defosforilazione di 
Drp1, dipendente da Calcio, funziona come una modificazione post-trascrizionale 
reversibile che regola la traslocazione e l’azione di questa proteina in funzione delle 
necessita’ metaboliche della cellula. 
Considerando il ruolo fondamentale del Calcio nella regolazione dell’attivita’ 
delle proteine, abbiamo voluto capire se la traslocazione di Parkin e la conseguente 
mitofagia indotta da CCCP dipendesse da Calcio e fosse regolata da modifiche post-
trasduzionali simile a quelle che controllano Drp1. Abbiamo utilizzato, quindi, un 
vettore codificante per una sonda fluorescente targettata ai mitocondri (mito-YFP) ed 
un vettore codificante per una sonda fluorescente legata a Parkin (mCherry-Parkin) per 
monitorare la localizzazione subcellulare di Parkin. Come ci aspettavamo in base a 
studi gia’ pubblicati, Parkin si trova principalmente nel citoplasma, ma trasloca ai 
mitocondri in seguito a trattamento con CCCP. Tuttavia, il trattamento con BAPTA, un 
chelatore di Calcio, prima del trattamento con CCCP, bocca la traslocazione di Parkin. 
Lo stesso si puo’ notare a seguito del trattamento con FK506, un inibitore della CaN. 
Abbiamo quindi utilizzato un approccio genetico, utilizzando i mutanti 
dominante negativo (ΔCnAH151Q) e costitutivamente attivo (ΔCnA) della CaN, gia’ 
presenti nel laboratorio. La cotrasfezione di cellule overesprimenti mCherry-Parkin con 
il dominante negativo della CaN, inibiva la traslocazione di Parkin in seguito a 
trattamento con CCCP. Inoltre, tramite saggio di mitofagia e’ stato possibile vedere 
come il dominante negativo della CaN inibisse anche la mitofagia indotta da CCCP. 
Quindi, l’inibizione farmacologica o genetica della CaN e’ sufficiente per bloccare la 
traslocazione di Parkin e la mitofagia indotta da CCCP. 
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La traslocazione e l’attivita’ di Parkin dipende fortemente da PINK1. Vari studi 
hanno infatti dimostrato che PINK1 fosforila direttamente Parkin e l’Ubiquitina a livello 
della Serina 65, e questa fosforilazione e’ necessaria per l’attivita’ di Parkin. Abbiamo 
quindi generato mutanti fosfo-mimetici di Parkin e dell’Ubiquitina per la Serina 65 
(rispettivamente Parkin S65E e Ub S65E) e abbiamo analizzato l’effetto della 
coespressione espressione di questi mutanti con ΔCnA o ΔCnAH151Q sulla traslocazione 
di Parkin. In cellule wildtype, l’espressione dei fosfo-mutanti non induceva la 
traslocazione di Parkin ai mitocondri per se, indice del fatto che la fosforilazione da 
parte di PINK1 di Parkin e dell’Ubiquitina non e’ sufficiente ad indurre la traslocazione 
di Parkin. 
Come atteso, in cellule PINK1 -/- trasfettate con Ub S65E, la localizzazione di 
Parkin S65E era citoplasmatica, ma traslocava in seguito ad trattamento di CCCP. In 
presenza del dominante negativo della CaN, inoltre, Parkin S65E non traslocava ai 
mitocondri in seguito a trattamento con CCCP, mentre in presenza del dominante 
costitutivamente attivo della CaN, Parkin S65E colocalizzava con i mitocondri. Questi 
dati sono a supporto con l’ipotesi che la CaN, in aggiunta a PINK1, e’ necessaria per la 
traslocazione di Parkin. 
Abbiamo quindi deciso di analizzare la traslocazione di Parkin in assenza di 
PINK1, utilizzando delle cellule PINK1 -/-. In questo modello, Parkin non trasloca ai 
mitocondri a seguito di trattamento con CCCP. Tuttavia, in presenza del mutante 
costitutivamente attivo della CaN, ΔCnA, Parkin era costitutivamente localizzato ai 
mitocondri. Inoltre, la mitofagia indotta da CCCP risultava essere significativamente 
aumentata. Quindi, i nostri dati suggeriscono che l’attivazione della CaN e’ sufficiente 
alla traslocazione di Parkin, anche in assenza di PINK1. 
Abbiamo quindi utilizzato un modello in vivo comunemente usato negli studi sul 
Parkinson, la Drosophila melanogaster, per valutare il significato fisiologico 
dell’inibizione o attivazione della CaN in un modello in cui PINK1 non fosse funzionale. 
L’overespressione di Parkin in un background PINK1 mutante (knock out) di questo 
modello e’ in grado di migliorarne il fenotipo. Abbiamo pensato che un aumento 
dell’attivita’ della CaN avrebbe potuto migliorare il fenotipo in un modo simile, 
favorendo la traslocazione di Parkin. Infatti, l’espressione di un mutante 
costitutivamente attivo della CaN in un background PINK1 mutante migliora 
significativamente il fenotipo delle mosche da noi analizzate. L’inibizione della CaN 
tramite FK506 e’ in grado di bloccare anche l’effetto dell’overespressione di Parkin 
nelle mosche con un background PINK1 mutante, sottolineando il ruolo fondamentale 
della CaN nell’attivazione di Parkin in un assenza di PINK1. 
Al momento, sono necessari ulteriori esperimenti per identificare i residui 
specifici su Parkin che sono defosforilati dalla CaN. Tramite un’analisi in silico abbiamo 
identificato la Serina 407 e la Treonina 410 come possibili siti di azione della CaN. 
Infatti i mutanti fosfomimetici per questi siti non traslocano ai mitocondri in seguito a 
trattamento con CCCP. Inoltre, stiamo procedendo con un’analisi di spettrometria di 
massa per Parkin, che e’ stata isolata da cellule in condizioni di non trattamento, 
trattamento con CCCP e trattamento con FK506. Al momento abbiamo isolato Fla-
Parkin da una linea stabile overesprimente la proteina, analizzando tramite 
Westernblot e Silver stain la purezza della proteina isolata. 
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La ricerca scientifica al momento sta esplorando l’effetto delle modifiche post-
traduzionali come punto di partenza per la terapia di malattie. Ad esempio, sono stati 
trovati dei composti chimici che sono essere utili per pazienti affetti da leucemia e topi 
modelli del morbo di Alzheimer. Parkin risulta essere insolubile e formare aggregati, in 
questi modelli e Imatinib e Nilotib sono in grado di migliorarne la solubilita’ e le 
funzioni. Questi studi risultano importanti per dimostrare come la manipolazione 
dell’attivita’ di Parkin possa avvenire tramite modifiche post-trascrizionali ed essere 
usata come approccio terapeutico. 
Anche l’ubiquitinazione sta emergendo come modificazione importante per 
regolare l’attivita’ di proteine, tramite la localizzazione subcellulare o l’abilita’ d 
interagire con altre proteine. L’attivita’ delle ubiquitin ligasi e delle deubiquitinasi 
regola l’ubiquitinazione specifica di preoteine target. Nello specifico, gli enzimi in grado 
di contrastare l’attivita’ ubiquitin ligasica di Parkin sono risultati candidati 
estremamente importanti per una terapia farmacologica. 
Quindi, il nostro lavoro mostra come la CaN potrebbe essere utilizzata come 
terapia nel morbo di Parkinson, per regolare la traslocazione di Parkin e la mitofagia. 
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2. Summary 
Mitochondria are crucial organelles in life and death of eukaryotic cells. 
Mitochondria are complex, double membrane-bound organelles, forming an extremely 
dynamic subcellular network. Their structure is fundamental for their function and 
their morphology undergoes continuous changes, sparing from an interconnected 
network to single units. Key components which regulate mitochondrial dynamics are 
the pro-fission proteins Drp1 and Fis1 and the pro-fusion proteins Mfn1/2 and Opa1. 
Mitochondria not only are the main site of energy conversion, but also have a 
crucial role in apoptosis and autophagy regulation. Besides that, they also regulate 
Ca2+ and red-ox homeostasis, cellular differentiation and growth, and amplification of 
signaling cascades. Moreover, mitochondria dysfunctions have been implicated in the 
onset of several human diseases; in more details, accumulation of dysfunctional 
mitochondria has been linked to neurodegenerative disorders, such as Parkinson’s 
disease. 
Parkinson’s disease (PD) is the second most common disorder after Alzheimer’s 
disease. Pathologically, this disease is characterized by the progressive loss of 
dopaminergic (DA) neurons in the Substantia Nigra pars compacta (SNpc) in the 
midbrain and, in most of the cases, by the presence of proteinaceous cytoplasmic 
inclusions called Lewy bodies. However, the etiology of this disorder is still unclear.  
PD is mainly a sporadic disorder, making it difficult, to find the etiology of the 
disease. However, 10% of PD cases are genetic and the analysis of familiar forms of PD 
resulted in a deeper understanding of the causes and molecular mechanisms of this 
disease. More in details, mutations in the PARK2 gene, encoding for Parkin, are the 
most common cause of Autosomal-Juvenile Recessive-Parkinsonism. PARK2 encodes 
for an E3-ubiquitin ligase which has a fundamental role in the recognition and 
elimination of dysfunctional mitochondria via autophagy. Its function is tightly related 
to another gene which has been found to be mutated in early PD, PINK1. 
Parkin structure consists of an N-terminal Ubiquitin-like domain (Ubl) and four 
zinc-finger RING-like domains: RING0, RING1, IBR and RING2. A linker region connects 
the former segments. This region has no similarity with any known protein, so it is also 
called unique Parkin domain (UPD). Parkin main function is to transfer ubiquitin from 
an E2-ubiquitin ligase to the target protein. It has been demonstrated that Parkin 
subcellular localization is mainly cytoplasmic and then it is selectively recruited to 
dysfunctional mitochondria and it promotes their elimination through mitophagy. 
Parkin translocation is PINK1 dependent, even if the mechanism is still not clear. Once 
on mitochondria, Parkin ubiquitinates different proteins, including Mitofusin, which 
results in mitochondrial fission. However, it is still unclear which post-transcriptional 
modifications occur on Parkin, regulating its recruitment to mitochondria. Here, we 
show how Calcium and Calcineurin have a fundamental role in Parkin recruitment and 
mitophagy. 
Free Ca2+ concentration is important in the regulation of metabolic processes 
and for signal transduction. Accordingly, the cytoplasmic pool of Ca2+ is very limited 
and is tightly regulated by mitochondria and ER. Besides all the other processes, Ca2+ 
dependent phosphorylation and dephosphorylation of targeted proteins affect their 
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activity by impinging on subcellular localization, conformation and protein-protein 
interaction. For example, phosphorylation and de-phosphorylation of mitochondria 
pro fission protein Drp1 regulates Drp1 translocation to mitochondria, an 
indispensable event for Drp1 dependent fission activity. In particular, translocation of 
Drp1 to mitochondria upon CCCP-induced depolarization is mediated by selective 
dephosphorylation of residue Serine 637, which is controlled by Ca2+ dependent 
phosphatase Calcineurin (CaN). On the other hands, protein kinase A (PKA) -dependent 
phosphorylation of Drp1 is retaining Drp1 in the cytoplasm during starvation, leading 
to elongated mitochondria, which cannot be eliminated by autophagy. Therefore, Ca2+ 
dependent regulation of phosphorylation and de-phosphorylation of Drp1 operates as 
a reversible post-transcriptional modification that impinges on Drp1 translocation, in 
response to metabolic changes. 
Considering the fundamental role of Ca2+ in the regulation of proteins activity, 
we evaluated whether Parkin translocation and CCCP-dependent mitophagy depended 
on Ca2+ and was regulated by similar post-transcriptional modifications that control 
Drp1 translocation. 
In our experiments, we transfected cells with fluorescent mCherry-Parkin and 
with mitochondrial targeted YFP (mito-YFP) constructs and looked at Parkin subcellular 
localization. Consistent with previous studies, we found that overexpressed Parkin 
mostly located in the cytosol of wild-type MEFs. Upon CCCP treatment, Parkin 
translocates to fragmented mitochondria in the 80% of the cells. Pre-treating cells with 
BAPTA, a Ca2+ chelator, abolished Parkin translocation, suggesting that its recruitment 
depended on Ca2+. Moreover, chemical inhibition of CaN with FK506 blocked Parkin 
translocation. 
Taking advantage of the already existing CaN dominant negative (ΔCnAH151Q) 
and constitutive active mutants (ΔCnA), we turned to a genetic approach to evaluate 
the effect of CaN inhibition upon Parkin recruitment. We cotransfected MEFs with 
mCherry-Parkin and ΔCnB plus ΔCnAH151Q and looked at Parkin localization. 
Interestingly, CCCP-induced Parkin translocation was impaired when in presence of the 
dominant negative mutant of CaN. To assess whether CaN played also a role in Parkin-
dependent mitophagy1,2, we next performed a mitophagy assay in presence of the 
dominant negative mutant of CaN. ΔCnAH151Q expression significantly delayed CCCP-
induced mitophagy. Taken together these data showed that pharmacological and 
genetic inhibition of CaN is sufficient to prevent Parkin translocation and CCCP-induced 
mitophagy. 
Different studies linked Parkin translocation and mitophagy to PINK1 activity. 
Indeed, PINK1 directly phosphorylates Parkin and Ubiquitin (Ub) at Serine 65, which is 
required for Parkin activity. We generated phopsho-mimetic Parkin and phopsho-
mimetic Ub at Serine 65 (Parkin S65E and Ub S65E, respectively) and investigated the 
effect of CaN constitutive active ΔCnA, and dominant negative ΔCnAH151Q expression 
upon Parkin translocation. In wildtype MEFs transfected with Ub S65E, Parkin S65E 
localized to the cytosol and translocated to impaired mitochondria upon CCCP 
treatment. In this condition, we did not observe a constitutive localization of Parkin 
S65E on mitochondria in untreated cells, indicating that PINK1-dependent 
phosphorylation of Parkin and Ubiquitin might not be sufficient for Parkin recruitment.   
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As expected, in PINK1 -/- MEFs transfected with Ub S65E, Parkin S65E also 
localized to the cytosol and translocated to impaired mitochondria upon CCCP 
treatment. In presence of CaN dominant negative ΔCnAH151Q, Parkin S65E did not 
translocate to mitochondria upon CCCP intoxication. Taken together, these 
observations supported the hypothesis that CaN, in addition to PINK1, is required for 
Parkin translocation.  
Then, we looked at Parkin translocation in PINK1 -/- cells. As already reported, 
wildtype Parkin did not translocate to mitochondria upon CCCP treatment. 
Interestingly, in the presence of the constitutive active CaN mutant ΔCnA, Parkin 
constitutively co-localized with mitochondria. Moreover, CCCP-induced mitophagy was 
significantly enhanced. 
As already reported, Parkin does not translocate to mitochondria upon CCCP 
treatment in the absence of PINK1. However, expression of constitutive active CaN was 
sufficient to promote Parkin translocation in PINK1 -/- cells, even in the absence of 
CCCP intoxication. Accordingly, mitophagy was enhanced in PINK1 -/- cells expressing 
CaN constitutive active. To conclude our data suggest that CaN activation can bypass 
PINK1 requirement in the induction of Parkin translocation and CCCP-induced 
mitophagy. 
Comforted by the findings that CaN plays a role in regulating stress induced 
mitophagy in vitro, we next turned to a well-established in vivo model system to 
evaluate the physiological significance of CaN inhibition and/or activation in a PINK1 
deficient model of PD. Parkin overexpression in a PINK1 mutant (knock out) 
background is able to rescue PINK1 mutant phenotype, as previously reported. We 
reasoned that enhancement of CaN activity in vivo would also ameliorate PINK1 
mutant phenotype by enhancing Parkin translocation and activity. Indeed, CaN 
constitutive active expression in PINK1 mutant background rescues PINK1 mutant flies 
climbing deficiency. This effect was specific for CaN, as chemical inhibition of CaN with 
FK506, abolished the rescue. Importantly, FK506 administration partially blocked the 
rescuing effect of Parkin overexpression in PINK1 mutant flies, further suggesting an 
indispensable role for CaN in Parkin activation downstream PINK1.  
Further experiments are required to identify the specific Parkin residue/s that 
is/are de-phosphorylated by CaN. An in silico analysis identified Serine 407 and 
Threonine 410 as potential candidates for CaN dependent de-phosphorylation. Indeed, 
translocation of phospho-mimetic Ser407Asp Parkin mutant was partially impaired, 
whereas phospho-mimetic Thr410Asp Parkin completely failed to translocate upon 
CCCP treatment. To convincingly prove that these are the residues that are de-
phosphorylated by CaN, we are in the process of performing mass-spectrometry 
analysis of Parkin protein that has been pulled down from untreated cells and 
following CCCP intoxication. 
Scientific research is exploring the effects of post-translational modifications as 
starting point for the developing of novel therapeutic targets for human diseases. In 
particular, Tyrosine Kinases Inhibitors (TKIs) such as Imatinib and Nilotib, are used as 
effective therapy for patients affected by leukemia. Recently, this drug resulted to be 
effective also in mouse models of Alzheimer’s Disease (AD). Administration of TKIs to 
AD mice increases soluble Parkin leading to amyloid clearance and cognitive 
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improvement. Although no Parkin mutations are found in AD, these studies 
demonstrate how manipulation of Parkin activity through the modulation of post-
transcriptional modifiers can be used as powerful therapeutic approach. 
Ubiquitination is also emerging as a powerful tool to modulate proteins activity, 
via regulation of protein subcellular localization and/or ability to interact with other 
proteins. The counteracting activity of ubiquitin ligases and deubiquitinating enzymes 
(DUBs) mediate and regulate protein ubiquitination. Specifically in the context of 
PINK1/Parkin pathway, much effort has been put to identify specific DUBs that 
counter-act the ubiquitin-ligase activity of Parkin and impact mitophagy. These 
enzymes are therefore emerging as extremely attractive druggable candidates.  
By exploring the role of CaN in Parkin translocation and stress induced 
mitophagy and in vivo in a PINK1 model of PD, this work ultimately identified a novel 
druggable target and has the potential to widen up medical intervention for the 
treatment of PD. 
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3.  Introduction 
3.1 Mitochondria 
Mitochondria are crucial organelles in life and death of eukaryotic cells. These 
organelles reside in almost every eukaryotic cell and participate in the regulation of 
many cellular processes. They not only are the main site of energy conversion, but also 
have a crucial role in apoptosis and autophagy regulation. Besides that, they also 
regulate Ca2+ and red-ox homeostasis, cellular differentiation and growth, and 
amplification of signaling cascades. Moreover, mitochondria dysfunctions have been 
implicated in the onset of several human diseases; in more details, accumulation of 
dysfunctional mitochondria have been linked to neurodegenerative disorders, such as 
Parkinson’s disease. 
Mitochondria are complex, double membrane-bound organelles, forming a 
subcellular network which occupies almost 25% of the cytoplasmic volume. Their 
structure is fundamental for their function and their morphology undergoes 
continuous changes, sparing from an interconnected network to single units. 
Mitochondrial shape is regulated by an increasing number of proteins, called 
mitochondria shaping proteins, which belong to the large family of dynamin-related 
GTPases. These proteins control mitochondrial ultrastructure, which organization is 
also extremely complex. Mitochondria have an outer mitochondrial membrane (OMM) 
and an inner mitochondrial membrane (IMM). The IMM can be further divided into an 
inner boundary membrane and the cristae compartment, in which reside the 
complexes of the respiratory chain. Changes in both mitochondrial ultrastructure and 
cytosolic organization have a strong effect in the different process that mitochondria 
regulate within a cell. 
3.1.1   Mitochondrial morphology and dynamics 
According to the endosymbiontic theory developed around 1960s, 
mitochondria have an extracellular origin as free-living prokariotes and they became 
organelles of eukaryotic cells1. Important evidences supporting this theory come from 
mitochondrial genome, as well as from biochemical and physiological symilarities of 
these organelles with prokariotes. A corollary to the endosymbiontic theory also 
explains how the reduced number of proteins encoded by mitochondrial genome is the 
consequence of a gene transfer to the nucleus, known as endosymbiontic gene 
transfer (EGT). During evolution, mitochondria became fundamental for the life of 
eukaryotic cells and vice-versa2. 
Mitochondria were firstly described by the anatomist Rudolf Albrecht von 
Koelliker, who called them “sarcosome” in 1857. In 1950s Sjöstrand and Palade were 
the first to use electron microscopy to analyze mitochondrial internal structure. The 
interpretation of their micrograph led to different models for mitochondrial structure, 
nevertheless they both recognized the presence of two different membranes. 
However, Palade’s model is the one that evolved to the currently accepted by the 
scientific community. According to this model, also called baffle model, mitochondria 
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have two membranes, an outer membrane (OMM) and an high convoluted inner 
membrane (IMM), and two soluble compartments, the intermembrane space (IMS) 
between the OMM and the IMM and the matrix, the central electrondense space3,4. 
While the OMM structure is quite simple and follows the shape of mitochondria, the 
IMM presents invaginations called cristae, which broadly open on the IMS on one side 
through the so called cristae juctions, and protrude across the matrix on the other 
side. The cristae house the complexes of the electron transport chain and the ATP-
synthase, thus are the sites of ATP production. The IMM is a continue surface, 
nevertheless new advances in technologies allowed to further subdivided it into inner 
boundary membrane and cristae compartment5. 
 
Figure 1. Tomography of a rat-liver mitochondrion. (A.) Three-dimensional reconstruction of an isolated rat-liver 
mitochondrion obtained by high-voltage electron microscopic tomography. OM: outer membrane; IM: inner membrane; C: cristae. 
(B.) Region of a 5-nm slice from the same tomogram. There are a lot of contact sites between OM and IM. Arrow points to binding 
site of the OM with putative endoplasmic reticulum. Bar, 0.4 mm5. 
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The OMM contains a large number of porins, which are integral proteins acting 
as non-specific pores and allow the access in the IMS to ions and metabolites smaller 
than 10KDa. The composition of this membrane is similar to the other eukaryotic 
membrane and it is enriched in protein of the import machinery, through which the 
nuclear-encoded proteins can be imported into the mitochondria. In comparison, the 
IMM is less permeable and only small molecules or metabolite are allowed to cross it 
and enter into the matrix. Metabolites and proteins can cross the IMM only through 
specific carriers, since it is permeable only to oxygen, carbon-dioxide and water. 
Another fundamental feature of the IMM consists in the restricted diffusion 
allowed between the internal compartments. This has profound implications since 
cristae, besides the site of ATP production, also store cytochrome c, which is released 
upon apoptosis.  
Both the IMM and the OMM can change shape in response to different 
metabolic requirements of the cell. Mitochondria continuously undergo fission and 
fusion events, which processes regulate their functions and maintenance6. Fusion and 
fission are events which involve two membranes, thus they are fine regulated by 
specific proteins. Changes in mitochondria shape and ultrastructure can be easily 
monitored through confocal or electron microscopy. 
 
3.1.1.1 Mitochondrial fission proteins 
Dinamin-related protein 1 (Drp1) is a largely cytoplasmic GTPases which plays a 
major role in mitochondrial fission. It is a protein with an N-terminal GTPase domain, a 
dynamin-like middle domain and a GTPase effector domain (GED) located in the C-
terminal region. Its translocation and activity is regulated by post-transcriptional 
modifications, in particular by phosphorylations at specific residues7. Drp1 can 
translocate to mitochondria in a Ca2+ and Calcineurin dependent manner8, where it 
forms oligomers and binds to its adaptors on the OMM (Fis1, Mff and MiDs), thus 
causing mitochondrial constriction and fragmentation. Therefore, mitochondrial 
fragmentation depends on a loop involving sustained Ca2+ rise, activation of 
Calcineurin, dephosphorylation of Drp1 and its translocation to the organelle. 
Other important players in fission are Drp1 receptors and adaptors on the 
OMM. Drp1 anchors to the OMM receptors to form the fission complex, which is an 
essential initial step for the fission process9. The role of the different receptors in Drp1 
recruitment and stabilization on the OMM is not completely clear. However, it has 
been shown a role for both Fis1 and Mff in Drp1 recruitment and mitochondrial fission, 
with Mff playing a bigger role in both events10. Moreover, MiD49 and MiD51 play a 
role in Drp1 recruitment independently from Fis1 and Mff, and they can maintain it at 
an inactive state until a cellular signal triggers mitochondrial fission.  
Many recent studies focused on identifying the sites where Drp1 is recruited 
and fission occurs. These sites are called fission foci, and seem to be marked by ER 
tubules11. Nevertheless, the complete mechanism of mitochondrial fission regulation is 
still far from being completely understood.  
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3.1.1.2 Mitochondrial fusion proteins 
Two families of proteins regulate mitochondrial fusion in mammals: Mfns and 
Opa1.  
The first identified mediator of mitochondrial fusion has been the large GTPase 
Fuzzy onion protein 1 (Fzo1), the D. melanogaster homologues of Mfns expressed 
during spermatogenesis12. Mutations in this gene cause male sterility in flies, and 
mitochondria cannot fuse normally. Besides Fzo1, D. melanogaster also possesses 
another Mfns homologue, the Mitochondrial assembly regulatory factor (Marf) which 
is ubiquitously expressed in both males and females13. In mammals, two Fzo1 
homologues, Mfn1 and Mfn2, are widely expressed in many tissues and acting in trans 
they promote mitochondrial fusion14. Mfn1 and Mfn2 possess a similar structure, with 
an N-terminal GTPase domain, two transmembrane domains spanning the OMM 
separated by two heptad repeat regions (HR1 and HR2)14-16. Despite their high 
similarity, Mfn1 and Mfn2 seem to have different roles within the cell. Functionally, 
Mfn1 has a higher GTPase activity compared to Mfn2 and it shows and higher capacity 
to induce fusion17-19.  Moreover, recent works form our lab showed that Mfn2 is also 
present on the ER, and it is enriched on the ER/mitochondria interface19. Interestingly, 
Mfn2 on the ER forms omo- and etero-typic complexes with Mfn1 and Mfn2 on the 
mitochondria, controlling the tether between the two organelles. By regulating 
mitochondrial/ER contacts, Mfn2 levels can affect Ca2+ exchange and signaling 
between the two organelles. Thus, it has been suggested that, while Mfn2 mainly 
regulates fusion, Mfn2 has additional regulatory functions15 
Optic Atrophy 1 (Opa1) is the other player in the process of mitochondrial 
fusion of the IMM20-22. The Opa1 gene produces different isoforms, in human there are 
eight different splice variants. The role of Opa1 in fusion or fission is controversial. 
Interestingly, Opa1 overexpression causes mitochondrial elongation in cells23, but high 
Opa1 levels can promote mitochondria fission24. Moreover, Opa1 has been found to 
have a fundamental role in apoptosis and cristae remodeling25,26.  
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Figure 2. Regulation of mitochondrial dynamics. (A.) Cartoon showing the roles of mitochondrial fusion proteins. Mfns, 
besides their role in OMM fusion, also have an important role in the mitochondria-ER tethering. MIB inhibits MFNs fusion activity, 
while phospholipase D (PLD), by providing lipid remodeling, facilitates it. Opa1 is the regulator of IMM fusion and of cristae 
biogenesis and remodeling, together with the prohibitin-MINOS complex which controls the formation of cristae junction and of 
F0F1ATPdimers that contribute to curve the cristae. (B.) Rappresentation of mitochondrial fission mechanism. Drp1 is normally 
phosphorylated and sequestered in the cytoplasm. Dephosphorylated Drp1 is recruited at the ER-mitochondria contact sites, 
where ER tubules cross over and wrap around mitochondria. Once translocated, Drp1 oligomerizes and interacts with MFF, 
MiD49/51, and FIS1, promoting mitochondrial fission27. 
 
3.1.1.3 Mitochondrial shape and physiological function 
Recently, many studies focused on the intimate connection between 
mitochondrial morphology and their function, specifically in the context of 
mitochondria quality control. For instance, mitochondrial fragmentation is a pre-
requisite for elimination of defective mitochondria, which are engulfed by 
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autophagosomes and eventually degraded28. Moreover, mutations in fusion genes 
have been found to be linked to neurodegenerative disorders, Charcot-Marie Tooth 
type 2A (CMT2A) and autosomal dominant optic atrophy (ADOA)29,30. Indeed, 
mitochondrial motility along the axon in neurons is linked to mitochondrial 
fragmentation31. Thus, mitochondrial distribution on neuronal synapsis is intimately 
related to their ability to fuse and divide, and these processes control also the density 
and plasticity of the synapsis32. Moreover, Drp1 -/- mice show developmental 
abnormalities, especially in the forebrain, which can be associated to abnormalities in 
synapsis formation33. It is not surprising how, in the last years, mitochondrial dynamics 
was reported to participate in the pathophysiology of different neuronal disorders and 
mutations in genes involved in this process have been shown to cause neuronal 
disorders. 
Opa1, which is genetically linked to ADOA, has been found to have different 
roles besides mitochondrial IMM fusion, such as cristae remodeling, supercomplex 
formation and regulation of mitochondrial autophagy25,34. These different functions 
seem to depend on the different isoforms and cleavage processes of Opa1.  
Mutations in Mfn2 are linked to the onset of CMT2A. Besides its role in 
mitochondria fusion, Mfn2 levels are correlated with oxidative metabolism of skeletal 
muscle35 and the proliferative ability of vascular smooth muscle cells by sequestering 
the protooncogene Ras36. Moreover, through its role in the regulation of ER-
mitochondrial tether, Mfn2 allows the regulation of many different processes, such as 
lipid synthesis, mitochondria energy metabolism, Ca2+ transfer between the two 
organelles and Ca2+ dependent cell death19. Finally, Mfn2 has a fundamental role in 
mitophagy, being the receptor for Parkin on the OMM37,38 and eventually getting 
ubiquitinated by Parkin. We will discuss its role in mitophagy in the following 
paragraphs. 
Both mitochondrial fusion and fission events are pro-survival for the cell: fusion 
helps overcoming stress by sharing the contents of damaged mitochondria, and fission 
regulates the segregation of unfunctional mitochondria so that they can be 
eliminated9,39.  
 
3.1.2 Self-eating and self-killing: autophagy and apoptosis 
regulation 
Autophagy and apoptosis are two main processes which regulate cell fate. Both 
are self-destructive processes which in the last years gained considerable interest in 
the context of different human pathologies. Autophagy is a highly regulated process 
involved in the turnover of long-lived proteins as well as whole organelles, and it can 
occur in a generalized fashion or can specifically target distinct organelles (f.i. 
mitochondria). There is a basal level of autophagy, which allows the turnover of 
cellular components. However, in some cases autophagy can be activated in response 
to stress conditions which can lead to apoptosis. Apoptosis is the best characterized 
programmed cell death process, which causes the rapid demolition of cellular 
components, upon the activation of a signaling cascade involving proteases mainly. 
Autophagy and apoptosis often occur in the same cell, in most of the cases with 
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autophagy preceding apoptosis40-42. The crosstalk between autophagy and apoptosis 
can determine cell fate. Similar stimuli can induce either autophagy or apoptosis in the 
cell. This is because a stress often stimulates an autophagy response first. When it 
exceeds, in terms of duration or intensity, apopototic lethal programs get activated. 
It is still not clear whether autophagy represents a mechanism for preventing 
apoptosis or for enacting non-apoptotic programmed cell death. 
 
3.1.2.1 Mechanism and regulation of autophagy 
Autophagy (literally meaning “self-eating”) is a catabolic process during which 
long-lived proteins and damaged cytoplasmic organelles are engulfed by double-
membrane structures named autophagosomes and eventually get degraded to basic 
components, which can then be recycled by the cell itself. Three different form of 
autophagy can be recognized (Figure 3): chaperone-mediated autophagy (CMA), 
microautophagy and macroautophagy. Macroautophagy (hereafter called autophagy) 
is a conserved pathway in eukaryotic cells, from yeast to mammals that enables the 
degradation of cytoplasmic components. Compared to microautophagy, autophagy is a 
more complex process, since the target engulfed by autophagosomes which then fuse 
with lysosomes, while microautophagy involves only lysosomes43. Finally, CMA is a 
specific form of autophagy which removes individual proteins containing a specific 
sequence recognized by the chaperone Hsp70 (70 kDa heat shock cognate protein). 
This chaperone recognizes and binds to the target, then translocates to the lysosome 
where it binds to LAMP-2A (lysosome-associated membrane protein 2A). Thus, the 
target protein gets unfolded and imported to the lysosome where eventually gets 
degraded44,45 
As already mentioned, autophagy is present at basal levels in every eukaryotic 
cell, but it can be strongly up-regulated by certain stimuli, such as starvation, hypoxia 
or pharmacological treatments, allowing the specific study of the pathways involved43. 
Autophagy can be divided into different stages, from the nucleation of the 
autophagosome, to its elongation and fusion with the lysosome, followed by 
engulfment and degradation of the target cargoes. 
Three main pathways can control the process of autophagy. In mammals, the 
major regulator of autophagy is the Target Of Rapamycin (mTOR). mTOR is a 
Threonin/Serine kinase which binding to RAPTOR, PRAS40 and mLST8 forms the Target 
Of Rapamycin Complex I (mTORC1) and acts as a nutrient sensor. In presence of 
nutrients, class I phosphatidylinositol 3-kinase (PI3K) activates protein kinase B (Akt) 
and TORC1, inhibiting autophagy. In case of nutrient restriction, mTOR is inhibited, 
leading to autophagy pathway activation. The autophagosome forms as consequence 
of Ubiquitin Like Kinase 1 (ULK1) activation, which is usually inhibited by mTOR. ULK1 
phosphorylates different substrates, among which mAtg13, FIP200 and AMBRA146. 
Moreover, ULK1 forms a complex with mAtg13 and FIP200, which is fundamental for 
organization and maturation of the autophagosome. 
A second pathway regulating autophagy is mediated by mammalian Beclin1. 
Activation of ULK1-mAtg13-FIP200 complex leads to Beclin1-Vsp34 complex formation 
on the lipid membrane of the forming autophagosome. Vsp34 is a class III PI3K, which 
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once in a complex with Beclin1 produces phosphatidylinositol 3-phosphate (PI3P), 
inducing the recruitment of other proteins of the autophagy complex47. Beclin1-
regulated autophagy protein- 1 (Ambra-1), ultraviolet radiation resistance-associated 
gene (UVRAG), and Bax interacting factor-1 (Bif-1) promote the interaction through 
Vps34 and Beclin1. This pathway is an important link between autophagy and 
apoptosis, since the anti-apoptotic proteins Bcl-1 and Bcl-XL binding Beclin1 inhibit 
autophagy48. 
Finally, two ubiquitin-like conjugation processes mediate the elongation of the 
autophagosome, the Atg5-Atg12-Atg16L and the Atg4-Atg8 (LC3). LC3 is constitutively 
cleaved by Atg4 to produce LC3-I. When autophagy is induced, LC3-I binds to the 
membrane lipid phosphatidylethanolamine, to form LC3-II, which is recruited 
selectively on the expanding autophagosome membranes and mediates its closure49. 
LC3-II then gets degraded after autophagosome fusion with lysosome. 
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Figure 3. Different types of autophagy. Macroautophagy: a portion of cytoplasm is engulfed by a double membrane 
structure, the phagophore, to form an autophagosome. The outer membrane of the autophagosome fuses with the lysosome for 
degradation of the cargoes in the autolysosome. Microautophagy: small parts of the cytoplasm are enclosed in an invagination of 
the lysosomal or late endosomal membrane. Chaperone-mediated autophagy: first, cytosolic Hsc70 and cochaperones recognize 
substrate proteins containing a KFERQ-like pentapeptide sequence. Then they are translocated into the lysosomal lumen after 
binding with lysosomal Lamp-2A. All the different type of autophagy result in degradation of the cargoes and recycling50. 
 
3.1.2.1.1. Mitophagy: a selective form of autophagy 
 
As previously mentioned, organelles-specific autophagy also exist as quality 
control mechanism to eliminate damaged or dysfunctional components. In the case of 
mitochondria, this process is defined mitophagy and depends on PINK1/Parkin 
pathway. In mammalian cells, mitophagy strongly depends on mitochondrial fission, 
during which mitochondria get divided into smaller pieces to get encapsulated by 
autophagosomes28,51. 
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The PTEN induced kinase 1 (PINK1) is a Serine/Threonine kinase, which 
normally is imported into mitochondria and rapidly degraded. However, in presence of 
depolarized mitochondria, PINK1 is stabilized on the OMM were it recruits the E3 
ubiquitin-ligase Parkin52. Once on mitochondria, Parkin leads to the ubiquitination of 
mitochondrial proteins (Mfn2, VDAC, TOM and other), as a signal for targeting selected 
mitochondria to the autophagosome53,54. It has been widely demonstrated that Parkin 
translocation is PINK1 dependent, but the mechanism is still unclear. Recent works 
show that PINK1-mediated phosphorylation of Parkin and Ubiquitin at residue Serine 
65 (Ser65) is necessary but not sufficient for Parkin translocation to defective 
mitochondria, and it is indeed fundamental for its E3-ubiquitin ligase activityRW.ERROR - 
Unable to find reference:182. The ubiquitinated proteins on the OMM recruit, in turn, p62, 
which targets the organelle to the autophagosome through its interaction with LC358.  
Interestingly, recent publications show a strong connection between Bcl-2 
family members and mitophagy. In particular, Bcl-2 family member antagonizes 
mitophagy through inhibition of Parkin translocation to mirochondria59. Moreover, 
AMBRA1, a pool of which in basal condition is localized at the mitochondria interacting 
with BCL-2, is able to interact directly with Parkin, facilitating mitophagy60. Surprisingly, 
upon mitophagy induction, AMBRA1 is also able to directly interact with LC3, inducing 
mitochondrial degradation regardless of PINK1/Parkin pathway61. 
Autophagy and mitophagy are two similar processes which occurs for different 
reasons. Autophagy occurs when cells are deprived of nutrients or in response to 
specific metabolic requirements. Proteins and organelles get degraded to be recycled 
and for providing ATP. Interestingly, during autophagy mitochondria elongate, to be 
spared from degradation and provide membranes for the autophagosome62. By 
contrast, mitophagy occurs to eliminate dysfunctional mitochondria, which fragment 
and separate from the functional ones to be degraded. 
23 
 
Figure 4. Selective and non-selective autophagy have different roles. (A.) Non selective autophagy occurs when cells 
are in starvation. The degradation of components of the cytoplasm supplies building blocks for re-use and for metabolism to 
provide ATP. (B.) Mitophagy occurs to eliminate defective mitochondria28.  
3.2. Parkinson’s Disease 
PD has been firstly described in 1817 by James Parkinson in his ‘‘Essay on the 
Shaking Palsy’’ as an “Involuntary tremulous motion, with lessened muscular power, in 
parts not in action and even when supported; with a propensity to bend the trunk 
forward, and to pass from a walking to a running pace: the senses and intellects being 
uninjured”. However only over 60 years after the term ‘‘Parkinson’s disease’’ was 
actually coined, by J. M. Charcout, expanding also the list of the symptoms.  
Pathologically, this disease is characterized by the progressive loss of 
dopaminergic (DA) neurons in the Substantia Nigra pars compacta (SNpc) in the 
midbrain and, in most of the cases, by the presence of proteinaceous cytoplasmic 
inclusions called Lewy bodies63. However, the etiology of this disorder is still unclear 
even though it is one of the most common progressive movement disorders in the 
elderly64.   
Mitochondrial dysfunction has been found to be a main contributing factor to 
PD development, with evidences coming from observations on MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine), rotenone and paraquat65-68. All of these chemicals 
are mitochondrial toxins, acting on Complex I, which have also been associated to PD. 
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Moreover, a reduction in Complex I activity was found in the substantia nigra, in 
platelets, lymphocytes and muscle tissue of PD patients69-71. 
However, the first familial PD gene was discovered a decade after these 
findings. A mutation in -synuclein gene was found to be associated with autosomal 
dominant familial parkinsonism72. This protein was found to be the major component 
of Lewy bodies both in sporadic PD. Since then, more genetic factors have been linked 
to PD and today there are 16 loci identified which are associated to heritable forms of 
PD (PDGene database). 
 
3.2.2. Clinical characteristic, symptoms and treatment 
PD is a progressive neurodegenerative disorder with average onset at 55 years 
old, with incidence increasing with age. About 90% of the cases have no apparent 
genetic linkage (called as “sporadic” PD cases), but the disease is inherited in the rest 
of the cases. Moreover, some genetic linked forms of PD show an earlier 
manifestation, thus complicating the diagnosis of the disease. Due to the slower 
progression of the disease, the first symptoms occur when at least 60% of DA neurons 
in the Substantia Nigra pars compacta (SNpc) are dead and dopamine release is 
reduced by about 80%. Current research on treatments is directed through the 
prevention of DA neuronal loss. 
Clinically, the term “parkinsonism” is used to describe a syndrome 
characterized by tremor at rest, rigidity, slowness or absence of voluntary movement, 
postural instability, and freezing, caused by striatal DA deficiency or damage.  
PD is characterized by both motor and non-motor features. Four symptoms are 
considered the cardinal ones, and they are known with the acronym of TRAP: Tremor 
at rest, Rigidity, Akinesia (or bradykinesia) and Postural instability. In addition, flexed 
posture and motor blocks have been included among classic features of parkinsonism. 
Non-motor features are abnormalities of affect and cognition, indeed some patients 
show a loss of initiative, anhedonia, slowed cognitive processes, depression, and, 
especially in older patients, also dementia73. 
As already mentioned, the neuropathological hallmarks underlying these 
clinical features are the loss of DA neurons and the presence of intraneuronal 
proteinacious cytoplasmic inclusions termed “Lewy bodies” (Figure 6 A.). These 
neurons normally contain conspicuous amounts of neuro-melanin and their loss causes 
the classic SNpc depigmentation in PD patients74. However, the neurodegeneration in 
PD affects also a lot of different neurochemical systems, beyond the DA neurons. As 
regards for the Lewy bodies, these are not specifically found in PD, but also in some 
forms of Alzheimer’s disease, in a condition called “dementia with LB disease” and also 
in a an incidental pathologic finding in people of advanced age75. Lewy bodies are 
spherical eosinophilic cytoplasmic proteins aggregates composed of numerous 
proteins, including α-synuclein, Ubiquitin, heat shock proteins, neurofilaments and 
Parkin, and they are found in all affected brain regions72. The role of Lewy bodies in 
neuronal cell death remains controversial.  
PD is diagnosed on clinical criteria; there is no definitive test for diagnosis. 
Diagnostic criteria have been developed by the UK Parkinson’s Disease Society Brain 
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Bank and the National Institute of Neurological Disorders and Stroke (NINDS), but the 
reliability and validity of these criteria have not been clearly established.  
The selection of the treatment for PD patients is highly individualized. It should 
take into account different factors, including the patient’s age, symptoms, symptom 
severity, occupational status, lifestyle, cognitive, behavioral and psychiatric status, and 
other medical characteristics. In the case of early Parkinson’s disease, one of the most 
common therapy is based on the administration of L-Dopa to patients, a precursor of 
dopamine. Usually this occurs in combination with Carbidopa/Levodopa 
administration, that inhibits DA Decarboxylase (DDC) present in the periphery, 
increasing the dose of L-Dopa that reaches the brain76. The administration of Levodopa 
can also be used in the case of advanced PD77. 
Other strategies involve the inhibition of dopamine catabolism76. These include 
inhibition of Monoamine Oxidase B (MAO-B) or of Catechol-O-methyl-transferase 
(COMT). Through the inhibition MAO-B, DA would no more be converted to DOPAC 
(3,4-Dihydroxyphenyl acetic acid) resulting in higher concentrations of DA and in 
prolonged effect of L-DOPA. To treat severe symptoms, COMT inhibitors (Entacapone) 
are given together with L-DOPA. COMT reduces DA levels by methylating DA to 3-
Methoxytyramine, and also acts in the periphery, resulting in too small amounts of L-
Dopa reaching the brain. In some other, more severe cases, tremor is treated with 
anticholinergics77.  
 
 
Figure 6. Anatomy and histology of brain 
of Parkinson’s disease patients. (A.) Midbrain 
section showing normal substantia nigra (on the 
top); midbrain section showing loss of pigmented 
cells of the substantia nigra in PD patients’ brain (on 
the bottom). From: CNS Pathology. (B.) Lewy bodies 
are the round eosinophilic inclusions composed of -
synuclein which can be clearly seen in this histology 
slide of the brain of a PD patient. 
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In case the patients cannot be treated using conventional oral medication, 
three invasive options can be used to ameliorate motor symptoms. The first option 
consists in continuous subcutaneous apomorphine infusion, the second in continuous 
duodenal levodopa carbidopa pump, or the third one in deep brain stimulation (DBS).  
It is important to underline that all available treatment strategies can alleviate 
the symptoms of the disease, but, at now, the neuronal degeneration cannot be 
stopped or slowed down. Further research is needed to identify a definitely 
neuroprotective agent, to develop new treatment strategies with consistent benefits 
and fewer side effects. 
 
3.2.2. Genetics of Parkinson’s Disease 
In recent years, major advantages have been made in the understanding of the 
genetic basis of PD, after the identification of SNCA gene encoding for -synuclein, 
which mutations are linked to familial PD72,78. Indeed until 1997, PD was considered to 
be a non-genetic disorder, since it was thought to be caused by environmental 
factors79. Until now, many loci have been identified to be linked with PD, through 
linkage analysis, genome sequencing and genetic association. Although mutations and 
loci were identified in a relatively small number of families and only 10% of PD cases 
have a genetic cause, it is likely that the molecular pathways causing DA neurons loss 
are conserved among monogenic and sporadic forms of the disease. 
Moreover, recent findings allowed the development of novel genetic animal 
models, providing the basis for a better understanding of PD pathogenesis and for the 
development of new therapeutic strategies73. So far, six are the most common genes 
identified in familial PD, and can be divided into genes causing autosomal dominant or 
autosomal recessive form of the disease 80 (see below). 
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Figure 7. Pathways to PD. General rappresentation of the most common PD-related genes mutations. Mutations and 
genomic moltiplications of SNCA lead to a cytoplasmic accumulation of  -synuclein monomer and its subsequent oligomerization. 
α-synuclein is involved in protein misfolding and aggregation, one of the main pathway of cell toxicity. Parkin and DJ-1 interact and 
are involved in the UPS function. Mutations in these proteins could lead to accumulation of misfolded protein and its aggregation. 
The mitochondrial pathway that involves impaired oxidative phosphorylation and decreased complex I activity is also crucial in PD 
progress. UPS function and aggregate clearance requires ATP synthesis by mitochondria, and normal mitochondrial function is 
notably compromised by loss of PINK1, DJ1 and parkin activities, resulting in early-onset parkinsonism. ROS accumulation and 
oxidative stress, in parallel with loss of mitochondrial membrane potential, trigger to opening of the PTP and then apoptosis. 
Dysfunction of both pathways leads to oxidative stress, which causes further dysfunction of these pathways by feedback and 
feedforward mechanisms, ultimately leading to irreversible cellular damage and death78. 
 
3.2.2.1. Autosomal dominant forms of Parkinson’s disease 
Three loci have been identified as associated with late-onset dominant forms of 
PD: PARK1/4, PARK3, and PARK8. No corresponding gene is known for PARK3 yet. 
PARK1/4 corresponds to SNCA gene, and PARK8 to LRRK2. 
 
SNCA encodes for -synuclein and it has been the first gene to be associated to 
the onset of PD. PD associated mutations of this gene include both missense mutations 
and amplification. In particular, three mutations have been identified, which segregate 
with familial PD: Ala53Thr, Ala30Pro, Glu46Lys81. In addition to these missense 
mutations, also genomic duplication or triplication have been found to cause 
autosomal dominant, early-onset PD82. The protein is small and contains an N-terminal 
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a-helical region, a hydrophobic central component and an acidic C-terminal region. 
This protein is normally expressed throughout the brain, with highest levels in deeper 
layers of the cerebral neocortex, the hippocampus and the SN83,84 The role of -
synuclein is not well understood, however its function correlates with signal 
transduction, membrane vesicle trafficking and cytoskeletal dynamics.  
-synuclein seems to be predominantly cytoplasmic in the brain, nevertheless 
it has been shown that it associates with native membranes and phospholipid vesicles 
in vitro, though its N-terminal region. The wild type protein is a potent inhibitor of 
phospholipase D2 and phospholipase C, which are enzymes involved in signal 
transduction, membrane vesicle trafficking and cytoskeletal dynamics. It is also a 
competitive inhibitor of tyrosine hydroxylase, the rate-limiting step in tyrosine to L-
dopa biosynthesis. This protein has naturally an high propensity to aggregate, due to 
its hydrophobic central region72. 
Strong evidences associate -synuclein accumulation with the early step of the 
pathogenesis of both sporadic and inherited PD. Pathogenic mutations in -synuclein 
easily aggregates both in vitro and in vivo. Initially there is the formation of an 
intermediate annular structure, and ultimately they give rise to insoluble polymers or 
fibrils, which are the main constituent of the Lewy bodies. It is still under debate 
whether fibril, the protofibril or the soluble species is the most toxic species in 
neurons85. 
 
PARK8 has been identified as the leucine rich repeat kinase 2 gene (LRRK2) ad it 
has been linked to autosomal dominant late onset of parkinsonism86. It is the most 
common form of inherited PD in the world and the clinical features are similar to those 
of sporadic PD. Until now, 20 missense or nonsense mutations have been reported. 
The most common mutation is the Glu2019Ser substitution, which accounts for 5% of 
familial PD and 1.5% of sporadic cases87. LRRK2 is an extremely large protein of 285 
kDa containing many different domains and highly expressed in the brain, even if the 
precise tissue and intracellular expression is not completely clear88. The function and 
the effects of the pathogenic mutations of LRRK2 also remain unclear. However, 
purified LRRK2 demonstrate a kinase activity in vivo, which increases in some 
pathogenic mutations89. It was reported to interact with Parkin, but also a genetic 
interaction with PINK1 and DJ-1 has been described. Other mutations in these gene 
promote dysregulation of mitochondrial function and oxidative damage90. 
 
3.2.2.2. Autosomal recessive forms of Parkinson’s disease 
Mutations in parkin (PARK2), PINK1 (PARK6) and DJ-1 (PARK7) genes can cause 
recessive forms of early-onset parkinsonism, usually with a relatively typical 
parkinsonian phenotype91. Among these genes, mutations in parkin are the most 
common and explain up to half of familial PD, compatible with recessive inheritance 
and early onset, and also ~15% of the sporadic cases with early-onset92. There are no 
specific clinical features that can distinguish patients with parkin mutations from the 
ones with PINK1 or DJ-1 mutations or from other early-onset PD forms. 
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Mutations in these genes, which include point or small mutations, but also 
large genomic rearrengements, leading to deletions or multiplications, have been 
identified worldwide. The probability of mutations in these genes is inversely 
proportional to the onset age of the symptoms: the earlier the onset, the higher the 
chance of finding mutations. 
 
More than 40 mutations in the parkin gene have been found so far, and it was 
the first gene to be associate to recessive PD. However, only a weak correlation 
between clinical manifestation and the type of mutation has been pointed out92. 
Interestingly, LBs have not been detected in parkin disease-causing mutations, 
suggesting pathogenetic differences between the autosomal recessive and the typical 
forms of PD93. A more detailed summary on parkin is given in the following paragraph 
on the role of mitochondria in PD and on Parkin-dependent PD. 
 
PARK6 has been identified as the gene coding for PINK1 (PTEN induced kinase 
1), a mitochondrial targeted protein. This protein is an highly conserved putative 
serine/threonine kinase ubiquitously expressed, which has been demonstrated to 
protect neurons from undergoing oxidative stress94. Depending on mitochondrial 
membrane potential, this protein can be localized on the OMM or IMM and regulate 
mitochondrial dynamics and respiratory functions95,96. In Drosophila, mitochondrial 
fission is accelerated upon PINK1 overexpression13. However its specific role in 
regulating mitochondrial dynamic is still under debate, after the observation that 
mammalian PINK1 knockout cells showed a more fragmented network, suggesting a 
pro-fusion role for PINK196,97. However, it is clear that this proteins plays a vital role in 
the balance of fission a fusion processes. Mutations in PINK1 have differential effects 
on protein stability, localization and kinase activity. Recently, a first patient with 
pathogenic PINK1 mutations was recently reported with Lewy-body pathology98. 
Moreover, PINK1 associated PD cases has been studied in a smaller number of 
patients, due to its infrequence but patitents show a broad phenotypic spectrum of 
symptoms,  spanning from an early manifestation with atypical symptoms to late 
manifestation with the typical clinical PD symptoms. 
 
DJ-1 is a multifactorial protein which participates in cells protection against 
oxidative stress99,100. Mutations in this gene were firstly found in an Italian and a Dutch 
family and linked to autosomal-recessive parkinsonism. After that, only another case of 
PD patient carrying DJ-1 mutation has been identified in an Uruguayan family. DJ-1 
may regulate different cellular functions depending on its localization. It has been 
found to be in the cytosol, in the nucleus and on mitochondria, as well as at synaptic 
terminals. It has many diverse biological functions. The normal function of DJ-1 and its 
role in dopamine cell degeneration is unknown, but this protein is linked to oxidative 
stress response and mitochondrial function101-103. It has also been reported to have a 
role in oncogenesis and male fertility102. Moreover, it was recently reported that DJ-1 
is involved in the protection of neurons from dopamine toxicity104. It has also been 
found around the Lewy bodies105. Several evidences suggested that DJ-I function as a 
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dimer. Analysis of the pathogenic Lys166Pro mutation showed that the dimer is less 
stable and an ectopic expression of these mutant is rapidly degraded106.  
 
When mitochondrial membrane depolarizes, PINK1 accumulates on the outer 
membrane of damaged mitochondria to achieve selective recruitment of Parkin and 
promote mitophagy. The complete pathway will be deeply discussed later on. 
However, these findings support the idea that the same molecular pathways underlie 
different forms of early-onset PD forms. Moreover, mitochondria quality control and 
function are fundamental events in this scenario91,107. The role of DJ-1 mutations in 
autophagy remain less clear. 
Moreover, this mechanism may reflect a more general process in 
neurodegeneration108.  
 
3.2.3. Molecular pathogenesis of Parkinson’s disease: 
mitochondrial quality control 
In the late 1970s, accidental exposure to 1-methyl-4-phenyl- 1,2,3,6-
tetrahydropyridine (MPTP) was found to cause parkinsonism and DA degeneration65. 
This has been the first evidence linking mitochondrial dysfunctions to 
neurodegeneration. Indeed, MPTP oxidized to MPP+ is taken up by the DA neurons 
and inhibits complex I109-111. Pesticides and herbicides, such as rotenone and paraquat, 
also inhibit complex I activity and cause parkinsonism in animal models and possibly 
also in human [67, 114]. All these findings suggested that DA neurons were particularly 
sensitive to mitochondrial dysfunction. Moreover, pathogenic mtDNA mutations are 
associated with PD. However, two are the main hypothesis on PD pathogenesis. One 
hypothesis suggests that the onset of PD is caused by mitochondrial dysfunction and 
subsequent oxidative stress. The other one suggests misfolding and aggregation of 
proteins as the primary cause108. Both hypotheses are plausible and perhaps 
interconnected. 
The first hypothesis is based on the finding that complex I inhibition could 
reproduce parkinsonism. The inhibition of complex I can have two major effects: 
depletion of ATP and ROS accumulation. This hypothesis is supported by the fact that 
reduction of complex I activity has been described in organs of idiopathic PD patients 
and that oxidative stress was found in the brain of patients with idiopathic and familial 
forms of PD. PINK1 and DJ-1 seem to be the proteins linking PD and oxidative stress112. 
On the other hand, accumulation of misfolded proteins has been found in many 
neurodegenerative diseases. Characteristic of PD is the polymerization and altered 
conformation of proteins, which results in the presence of intracellular protein 
aggregation. As already mentioned, the main protein known to form aggregates in PD 
is -synuclein, which gives rise to the Lewy bodies72,93. The significance of these 
inclusions remains unclear. Recent evidences suggest that Parkin protects neurons 
from these pathogenic protein accumulations, targeting them to the ubiquitin-
proteasome system (UPS) and promoting their elimination. Thus, dysfunction of the 
UPS system could be responsible for the accumulation of cytosolic damaged proteins, 
and also could be important for the formation of Lewy bodies. 
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Both mitochondria damage and protein aggregation have to be taken into 
account for PD dependent degeneration, and because these processes are likely to be 
interconnected. 
 
3.3. Parkin dependent Parkinson’s disease 
Mutations in parkin gene are the most common cause of Autosomal Juvenile 
Recessive Parkinsonism (AJ-RP)113. AJ-RP patients show the same clinical symptoms of 
patients affected by other forms of PD, except for earlier onset, dystonic features, 
brisk reflexes and sleep benefit. The normal gene product, the E3 ubiquitin ligase 
parkin, has a neuroprotective role, and acts together with the Serine/Threonine kinase 
PINK1 in the mitochondrial quality control pathway.  
There is considerable disparity in age of onset, presentation, progression and 
response to drug treatment in Parkin-associated PD case114. Moreover, there is only a 
weak correlation between clinical manifestation and type of mutation, even if recent 
findings show that patient with point mutations tend to be less affected than patient 
with deletion. 
Also the pathology of Parkin-related disease is under discussion, since only few 
Parkin-associated PD cases have been neuropathologically examined. All of these have 
PARK2 gene and show at selective loss of dopaminergic neurons in the SN and the 
locus coeruleus. In most cases no Lewy bodies are seen, just recently they have been 
found in some Parkin-associated cases115. These findings indicate that pathology in 
Parkin-positive cases seem to be variable, probably due to the “cross-talk” between 
the different pathways involved in dopaminergic neurons degeneration. 
 
3.3.1. Parkin structure and mechanism of activation 
Parkin is a member of ring-between-ring (RBR) E3 ubiquitin ligases, and is able 
to ubiquitinate a wide variety of cytosolic and OMM proteins upon mitochondria 
depolarization116. It is encoded by a 1.3 Mb gene, localized on chromosome 6q25.2-
q27 and consists of 12 exons, and gives rise to the protein of 465 amino acids113. The 
Parkin locus (PRKN) is hyper-recombinable and it lies within FRA6E, the third most 
common fragile site in tumor issue, even if the potential role of Parkin in cancer is yet 
to be determined. 
Probably due to its fundamental role for cell survival, this protein is well 
conserved during evolution, allowing the characterization of its function and molecular 
mechanism. It is conserved not only in mammals, but also in invertebrates117.  
Ubiquitination has firstly been found as a post-translational modification which 
tipically marks proteins for degradation by the proteasome118. However, in the last 
years it emerged as a powerful tool to modulate proteins activity, via regulation of 
their subcellular localization and ability to interact with other proteins. In the process 
of ubiquitination, enzymes called ubiquitin ligases covalently attach ubiquitin  (Ub) 
and/or Ub chains to Lysine (Lys) residues or the N-terminal amino group (so-called 
“linear ubiquitination”) of a substrate protein. Ubiquitination is carried through the 
sequential action of three enzymes: E1 (Ub-activating), E2 (Ub-conjugating) and E3 
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(Ub-ligase). Ub itself contains different Lys residues, thus allowing the formation of 
different Ub chains119. In particular, Ub can form polyubiquitin chains of eight different 
linkages that mediate distinct biological functions120. The most common chain types 
are Lys48 and Lys63. In the ubiquitination pathway, usually the E3 enzymes show a 
higher specificity and tighter regulation in recognition of the substrates and control of 
its activity, compared to E1 and E2121. In this context, a common regulatory mechanism 
for many E3 ligases is the ability to self-catalyze the ubiquitination of themselves, 
through the so called “auto-ubiquitination”. There are three different E3 ligases 
families, which differ both on general structure and chemistry: RING-type (including U-
box ligases), HECT-type and RING-HECT hybrids. 
Post-translational modifications can influence each other and cooperate in 
regulating signaling pathways122. Phosphorylation is a reversible post-transcriptional 
modification which plays a regulatory role in almost every aspect of cell life, 
modulating the activity and the subcellular localization of proteins. Phosphorylation on 
Threonine, Serine and Tyrosine are the most common, however, recently also 
Histidine, Arginine and Lysine have found to undergo phosphorylation123. 
Phosphorylation and dephoaphorylation are catalyzed by protein kinases and 
phosphatases, respectively. More than five hundred different kinases have been 
identified in humans, and are classified into broad groups by their target substrate: 
protein kinases, lipid kinases, carbohydrate kinases124. Rukariotic protein phosphatase 
are represented by three distinct gene families: the PPP and PPM families, 
dephosphorylate dephosphorylate phosphoserine and phosphothreonine residues; 
protein tyrosine phosphatases (PTPs) dephosphorylate phosphotyrosine amino 
acids125. Interestingly, Tyrosin Kinases Inhibitors (TKIs) such as Imatinib and Nilotib, are 
used as effective therapy for patients affected by leukemia126,127. Recently, this drug 
resulted to be effective also in mouse models of Alzheimer’s Disease (AD)128. AD is a 
neurodegenerative disease characterized by the by accumulation of β‐amyloid 
(plaques) and hyper‐phosphorylated Tau (tangles). AD animals present high levels of 
insoluble Parkin and decreased Parkin-Beclin-1 interaction. Administration of TKIs to 
AD mice increases soluble Parkin leading to amyloid clearance and cognitive 
improvement. Although no Parkin mutations are found in AD, these studies 
demonstrate how manipulation of Parkin activity through the modulation of post-
transcriptional modifiers can be used as powerful therapeutic approach. 
Parkin structure consists of an N-terminal Ubiquitin-like domain (Ubl) and four 
zinc-finger RING-like domains: RING0, RING1, IBR and RING2129,130. A linker region 
connects the former segments. This region has no similarity with any known protein, 
so it is also called unique Parkin domain (UPD)131. Similar to other RBR enzymes, Parkin 
possesses a catylitic cystein within its RING2 domain (Cys431) that acts as an 
intermediate ubiquitin acceptor between E2 and the substrate132. It can form Lys63, 
Lys48, Lys11 and Lys6 Ub chains on its targets133. As other E3 ligases, Parkin can be 
ubiquitinated and ubiquitinates itself, by the attachment of Lys6 chains, which seem to 
play a role in its degradation134. 
Recently, several groups reported high resolution crystal structures for a Parkin 
fragment consisting of the RING0, RING1, IBR and RING2 domains and low resolution 
crystallography of the Ubl domain129. This structures allowed to better understand 
33 
 
how this protein, which is usually kept inhibited, gets activated. Moreover, it provides 
a rationale for many of the PD associated mutations. It seems that certain mutations 
compromise the structural integrity of the protein, whereas others interfere with the 
binding of the substrate or affect the cathalytic activity directly. We will deeper discuss 
about Parkin mutations in the next paragraph. 
Parkin structure shows how the RING0, RING1 and the IBR domains interact 
while the linker domain wraps around RING0-RING1 interface to reach the RING2. 
Normally, the Cys431is occluded in the RING0, and the E2-binding site on RING1 is 
blocked by the linker region, thus it results auto-inhibited130,135,136. Recent studies 
found that Parkin activation occurs upon PINK1 phosphorylation at Serine 65, which 
together with phospho-ubiquitin binding, causes a dramatical conformational change 
in the protein. In this context, the ubiquitin-E2-binding site on RING1 gets probably 
shifted proximal to the Cys431 acceptor site on RING2, activating Parkin55,137,138.  
Similar to other post-translational modifications, such as phosphorylation and 
acetylation, ubiquitination is also a reversible modification, mediated by a large family 
of deubiquitinating enzymes (DUBs). Interestingly, a large set of DUBs has opposite 
role of the E1/E2/E3 activity. Recent works, identified DUBs interacting with and 
regulating proteins associated with familial forms of PD, such as a-synuclein139 and 
Parkin134,140-142. In a recent review, we focused on how this proteins impact on Parkin 
function and actvity, and how they could be a target for PD treatments143. In particular, 
ataxin-3, USP8, USP15 and USP30 have been found to have a role in modulating Parkin 
auto-ubiquitination and Parkin-mediated mitophagy. By modulating the activity of 
these enzymes, it might be possible to modulate Parkin dependent mitophagy, and 
interfere with the pathogenic pathway. 
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Figure 7. The Pink/Parkin pathway in mitophagy. In healthy miochondria, Pink1 is targeted to the outer mitochondrial 
membrane (OMM) owing to its mitochondrial target sequencing (MTS). It is then imported to the inner mitochondrial membrane 
(IMM) through the TOM/TIM complex and cleaved by the TIM-associated mitochondrial processing peptidase (MPP). This MPP-
cleaved form of PINK1 is thereafter cleaved within its membrane-spanning domain by the presenilin associated rhomboid-like 
protease (PARL), and then rapidly undergo a proteolysis in a proteasome-dependent manner, allowing  very low level of 
endogenous PINK1 levels to prevent mitophagy of healthy mitochondria. However in depolarized mitochondria (after damages, or 
CCCP uncoupler treatment), TIM-mediated import of mitochondria is reduced, and Pink1 accumulates in the OMM. The OMM-
accumulation of Pink1 will lead to the selective recruitment of Parkin, its phosphorylation, and the phosphorylation of its ubiquitin 
at ser65. PINK1-dependent phosphorylation of both Parkin and ubiquitin is sufficient for full activation of Parkin E3 activity, and 
numerous OMM-located proteins will be target for Parkin-mediated ubiquitination (among them Mfn, TOM, VDAC or Fis1). These 
ubiquitinated proteins serve to recruit essential adapter proteins such as p62, HDAC6 or p97, which will tether the phagophore 
membrane and induce the mitophagic process143. 
 
3.3.2. Parkin mutations 
The first mutations identified in the parkin gene was found in 1998, carried by a 
Japanese family with AJ-RP113,144. In these patients were detected large homozygous 
deletions of the gene. After that, a lot of other parkin mutations were detected, both 
in cases of parkinsonism and PD: in cases of autosomal recessive early onset (<45 
years) parkinsonism, in isolates young onset cases presenting as fairly typical 
Parkinson’s disease and in familial cases with an age at onset of symptoms as late as 64 
years145. Nowadays, over 170 disease-linked mutations are known, spread trhoughout 
the parkin domains, and include multiplications, small deletions/insertions and a 
variety of point mutations in different ethnic groups. However the pathogenic 
relevance of these mutations is still controversial for several of these mutations. All 
these mutations have been listed in the Parkinson’s disease Mutation Database146. 
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Mutations have different effects on the function and structure of the protein. 
Recent bioinformatic advances allowed the modelling and the study of Parkin structure 
and function in the presence of several pathogenic mutations145. Mutations on the Ubl 
domain can affect Parkin activation and enzymatic function. Mutations in RING0 were 
disrupting the folding and stability of the protein structure and exhibited a reduction in 
free poly-Ub chain formation. RING1 harbours the E2 binding site, which usually is 
blocked by the linker region. Mutations in this domain affect Parkin ability to interact 
with E2. Other mutations affect Parkin ability to bind Ub or to translocate to damaged 
mitochondria. 
 
3.3.3. Mitochondria and Parkin interacting proteins 
A lot of proteins have been found to interact with Parkin, and include several 
E2-ubiquitin conjugating enzymes and many different Parkin substrates. Not all of 
Parkin interactors are involved in Parkin-dependent mitophagy, but they are linked to 
other Parkin functions within the cell. The first proteins found to interact with Parkin 
were UbcH7 and UbcH8147. In addition, also Ubc6 and Ubc7 on the ER were identified 
to interact with Parkin148. These protein link Parkin with the Ub-dependent 
proteasome machinery, allowing its ubiquitination and degradation. Accordingly, 
neuropathologic examination of Parkin-associated PD patients brains show 
accumulation of these substrates that cannot be ubiquitinated and subsequently 
degraded.  
Starting from 2006, many studies focused on PINK1/Parkin interaction. Indeed, 
three independent groups showed that these two proteins function in the same 
molecular pathway, with PINK1 acting upstream of Parkin149-151. A couple of years 
after, an elegant work by Poole et al. showed a strong genetic interaction between 
PINK1/Parkin pathway and mitochondrial fission/fusion machinery152. Using a fruit fly 
genetic interaction screening, a strong interaction has been found between fission 
protein Drp1 and PINK1/Pakin. Indeed, Drp1 loss-of-function mutations were lethal in 
absence of functional PINK1 or Parkin. Also, PINK1 and Parkin mutant phenotypes 
were rescued by increased Drp1 gene dosage or decreased Mfn gene dosage. These 
results were the first evidence of a genetic interaction between PINK1/Parkin pathway 
and of mitochondrial dynamics, and suggested that this pathway might promote 
mitochondrial fission (or inhibit mitochondrial fusion). After this study, Parkin has been 
demonstrated to directly interact with Drosophila Mfn, mediating its ubiquitination on 
the outer mitochondrial membrane54. Loss of Drosophila Parkin or PINK1 leads to an 
increased abundance of Mfn in vivo and hyperfused mitochondria. Increased protein 
level of Mfn in vivo and hyperfused mitochondria. Moreover, ubiquitination of Mfn 
operates as a molecular tag for targeting dysfunctional mitochondria for degradation54. 
On the other hand, Parkin was found to regulate the protein levels of Opa1 and Drp1, 
supporting the physiological relevance of Parkin in mitochondrial morphology 
regulation at different levels153,154. 
Recently, PINK1/Parkin pathway function and regulation became clearer, even 
if the scenario is not yet complete. The mitochondrial uncoupler carbonyl cyanide m-
chlorophenyl hydrazine (CCCP) causes mitochondrial depolarization, and has been 
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found to induce Parkin translocation155. Thus, this chemical has been broadly used to 
study Parkin translocation and Parkin-dependent mitophagy in living cells. Upon CCCP 
treatment, PINK1 is stabilized on impaired mitochondria where, through an unknown 
mechanism, recruits Parkin, which, in turn, promotes their elimination via 
mitophagy52,156,157. Although the signal triggering Parkin translocation is still not 
known, it has been recently demonstrated that PINK1 once stabilized on the OMM 
phosphorylates Parkin at Ser65, stimulating Parkin E3 ubiquitin ligase activity57. At the 
same time, PINK1 also phosphorylates Ub at Ser65, which binds Parkin and fully 
activates its Ub ligase function137,158. Mfn2 is another fundamental protein which gets 
phosphorylated by PINK1, and function as a mitochondrial receptor for Parkin on the 
OMM37. Once recruited to impaired mitochondria and activated by PINK1, Parkin 
selectively ubiquitinates pro-fusion protein Mfns54,159. Currently, the functional 
meaning of Parkin-dependent Mfns ubiquitination is unclear. Mfns ubiquitination 
might act as a molecular tag, which targets impaired mitochondria for degradation, 
thus providing an elegant biochemical mechanism for Parkin mediated mitophagy. 
Another possibility is that Parkin regulates Mfns steady state levels by targeting Mfns 
for proteasome dependent degradation, decreasing Mfn levels and mitochondrial 
fusion, and resulting ultimately in the accumulation of fragmented non-functional 
mitochondria, which eventually get eliminated by mitophagy. 
 
3.4. Animal models of Parkinson’s disease 
While in vitro studies are widely used for understanding molecular pathways in 
biologic systems, animal models allow the investigation of disease pathophysiology in 
vivo. In vivo models provide useful information and the possibility to test new 
therapeutic approaches. In the case of PD, initially, only toxin-based models were 
used, however recently also transgenic models are available160. 
Toxin-based models of PD aim to reproduce the phenotypical changes of 
human diseases in rodents or primates using pharmacological agents called 
neurotoxins, which induce selective loss of dopaminergic neurons. These toxins can be 
sistematically or locally administrated. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) and pesticites are the most common sistematically administrated neurotoxins. 
6-hydroxydopamine (6-OHDA) and lypopolisacharide are locally administrated to cause 
PD similar phenotypes. 
MPTP was the first drug identified to be linked to the loss of dopaminergic 
neurons and to parkinsonism features65. When MPTP gets metabolized, it gets 
converted into its active form 1-methyl-4-phenylpyridinium (MPP+), which is then 
carried by DA transporters into dopaminergic neurons of the SNpc, where it blocks 
mitochondrial complex I activity. Primates and mice were broadly treated with these 
toxins to study their effects and correlation with PD, since they show a reaction to the 
drug, which is similar to human.  
MPTP shares a high structural similarity with some pesticides like paraquat and 
rotenone66. Moreover epidemiological analysis showed that chronical exposure to this 
pesticides resulted in higher probability of developing PD. Rotenone is able to directly 
inhibit complex I activity, causing massive formation of ROS species. In rats, rotenone 
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was observed to cause selective degeneration of dopaminergic neurons as well as the 
formation of cytoplasmic inclusions similar to Lewy bodies. However, the effects of 
rotenone in animal models are variable, and the high toxicity of this drug often causes 
death of the animal. Paraquat is also a widely-used pesticide able toinduce PD 
phenotypes both in humans and animals. Once entered the cell through a transporter, 
paraquat acts as a redox cycling compound and generates massive oxidative stress. 
The first animal model ever generated which was reproducing PD hallmarks 
was based on local (i.e. intracerebral) administraton of 6-OHDA161. This compound is a 
hydroxylated analogue of DA, with an higher affinity for DA transporters, which 
transport the toxin inside dopaminergic neurons. Once in the neurons, 6-OHDA 
accumulates in the cytosol and generates highly reactive products, suggested to be 
peroxides, superoxides, hydroxyindoles, and quinones. Additionally, it can accumulate 
on mitochondria, where it inhibits complex I. The effects of this drug are highly 
reproducible, which represent an important aspect for the developing of new 
therapeutic approaches.  
Lipopolisaccharide (LPS) injection was the newest toxin-based model of PD, 
since inflammation has been found to be a key player in PD pathogenesis. LPS is a 
bacterial endotoxin, which causes intense tissue inflammation and usually is directly 
injected into the brain162. LPS per se is not toxic in neurons, its neurotoxicity is 
mediated by microglia activation and the release of cytotoxic molecules. 
These toxin-based models have been powerful tools for the understanding of 
PD pathogenesis, however the lack of age-dependent, slowly progressive lesions and 
the fact that Lewy bodies were not observed forced the studies to move to genetic 
models. The most used PD animals models have been Mus musculus and Drosophila 
melanogaster.  
 
3.4.1. Mouse genetic models of Parkinson’s disease 
 
Several genetic models of PD have been generated in mice. Mutations in the 
SNCA gene were the first associated to PD pathogenesis. To date, various transgenic -
synuclein mice have been generated, no significant nigrostriatal degeneration has 
been observed. Expression of wild-type, mutated or truncated  -synuclein in 
catecholaminergic neurons of mice didn’t show any neuronal death163. However 
expressing the protein in other region of the brain, led to time-dependent striatal DA 
content decrease, reduced tyrosine hydroxilase expression as well as some PD typical 
beahavioural hallmarks in those mice164. Interestingly, some of these models also show 
non-motor phenotypes associated with early PD stages, such as gastrointestinal 
alterations and olfactory deficits. 
Overexpression of LRRK2 in mice induces increased DA release in the striatum 
and motor hyperactivity, whereas the overexpression of a PD-linked mutant form 
causes  age-dependent reduction of the striatal content, release and uptake of DA, 
suggesting a role for this protein in DA transmission165. However, overexpression of 
wild-type LRRK2 or of its mutated form does not induce neuronal cell death in mice. 
LRRK2 KO mice are viable and do not show any increased susceptibility to MPTP. 
38 
 
Several Parkin or PINK1 embryonic KO mice have been generated. In both 
cases, no changes in DA neurons number or DA levels have been observed. 
Nevertheless, in PINK1 KO mice a mild mitochondrial and nigrostriatal deficit can be 
present, and they show increased susceptibility to oxidative stress and ROS 
production96,166. Parkin mice show higher susceptibility both to neurotoxins and 
inflammatory stimuli167,168. Similarly, DJ-1 KO mice do not show any dopaminergic 
neuronal loss, although they show  increased susceptibility to toxins and oxidative 
stress169. 
The lack of evindent phenotypes and potential compensatory mechanisms preventing 
neurodegeneration in conventional KO models, , promted scientists to generate 
conditional KO mouse models. By using tissue-specific Cre-expressing lines, exons or genes 
flanked by loxP sites in conditional mice can be deleted in desired tissues. By conditionally 
knocking out Parkin in adult mice, this approach allowed the generation of the first genetic 
model of PD showing progressive neurodegeneration170. Parkin flox/flox mice show 
progressive nigral neuron death 10 months after lentiviral-Cre nigral injection. The pathways 
revealed in this adult conditional parkin KO model may be quite relevant to PD pathogenesis 
and may represent a promising model to test new therapies. 
 
3.4.2. Drosophila as a model for human diseases 
 
In the past years, Drosophila melanogaster has emerged as one of the most 
effective model to study PD-related neurodegeneration in vivo171. Not only diseases-
related genes are conserved between fruit fly and human172, but in flies it is also 
possible to detect clusters of dopaminergic neurons and the metabolic pathways for 
DA syntesis are conserved. Compared to higher model organisms, Drosophila presents 
some attractive features, which make it suitable for studying complex biological 
pathways. First, flies can be maintained easily in large numbers in stock and 
populations without specialized instrumentation. Drosophila has a short life cycle, thus 
a large number of progeny can be easily produced in a short period. The fruit fly is 
widely used for genetic screens, due to its reduced 4-pairs chromosomes genome173. 
Moreover, genetic mutants can be easily generated through some well-known 
techniques, such as the P-element transposons for  loss-of-functions studies174,175, the 
UAS-GAL4 system for tissue-specific downregulation or overexpression of proteins176 
or site-specific gene integration via specific donor plasmids177. Furthermore, using X-
ray or other mutagenic agents, gives the possibility to rapidly generate large number of 
mutant stocks173. The already established disease models are also used for the screen 
of chemical compounds, which ameliorate the phenotype, in order to point out 
putative drugs to use as treatment in humans178. 
 
3.4.2.1. Drosophila as a model for Parkinson’s disease 
 
In 2000, the neuronal overexpression of wild-type or mutant human -
synuclein, which has no homologue in flies, has been induced using GAL4/upstream 
activation system, thus generating the first PD-like Drosophila model179. Transgenic 
flies showed age-dependent selective degeneration of dopaminergic neurons, as well 
as -synuclein-positive inclusions. Moreover they showed a progressive loss of 
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climbing ability, and they were positively responding to L-DOPA or DA-antagonists 
treatments. Exept for -synuclein, all the other PD-related genes have at least one 
homologue in flies. Loss of function mutations in PINK1, parkin, DJ-1 or LRRK2 fly 
homologues induce selective dopaminergic neuronal loss and motor deficits.  
Unlike humans, Drosophila has two DJ-1 homologues: DJ-1, which is 
expressed only in male germline, and DJ-1, which is ubiquitously expressed. DJ-1 KO 
flies show an increased susceptibility to cytotoxins, supporting the idea of the redox 
function of DJ-1. Mutations in these protein can cause accumulation of ROS in the 
brain. The results on LRRK2 KO and mutant flies are inconsistent, they do not show 
dopaminergic neurodegeneration. 
The first in vivo evidences showing that PINK1 and Parkin work in the same 
pathway, with PINK1 upstream of Parkin, came from studies in flies151,180. Parkin loss-
of-function mutants showed reduced life span, male sterility and severe defects in 
flight and climbing ability. They also show mitochondrial defects and indirect flight 
muscle degeneration, as well as reduced 26S proteasomal activity181,182. Drosophila 
mutant flies share phenotypic hallmarks with mammalian Parkin mutants, including 
dopaminergic neurodegeneration and mitochondrial defects151,180. Both mutants show 
disrupted cristae, resulting in reduced ATP levels and mtDNA, which then leads to 
flight muscle degeneration. It has been shown that transgenic overexpression of Parkin 
can compensate for PINK1 loss, whereas PINK1 overexpression cannot compensate for 
Parkin loss. Furthermore, double mutants show the same phenotypes as the single. All 
these data provided the first in vivo evidence that PINK1 and Parkin act in the same 
pathway, with Parkin downstream of PINK113,152,155.  
Genetic interaction experiments revealed putative additional components of 
the PINK1/Parkin pathway, like Rhomboid-7 and HtrA2/Omi183-185. Rhomboid-7, which 
is a mitochondrial protease homologue of PARL, could act as an . upstream component 
of the PINK1/Parkin pathway. Cleaving the mitochondrial target sequence of PINK1, 
Rhomboid-7 seems to allow PINK1 activity in the cytosol. Differently, the mitochondrial 
protease HtrA2/Omi acts downstream of PINK1, independently of Parkin. PINK1:HtrA2 
double mutants display an identical phenotype to PINK1 mutants alone, suggesting 
they act in a common pathway, whereas Parkin:HtrA2 double mutants display a 
stronger phenotype than either mutant alone, suggesting HtrA2 acts in a parallel 
pathway to Parkin. 
Interestingly, overexpression of human PINK1 or Parkin in mutant flies, 
abolishes the typical PD-like phenotypes, underlining the functional conservation of 
this pathway among species. This is supported by the facts that also patients’ 
fibroblasts display mitochondrial alteration and the neurons show Parkin translocation 
impairment186,187.  
Studies in Drosophila also provided the first evidence that PINK1 and Parkin 
promote mitophagy in vivo. This has long been debated, since all studies on the 
PINK1/Parkin mitophagic pathway have always been based on toxin-treated cell 
models and on PINK1 or Parkin overexpression. Through a proteomic in vivo approach, 
it has been proved that the turnover of mitochondrial proteins in wild-type flies was 
higher than in Parkin or PINK1 mutants, giving the final proof that this pathway induces 
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mitophagy in vivo188. Along with that, PINK1 was also found to phosphorylate Complex 
I on NDUFA10/ND42 subunit in vivo, thus regulating Complex I activity189. 
Interestingly, overexpression of Drp1 or downregulation of Marf, the fly 
homologue of mammalian Mfns, can rescue defects in mitochondrial morphology, cell 
death, muscle degeneration and locomotor deficits in PINK1 and Parkin loss of function 
Drosophila models13,152. Furthermore, increased Drp1 gene dosage can rescue the 
alterations in assembly of electron transport chain complexes and heterozygosity of 
Drp1 is lethal in a PINK1 or Parkin mutant background190. All these data support the 
hypothesis that manipulation of mitochondrial dynamics could provide a novel 
therapeutic strategy. 
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Abstract 
 
PARK2 gene encodes for an E3 ubiquitin ligase called Parkin. Loss-of-function 
mutations in this gene cause early onset of Parkinson’s disease, a neurodegenerative 
disorder of unknown etiology. The role of Parkin in neuron maintenance is still 
unknown, however it has been linked to the regulation of mitochondria dynamic. 
Recent works show that Parkin is selectively recruited to dysfunctional mitochondria, 
where it mediates their elimination via autophagy. Parkin translocation and Parkin-
mediated autophagy depend on the Serine/Threonine-protein kinase PINK1 (PTEN-
induced putative kinase 1), which is selectively stabilized on dysfunctional 
mitochondria where it recruits Parkin. However, it remains unknown which cellular 
signals or covalent modifications directly regulate Parkin translocation. 
Confocal microscopy of EYFP-Parkin transfected MEFs shows that Parkin has a 
cytoplasmic localization. After treatment with the mitochondrial uncoupling agent 
Carbonyl cyanide m-chlorophenyl hydrazine (CCCP), Parkin appears as spots that co-
localize with mitochondria. We found that pretreatment with the Ca2+ selective 
chelator BAPTA completely blocked Parkin translocation. We also found that inhibition 
of Ca2+ dependent phosphatase Calcineurin A (CnA) impaired Parkin recruitment and 
that CaN constitutive active expression was able to induce Parkin translocation per se, 
independently from PINK1. In accordance to the in vitro data, we showed that in the 
Drosophila fruit fly, Calcineurin constitutive active expression is able to rescue the 
climbing ability of a PINK1 in vivo model of Parkinson’s Disease.  
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Introduction 
 
Mutations in the PARK2 gene, encoding for the E3-ubiquitin ligase Parkin, is the 
most common cause of Autosomal-Juvenile Recessive-Parkinsonism1. The normal gene 
product has a neuroprotective role and it is involved in the degradation of 
dysfunctional mitochondria, through a process called mitophagy. Its action is closely 
related to the activity of another PD-related gene, PARK6, which encodes for a protein 
called PINK12-4.  
PINK1 is a Serine/Threonine kinase that is imported into mitochondria, where it 
gets cleaved by the inner membrane protease PARL and then eliminated by the 
proteasome5-7. On depolarized mitochondria, PINK1 accumulates on the outer 
mitochondrial membrane, where it recruits Parkin and activates its activity8-11. These 
events lead to proteasomal degradation of OMM proteins and eventually to selective 
autophagy of damaged mitochondria, a process called mitophagy12-15. 
In flies, PINK1 and Parkin mutants (knock out) develop reduced life span, male 
sterility, flight muscles degeneration, dopaminergic neurons loss, locomotor deficits 
and mitochondrial defects16,19. Combined mutation of both PINK1 and Parkin genes do 
not result in the worsening of the phenotype. Moreover, transgenic overexpression of 
Parkin can compensate for PINK1 loss, whereas PINK1 overexpression cannot 
compensate for Parkin loss. These data provided in vivo evidence that PINK1 and 
Parkin act in the same molecular pathway, with Parkin downstream of PINK116-18. In 
2008, Poole et al. showed a strong genetic interaction between PINK1/Parkin pathway 
and mitochondrial fission/fusion machinery20. By using a fruit fly-based genetic 
interaction approach, they found that loss-of-function mutations of Drp1, a pro 
mitochondrial fission protein, are lethal in a PINK1 or Parkin mutant (knock out) 
background. Conversely, PINK1 and Parkin mutant phenotype is suppressed by 
increased Drp1 gene dosage or by decreasing gene dosage of pro-fusion proteins OPA1 
and Mfn20. The biochemical explanation for the genetic interaction evidences 
illustrated by Poole et al. became clear when a direct biochemical interaction between 
Parkin ubiquitin activity and Mfn was discovered. In particular, Parkin was found to 
physically interact with and ubiquitinate the pro-mitochondrial fusion protein Mfn, 
providing the biochemical mechanism by which damaged mitochondria are labeled 
and sequestered by mitophagy21.   
Indeed, mitochondrial dysfunctions have been largely implicated in the onset of 
several human diseases. In particular, accumulation of dysfunctional mitochondria has 
been linked to neurodegenerative disorders, such as Parkinson’s disease, which is the 
second most common neurodegenerative disorder after Alzheimer’s disease and for 
which there is no cure. 
It has been widely demonstrated that Parkin translocation is PINK1 dependent, 
but the molecular mechanism behind PINK1 dependent activation of Parkin is still 
unclear. Recent works show that PINK1-mediated phosphorylation of Parkin and 
Ubiquitin at residue Serine 65 (Ser65) is necessary but not sufficient for Parkin 
translocation to defective mitochondria, and it is indeed fundamental for its E3-
ubiquitin ligase activity23-25. Moreover, PINK1 phosphorylates the pro-fusion protein 
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Mfn 2, which in turn gets stabilized on depolarized mitochondria and works as Parkin 
receptor26. 
All together these evidences suggest a tightly regulated control of the 
mitophagic process that operates at the post-transcriptional level via reversible 
modifications of proteins in the form of phosphorylation25,27-29, ubiquitination30-33, de-
ubiquitination34-39, sumoylation40,41 and nitrosylation42,43 and possibly other not yet 
characterized post-transcriptional events. 
Free Ca2+ concentration is important in the regulation of metabolic processes 
and for signal transduction. Accordingly, the cytoplasmic pool of Ca2+ is very limited 
and is tightly regulated by mitochondria and ER44-46. Ca2+ controls apoptosis and the 
opening of the permeability transition pore (PTP)47,48, a process linked to 
mitochondrial dysfunctions that increases the permeability of the mitochondrial inner 
membrane eventually leading to the release of pro-apoptotic factors from 
mitochondria47. Furthermore, Ca2+ dependent phosphorylation and dephosphorylation 
of targeted proteins affect their activity by impinging on subcellular localization, 
conformation and protein-protein interaction. For example, phosphorylation and de-
phosphorylation of mitochondria pro fission protein Drp1 regulates Drp1 translocation 
to mitochondria, an indispensable event for Drp1 dependent fission activity. In 
particular, translocation of Drp1 to mitochondria upon CCCP-induced depolarization is 
mediated by selective dephosphorylation of residue Serine 637, which is controlled by 
Ca2+ dependent phosphatase Calcineurin (CaN)49. On the other hands, protein kinase A 
(PKA) -dependent phosphorylation of Drp1 is retaining Drp1 in the cytoplasm during 
starvation, leading to elongated mitochondria, which cannot be eliminated by 
autophagy. Therefore, Ca2+ dependent regulation of phosphorylation and de-
phosphorylation of Drp1 operates as a reversible post-transcriptional modification that 
impinges on Drp1 translocation, in response to metabolic changes. 
 
Here, we show that Parkin translocation depends on Ca2+ and on the 
Ca2+/Calmodulin dependent phosphatase Calcineurin. Calcineurin activity is required 
for Parkin translocation, and it regulates Parkin-dependent mitophagy regardless of 
PINK1 presence. By using an in vitro and in vivo approach, we demonstrated that 
Calcineurin is indispensable and sufficient for Parkin translocation. Accordingly, we 
showed that Calcineurin constitutive active expression in the D. Melanogaster fruit fly 
rescues PINK1 deficiency in vivo. 
 
Results 
 
Parkin translocation and dependent mitophagy requires Calcineurin. 
Considering the fundamental role of Ca2+ in the regulation of proteins activity, we 
evaluated whether Parkin translocation and CCCP-dependent mitophagy depended on 
Ca2+ and was regulated by similar post-transcriptional modification that control Drp1 
translocation. 
We transfected cells with fluorescent mCherry-Parkin and with mitochondrial 
targeted YFP (mito-YFP) constructs and looked at Parkin subcellular localization. 
Consistent with previous studies14,50, we found that overexpressed Parkin mostly 
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located in the cytosol of wild-type MEFs (Fig. 1A). Upon CCCP treatment, Parkin 
translocates to fragmented mitochondria in the 80% of the cells (Fig. 1B-C). Pre-
treating cells with BAPTA, a Ca2+ chelator, abolished Parkin translocation, suggesting 
that its recruitment depended on Ca2+ (Suppl. Fig. 1A). Moreover, chemical inhibition 
of CaN with FK506 blocked Parkin translocation (Suppl. Fig. 1B). 
Taking advantage of the already existing CaN dominant negative (ΔCnAH151Q) 
and constitutive active (ΔCnA)51,52 mutants, we turned to a genetic approach to 
evaluate the effect of CaN inhibition upon Parkin recruitment. CaN exists as an 
heterodimer, composed of a catalytic subunit (CnA) that binds calmodulin and a 
regulatory subunit (CnB) that binds Ca2+. Ca2+/calmodulin activate CaN upon binding 
to the calmodulin-binding domain of CnA and inducing the dissociation of the 
autoinhibitory domain from the catalytic domain. CnA lacks the calmodulin binding 
domain in the catalytic subunit, due to the introduction of a stop codon at position 
392. Previous reports showed that ΔCnA increased fragmentation per se, by 
dephosphorylating Drp1 and inducing its translocation to mitochondria49. On the other 
hand, ΔCnAH151Q misses the calmodulin binding domain and the autoinhibitory domain 
and harbors an inactivating His-151 to Gln point mutation. It has been previously 
demonstrated that the inhibition of CaN efficiently blocked CCCP-induced 
fragmentation49. We cotransfected MEFs with mCherry-Parkin and ΔCnB plus 
ΔCnAH151Q and looked at Parkin localization. Interestingly, CCCP-induced Parkin 
translocation was impaired when in presence of the dominant negative mutant of CaN 
(Fig. 1D-E).  
To assess whether CaN played also a role in Parkin-dependent mitophagy9,53, 
we next performed a mitophagy assay in presence of the dominant negative mutant of 
CaN. ΔCnAH151Q expression significantly delayed CCCP-induced mitophagy (Fig. 1F). 
Taken together these data showed that pharmacological and genetic inhibition 
of CaN is sufficient to prevent Parkin translocation and CCCP-induced mitophagy. 
 
Parkin-dependent mitophagy is regulated by Calcineurin and PINK1-
dependent phosphorylation. Different studies linked Parkin translocation and 
mitophagy to PINK1 activity11,21,54. Ideed, PINK1 directly phosphorylates Parkin and 
Ubiquitin (Ub) at Serine 65, which is required for Parkin activity23,28,29,55. We generated 
phopsho-mimetic Parkin and phopsho-mimetic Ub at Serine 65 (Parkin S65E and Ub 
S65E, respectively) and investigated the effect of CaN constitutive active ΔCnA, and 
dominat negative ΔCnAH151Q expression upon Parkin translocation. In wildtype MEFs 
transfected with Ub S65E, Parkin S65E localized to the cytosol and translocated to 
impaired mitochondria upon CCCP treatment (Suppl. Fig. 2A). In this condition, we did 
not observe a constitutive localization of Parkin S65E on mitochondria in untreated 
cells, indicating that PINK1-dependent phosphorylation of Parkin and Ubiquitin might 
not be sufficient for Parkin recruitment.   
As expected, in PINK1 -/- MEFs transfected with Ub S65E, Parkin S65E also 
localized to the cytosol and translocated to impaired mitochondria upon CCCP 
treatment (Fig. 2C-D). In presence of CaN dominant negative ΔCnAH151Q, Parkin S65E 
did not translocate to mitochondria upon CCCP intoxication (Fig 2C-D). Interestingly, in 
cells transfected with Ub S65E and CaN constitutive active ΔCnA, Parkin S65E 
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translocated to mitochondria 24hrs after transfection without CCCP intoxication (Fig. 
2A-B). Also, 48 hours after transfection, mitochondria were clumped and localized 
around the perinuclear area, a structural feature preceding mitophagy (Fig. 2A). 
Taken together, these observations supported the hypothesis that CaN, in 
addition to PINK1, is required for Parkin translocation.  
 
Parkin translocation is induced by Calcineurin, in a PINK1-independent 
manner.  
In order to further investigate the role of CaN in the regulation of Parkin 
translocation in the context of PINK1 deficiency, we looked at Parkin translocation in 
PINK1 -/- cells. Interestingly, in the presence of the constitutive active CaN mutant 
ΔCnA, Parkin constitutively co-localized with mitochondria in almost 80% of the 
analyzed cells (Fig. 3A-B). Moreover, CCCP-induced mitophagy was significantly 
enhanced (Fig. 3C). 
As already reported, Parkin does not translocate to mitochondria upon CCCP 
treatment in the absence of PINK1 (Fig. 3D-E). However, expression of constitutive 
active CaN was sufficient to promote Parkin translocation in PINK1 -/- cells, even in the 
absence of CCCP intoxication (Fig. 3D-E). Accordingly, mitophagy was enhanced in 
PINK1 -/- cells expressing CaN constitutive active (Fig. 3F). 
To conclude, our data suggest that CaN activation can bypass PINK1 
requirement in the induction of Parkin translocation and CCCP-induced mitophagy. 
 
Constitutive active Calcineurin in Drosophila rescues PINK1B9 climbing ability.  
PINK1 and Parkin flies mutants (knock out) recapitulate several features of PD, 
including characteristic locomotor defects in flight and climbing ability, as well as 
degeneration of thorax muscle and of dopaminergic neurons. Combined mutation of 
both PINK1 and Parkin genes induce the same overall phenotype. Also, PINK1 mutant 
phenotype can be rescued by overexpression of Parkin, whereas Parkin mutant 
phenotype cannot be rescued by PINK1 overexpression. Together these evidences 
have been interpreted as PINK1 and Parkin interacting functionally in a linear pathway 
with PINK1 operating upstream Parkin16,17,56. With that in mind and to assess the role 
of CaN in this pathway, we evaluated the effect of CaN costitutive activation and 
inhibition in vivo in PINK1 mutant background. We therefore turned to a well-
established locomotor assay previously used to study PINK1-Parkin genetic 
interactions in vivo. In such assay, 10 flies for each strain were collected in a vertical-
positioned plastic tube positioned with a line drawn at 6 cm from the bottom of the 
tube and under a light source. After tapping the flies to the bottom of the tube, the 
flies that successfully climbed above the mark after 10 seconds were counted (Fig. 4A). 
As already reported, PINK1B9 mutant (knock out) flies performed poorly in the 
climbing assay compared to wild type (Fig. 4B). Parkin overexpression (Pk OE) partially 
rescued PINK1B9 mutants climbing defects (Fig. 4B), as expected. Interestingly, 
overexpression of CaN constitutive active (CanA-14F) almost completely rescued 
PINK1B9 mutant climbing defects (Fig. 4B) and inhibition of CaN with specific inhibitor 
FK506 abolished the protective effect of CaN (Fig. 4C). Finally, FK506 administration 
partially blocked the effect of Parkin overexpression in PINK1 mutant phenotype (Fig. 
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4D), further indicating that CaN is an indispensable requirement for Parkin activation 
downstream PINK1. 
Thus, our results suggest that CaN plays a fundamental, indispensable role in 
the control of Parkin translocation and Parkin-dependent mitophagy in vitro and that 
its activation has a physiological impact in an in vivo PINK1 model of PD.  
 
Conclusion and discussions 
 
Mitophagy, a selective kind of autophagy during which defective mitochondria 
are recognized and degraded, depends on PINK1/Parkin, two genes which mutations 
have been linked to the onset of an autosomal recessive juvenile form of Parkinson’s 
Disease. PINK1 is stabilized on depolarized mitochondria where it recruits Parkin. Once 
on mitochondria, Parkin ubiquitinates a subset of outer mitochondrial membrane 
(OMM) resident proteins, thus selecting unfunctional, depolarized mitochondria for 
autophagy dependent degradation. Up to now, it is still unclear how Parkin 
translocation to depolarized mitochondria is regulated.  
Here we show a fundamental role for the Ca2+-Calmodulin dependent 
Calcineurin in the regulation of this pathway. 
As shown in previous studies14,21, Parkin is mostly cytosolic, but it translocates 
to a subset of depolarized mitochondria upon CCCP intoxication (Fig 1A-B). CCCP has 
additional effects beside mitochondrial depolarization, which includes increasing in 
cytoplasmic Ca2+. Ca2+ regulates many processes spanning from cells origin at 
fertilization to cellular differentiation and reprogramming, to cell demise. The 
pleiotropic role of Ca2+ led to the present concept as an essential messenger in cell life. 
The many ways by which Ca2+ impinges on cell physiology include the activation of 
proteins that are required for post-transcriptional modifications of molecular targets, 
which further amplify the signaling cascade. For instance, Ca2+-activated phosphatase 
CaN is required for Drp1 mitochondria recruitment and subsequent mitochondria 
fission.  
With that in mind, we embarked on a project that aimed at investigating the 
potential role of Ca2+ and Ca2+-dependent post-transcriptional modifications in the 
regulation of Parkin translocation and Parkin-dependent mitophagy. The investigation 
of such topic is extremely relevant at present, as the identification of novel regulators 
of Parkin translocation and activity might be instrumental in characterizing novel 
therapeutic targets that enhance mitophagy downstream PINK1/Parkin. Indeed 
accumulation of unprocessed, undegraded proteins and organelles is a common 
hallmark in different neurodegenerative diseases, including PD. 
In this study, we found that both chemical and genetic inhibition of CaN results 
in impaired Parkin recruitment, indicating that CaN is an indispensable requirement for 
Parkin translocation (Suppl. Fig. 1A-B and Fig. 1D-E). Furthermore, the phospho-
mimetic mutant Parkin S65E does not translocate to mitochondria in untreated cells 
(Suppl. Fig. 2A) and CCCP-induced translocation is blocked in presence of dominant 
negative CaN (Suppl. Fig. 2B).  
We also found that constitutive active CaN is able to induce Parkin 
translocation per se, independently of CCCP intoxication (Fig. 3A-B). Accordingly, CaN 
 50 
 
inhibition results in impairment CCCP-induced mitophagy (Fig. 1F), while its activation 
enhances mitochondrial degradation (Fig. 3C). Different studies underlined the 
importance of PINK1 for Parkin translocation and activation9,11,21,24. PINK1 
phosphorylates Parkin and ubiquitin in order to regulate Parkin E3-ubiquitin ligase 
activity28,55,57. Indeed, in line with published data, we found that Parkin does not 
translocate in PNK1 -/- MEFs upon CCCP treatment (Fig. 3D-E). However, the presence 
of CaN constitutive active is sufficient to induce Parkin translocation in the absence of 
PINK1 (Fig. 3D-E).  
These findings suggest that CaN activity is necessary and sufficient to induce 
Parkin translocation to mitochondria and that CaN activation can bypass PINK1 
requirement in the induction of Parkin translocation and CCCP-induced mitophagy. 
According to the current model, PINK1 gets sequentially imported into the IMM 
of healthy mitochondria, where it is cleaved by proteases and eventually degraded in a 
proteasome-dependent manner58,59. In this scenario, Parkin stays cytosolic and it is not 
active. However, upon mitochondrial depolarization, PINK1 is stabilized on the OMM 
where it recruits and phosphorylates Parkin21,60. Parkin phosphorylation leads to its 
activation and subsequent mitophagy23,25. However, the mechanism by which Parkin 
was recruited to mitochondria was still not clear. Our data suggest that mitochondrial 
depolarization, followed by mitochondrial Ca2+ release, activates Calcineurin, which 
dephosphorylates Parkin, triggering its translocation to mitochondria (Fig. 5). 
Comforted by the findings that CaN plays a role in regulating stress induced 
mitophagy in vitro, we next turned to a well-established in vivo model system to 
evaluate the physiological significance of CaN inhibition and/or activation in a PINK1 
deficient model of PD (Fig. 4A). Parkin overexpression in a PINK1 mutant (knock out) 
background is able to rescue PINK1 mutant phenotype, as previously reported (16,17 
and Fig. 4B). We reasoned that enhancement of CaN activity in vivo would also 
ameliorate PINK1 mutant phenotype by enhancing Parkin translocation and activity. 
Indeed, CaN constitutive active expression in PINK1 mutant background rescues PINK1 
mutant flies climbing deficiency (Fig. 4B). This effect was specific for CaN, as chemical 
inhibition of CaN with FK506, abolished the rescue (Fig. 4C). Importantly, FK506 
administration partially blocked the rescuing effect of Parkin overexpression in PINK1 
mutant flies (Fig. 4D), further suggesting an indispensable role for CaN in Parkin 
activation downstream PINK1.  
Further experiments are required to identify the specific Parkin residue/s that 
is/are de-phosphorylated by CaN. An in silico analysis identified Serine 407 and 
Threonine 410 as potential candidates for CaN dependent de-phosphorylation (Suppl. 
Fig. 4A). Encouraged by this analysis, we generated two phospho-mimetic Parkin 
mutants (Ser407Asp and Thr410Asp, respectively), and assessed their ability to 
translocate to mitochondria upon CCCP intoxication. In this analysis, translocation of 
phospho-mimetic Ser407Asp Parkin mutant was partially impaired, whereas phospho-
mimetic Thr410Asp Parkin completely failed to translocate upon CCCP treatment 
(Suppl. Fig. 4B). To convincingly prove that these are the residues that are de-
phosphorylated by CaN, we are in the process of performing mass-spectrometry 
analysis of Parkin protein that has been pulled down from untreated cells and 
following CCCP intoxication (Suppl. Fig. 4C). At the present we were able to pull down 
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flag-tagged Parkin from MEFs stably expressing pMSCV-Flag-Parkin vector. Western 
blot and Silver stain analysis (Suppl. Fig. 4C) revealed the purity of the isolated protein. 
Mass-spectrometry analysis of these samples will be instrumental to reveal Parkin 
post-transcriptional modifications involved in the regulation of its translocation. 
Protein functions can be regulated by post-translational modifications 
(phosphorylation Ubiquitination, Acethylation, Nitrosylation, Sumoylation). In that 
respect, scientific research is exploring the effects of post-translational modifications 
as starting point for the developing of novel therapeutic targets for human diseases. In 
particular, Tyrosine Kinases Inhibitors (TKIs) such as Imatinib and Nilotib, are used as 
effective therapy for patients affected by leukemia61,62. Recently, this drug resulted to 
be effective also in mouse models of Alzheimer’s Disease (AD)63. AD is a 
neurodegenerative disease characterized by the accumulation of β‐amyloid (plaques) 
and hyper‐phosphorylated Tau (tangles). AD animals present high levels of insoluble 
Parkin and decreased Parkin-Beclin-1 interaction. Administration of TKIs to AD mice 
increases soluble Parkin leading to amyloid clearance and cognitive improvement. 
Although no Parkin mutations are found in AD, these studies demonstrate how 
manipulation of Parkin activity through the modulation of post-transcriptional 
modifiers can be used as powerful therapeutic approach. 
Ubiquitination is also emerging as a powerful tool to modulate proteins activity, 
via regulation of protein subcellular localization and/or ability to interact with other 
proteins. The counteracting activity of ubiquitin ligases and deubiquitinating enzymes 
(DUBs) mediate and regulate protein ubiquitination. Specifically in the context of 
PINK1/Parkin pathway, much effort has been put to identify specific DUBs that 
counter-act the ubiquitin-ligase activity of Parkin and impact mitophagy35. These 
enzymes are therefore emerging as extremely attractive druggable candidates.  
By exploring the role of CaN in Parkin translocation and stress induced 
mitophagy and in vivo in a PINK1 model of PD, this work ultimately identified a novel 
druggable target and has the potential to widen up medical intervention for the 
treatment of PD. 
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Materials and Methods 
 
Cells  
Mouse embryonic fibroblast cells (MEFs) were cultured in Dulbecco's modified Eagle medium 
(DMEM) (Gibco) supplemented with 1% penicillin/streptomycin, with 10% Fetal Bovine Serum 
(FBS), with L-glutammine, and 1% non-essential amino acids solution and incubated at 37°C, in 
a humidified 5% CO2 atmosphere. PINK1 -/- MEFs cell line was gently provided by Prof. F. 
Cecconi, IRCSS F. Santa Lucia and Department of Biology, University of Rome Tor Vergata. 
Transfection was performed using Transfectin™ Lipid Reagent (BIO-RAD) following 
manufacturer instruction. 4-6 hours after transfection the medium was changed and cells were 
processed for the indicated experiment 24/48 hours after. This protocol has been used both 
for confocal microscope analysis and for protein assays. When indicated, cells were treated 
with 10 μM CCCP for 3 hours.  
 
Constructs and Molecular Biology 
mCherry-Parkin and HA-Ubiquitin plasmids were obtained from Addgene. Site directed 
mutagenesis, using QuickChange II XL kit (Agilent) and the following primers were used to 
generate a point mutation on Serine 65 in Parkin (S65E): F-MutpkSer65E (5’- GAC CTG GAT 
CAG CAG GCC ATT GTT CAC ATT GT- 3’) and R-MutpkSer65E (5’-ACA ATG TGA ACA ATG GCC 
TGC TGA TCC AGG TC- 3’). The same protocol was used for Ubiquitin point mutation at 
Serine65, and the following primers were used: F-MutUbSer65E (5’-ATC CAG AAG GAG GAG 
ACC CTG CAC CT- 3’) and R-MutUbSer65E (5’- AGG TGC AGG GTC TCC TCC TTC TGG AT- 3’). 
These constructs were named Parkin S65E and Ub-S65E.  
The following primers were used to generate a point mutation on Threonine 410 and Serine 
407, using the same Agilent mutagenesis kit: Thr410Ala forward (5’- GAA GCA GCC TCC AAA 
GAA GCC ATC AAG AAA ACC ACC AAG- 3’) and reverse (5’ -CTT GGT GGT TTT CTT GAT GGC TTC 
TTT GGA GGC TGC TTC- 3’); Thr410Asp forward (5’- GAA GCA GCC TCC AAA GAA GAC ATC AAG 
AAA ACC ACC AAG- 3’) and reverse (5’- CTT GGT GGT TTT CTT GAT GTC TTC TTT GGA GGC TGC 
TTC- 3’); Ser407Ala forward (5’- GCT CGT TGG GAA GCA GCC GCC AAA GAA ACC ATC AAG AAA- 
3’) and reverse (5’- TTT CTT GAT GGT TTC TTT GGC GGC TGC TTC CCA ACG AGC- 3’); Ser407Asp 
forward (5’- GCT CGT TGG GAA GCA GCC GAC AAA GAA ACC ATC AAG AAA- 3’) and reverse (5’- 
TTT CTT GAT GGT TTC TTT GTC GGC TGC TTC CCA ACG AGC- 3’). These constructs were named 
Parkin Thr410Ala, Thr410Asp,  Ser407Ala and Ser407Asp, respectively. 
Flag-tagged Parkin was inserted into pMSCV vector by using the pCR®8/GW/TOPO® TA 
Cloning® Kit (Invitrogen). To perform the pCR®8/GW/TOPO® cloning, Flag-Parkin construct was 
PCR amplified from pEYFP-C1-Parkin vector (available in the lab) using the following primers: 
Parkin-forward-BglII-Flag (5’ -AGCT AGATCT ATG GAT TAC AAG GAT GAC GAC GAT AAG ATG 
ATA GTG TTT GTC AGG- 3’) and EYFP-reverse (5’ -ACC ATG GTG AGC AAG GGC GAG- 3’).  
pcDNA3.1-ΔCnAH151Q (ΔCnAH151Q), pDCR-HA-ΔCnA (ΔCnA), pDCR-HA-CnB and mito-YFP were 
plasmids already available in the lab and described in 49,64,65. 
 
Imaging 
For confocal imaging experiments of Parkin localization, transfected MEFs cells were seeded 
onto 24 mm-round glass coverslips in 6-well culture plates.  Cells were co-transfected with one 
of the mCherry-constructs together with mito-YFP. When indicated, cells where cotransfected 
with CnB, the regulatory Calcineurin (Cn) domain, plus ΔCnA (constitutively active Cn) or 
ΔCnAH151Q (dominant negative mutant of Cn), and/or one of the Ubiquitin constructs (Ub or 
UbS65E). Image analysis was performed using ImageJ. These constructs were then excited 
using 561 or 488 laser and using a UPlanSApo 60x/1.35  objective (iMIC Andromeda). Stack of 
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images separated by 0.25 0.4μm along 410 the z axis were acquired. The quantification was 
performed as calculation of the percentage of cells with Parkin puncta on mitochondria or 
through an ImageJ plugin for colocalization quantification (see following paragraph for details). 
 
Image analysis using Squassh 
To quantify Parkin colocalization with mitochondria, we created maximum-intensity 
projections of z-series with 0.25 µm increments. Quantification was then performed by using 
‘Squassh’ (Segmentation and QUAntification of Subcellular SHapes), a new plugin compatible 
with the imaging processing softwares ImageJ or Fiji, freely available from http://mosaic.mpi-
cbg.de/?q=downloads/imageJ66. Squassh is a segmentation method that enables both 
colocalization and shape analyses of subcellular structures in fluorescence microscopy images. 
For our analysis, segmentation was performed with the minimum intensity threshold for the 
first channel set to 0.35, for the second to 0.15 and the regularization weight to 0.015. Among 
the three different colocalization coefficients (Csignal, Cnumber and Csize), we preferentially used 
Cnumber.  
 
Immunoblotting 
At the established time points, the medium was removed and MEFs washed with PBS. After 
withdrawing PBS, cells were scraped off the wells using a plastic cell scraper, they were 
resuspended in 1,5 ml of cold PBS and they were centrifuged at 4’000 rpm at 4 °C for 5 min. 
Supernatant was discarded and then the pellet was resuspended in an appropriate volume of 
radioimmunoprecipitation assay (RIPA) buffer (RIPA buffer for 100 ml: 0,79 g of Tris base, 0,9 g 
of NaCl, 10 ml of NP-40 10%, 2,5 ml of Na-deoxycholate 10%, 1 ml of EDTA 0,1 M, and distilled 
water to 100 ml volume; adjust pH to 7.4) with freshly added protease inhibitor (PIC). Cells 
were kept on ice for 30 mins. The lysate was then centrifuged at 14’000 x g for 15 mins at 4 °C 
and then stored at -20 °C. 
Protein concentrations of samples have been quantified using Pierce™ BCA Protein Assay Kit 
(ThermoFisher SCIENTIFIC). 
NuPAGE® LDS Sample Buffer (Invitrogen) and 2-Mercaptoethanol (SIGMA) were mixed to 
samples and proteins were then denaturated at 95°C for 15 min. Samples were then 
centrifuged at 13300 rpm for 8 sec and separated on NuPAGE 4-12% Bis-Tris gels (NuPAGE®, 
Invitrogen) applying a constant voltage of 135 mV for 1 hour and 30 min. After electrophoresis 
run, proteins were electroblotted from gel matrix onto polyvinylidene fluoride transfer 
membranes (Thomas Scientific). The protein transfer was performed applying a constant 
voltage of 100 mV for 1 hours at 4 °C. 
The following antibodies were used: anti-PMP70 (Sigma, 1:1000), anti-ATP5A (Abcam, 1:1000), 
anti-Actin (Chemicon, 1:20’000), anti-PINK1 (Cell Signalling, 1:100), anti-HA (Roche, 1:1000), 
anti-Parkin (Santa Cruz Biosience, 1:400).  
 
Statistical analysis 
All data are expressed as mean ± SE from at least three different experiments unless specified 
otherwise (Microsoft Office Excel and Origin 7.0 Professional). Statistical significance was 
measured by an unpaired t-test and p-values are specifically. 
 
Fly stocks and breeding conditions 
Flies were raised on standard cornmeal medium and were maintained at 23° C, 70% relative 
humidity, on a 12 h light : 12 h dark cycle. 
We used ActGal4 standard lines, generous gifts from Dr. Alexander Whitworth (University of 
Sheffield) as control. PINK1B9 and PK OE lines were already described before16,19 and were a 
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kind gift from Dr. Alexander Whitworth. CanA-14F line was already described before67 and was 
a kind gift by Prof. Pascal Dijkers. 
 
Climbing assay 
The climbing assay (negative geotaxis assay) was used to assess locomotor ability (Fig . 4A). 
Climbing data were obtained from groups of untreated wildtype, untreated PINK1B9, FK506-
treated wildtype, and FK506-treated PINK1B9.  Briefly, 10 flies for each strain were collected in 
a vertically-positioned plastic tube (length 12 cm; diameter 5 cm) with a line drawn at 6 cm 
from the bottom of the tube. Flies were gently tapped to the bottom of the tube, and the 
number of flies that successfully climbed above the 6-cm mark after 10 seconds was noted. 
Fifteen separate and consecutive trials were performed for each experiment, and the results 
were averaged. At least 30 flies were tested for each genotype or condition.   
The number of flies that could climb unto, or above, this line within 10 or 20 seconds was 
recorded and expressed as percentage of total flies. 
 
In silico analysis 
In silico analysis were performed by using Motif Scan (http://myhits.isb-sib.ch/cgi-
bin/motifscan) and NetPhos 2.0 (http://www.cbs.dtu.dk/ services/NetPhos/). Human, murine 
and Drosophila Parkin protein sequences were aligned and compared for highly conserved 
residues. 
 
Immunoprecipitation 
For immunoprecipitation, cells were lysed in the following buffer: 10 mM Tris HCl pH 7.9, 340 
mM Sucrose, 3 mM CaCl2, 2 mM Mg(OAc), 0.1 mM EDTA, 1 mM DTT, 0.5% NP-40, protease 
inhibitors, phosphatase inhibitors. Anti-FlagM2 (Sigma) or anti-IgG Mouse (Sigma) were 
incubated overnight with the lysates. Protein A agarose beads (Roche) were conjugated 
overnight with the lysates. Beads were washed using the following washing buffer: 20 mM 
HEPES pH 7.9, 250 mM KOAc, 1% Tryton, 10% Glycerol, 3 mM EDTA, 1 mM DTT. The protein 
was eluted using the following buffer: 20 mM HEPES pH 7.9, 100 mM KOAc, 10% glycerol, 
3mM EDTA, 200ug/ml Flag peptide. The samples were then analyzed by westernblot or Silver 
stain (SilverQuest™ Silver Staining Kit, Invitrogen). 
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Figure legends 
 
Figure 1: Parkin translocation to mitochondria is blocked upon Calcineurin genetic 
inhibition. (A) Wildtype MEF cells transfected with mCherry-Parkin and mito-YFP as 
described in Materials and methods, treated with DMSO as control or 10 M CCCP (B). 
The panels at the right show enlarged views of the boxed areas. Arrows indicate 
mitochondria that colocalize with overexpressed Parkin. (C) mCherry-Parkin 
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colocalization with mitochondria expressed as percentage of cells with Parkin on 
mitochondria (upper panel) for at least ≥ 300 cells or Squassh colocalization parameter 
for at least ≥ 50 images (bottom panel). At least 4 independent experiments were 
performed for both quantifications. (D) MEF cells transfected with mCherry-Parkin and 
mito-YFP plus empty vector (top) or CnB and CnAH151Q (bottom). Cells were treated 
with DMSO or CCCP when indicated. The panels on the right show enlarged views of 
the boxed areas. Arrows indicate mitochondria that colocalize with overexpressed 
mCherry-Parkin. (E) mCherry-Parkin colocalization with mitochondria were scored as in 
Fig. 1 C. (F) Wildtype MEFs transfected with mCherry-Parkin plus empty vector or CnB 
and CnAH151Q as indicated, were treated with 10 M CCCP at different time points 
and lysed. Lysates were separated by SDS–PAGE and immunoblotted using the 
indicated antibodies. Ratio between the densitometric levels of ATP5 and those of 
PMP70 in MEFs transfected as indicated on the upper panel. One representative 
experiment at least three independent repetitions performed is shown in the lower 
panels.  
 
Figure 2: Parkin translocation is induced by Calcineurin constitutive active mutant, in 
a PINK1-independent manner. (A) Wildtype MEFs transfected with mCherry-Parkin 
and mito-YFP plus empty vector (top) or CnB and CnA (two bottom panels). Cells 
were treated with DMSO or CCCP when indicated. The panels on the right show 
enlarged views of the boxed areas. Arrows indicate mitochondria that colocalize with 
mCherry-Parkin. (B) mCherry-Parkin colocalization with mitochondria were scored as in 
Fig. 1 C. (C) Wildtype MEFs transfected with mCherry-Parkin plus empty vector or 
CnB and CnA as indicated, were treated with 10 M CCCP at different time points 
and lysed. Lysates were separated by SDS–PAGE and immunoblotted using the 
indicated antibodies. Ratio between the densitometric levels of ATP5 and those of 
PMP70 in MEFs transfected as indicated on the upper panel. One representative 
experiment at least three independent repetitions performed is shown in the lower 
panels. (D) PINK1 -/- MEFs transfected with mCherry-Parkin and mito-YFP plus empty 
vector (left) or CnB and CnA (right) as indicated. Cells were treated with DMSO or 
CCCP when indicated. The panels on the bottom show enlarged views of the boxed 
areas. Arrows indicate mitochondria that colocalize with mCherry-Parkin. (E) mCherry-
Parkin colocalization with mitochondria in PINK1 -/- MEFs were scored as in Fig. 1 C. (F) 
PINK1 -/- MEFs transfected with mCherry-Parkin plus empty vector or CnB and CnA 
as indicated, were treated with 10 M CCCP at different time points and lysed. Lysates 
were separated by SDS–PAGE and immunoblotted using the indicated antibodies. 
Ratio between the densitometric levels of ATP5 and those of PMP70 in MEFs 
transfected as indicated on the upper panel. One representative experiment at least 
three independent repetitions performed is shown in the lower panels. 
 
Figure 3: Parkin-dependent mitophagy is regulated by Calcineurin and PINK1-
dependent phosphorylation. (A) Wildtype MEFs transfected with mCherry-Parkin S65E 
mutant and mito-YFP plus Ub S65E mutant, CnB and CnA. Cells were imaged 24 or 
48 hours after transfection, as indicated. The panels on the right show enlarged views 
of the boxed areas. (B) mCherry-Parkin colocalization with mitochondria were scored 
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as in Fig. 1 C. (C) PINK1 -/- MEFs transfected with mCherry-Parkin S65E, Ub S65E and 
mito-YFP plus empty vector (left) or CnB and CnAH151Q (right) as indicated. Cells 
were treated with DMSO or CCCP when indicated. The panels on the bottom show 
enlarged views of the boxed areas. Arrows indicate mitochondria that colocalize with 
mCherry-Parkin. (D) mCherry-Parkin colocalization with mitochondria were scored as 
in Fig. 1 C. 
 
Figure 4: Constitutive active CnA in Drosphila rescues PINK1B9 climbing ability. (A) 
Schematic representation of the climbing assay. 10 flies were put into a tube in a dark 
room. A light was put on the top of the tube. After tapping the flies on the bottom of 
the tube, the number of flies that successfully climbed above the 6-cm mark after 10 
seconds was noted. (B) Evaluation of the climbing ability of flies of the indicated 
genotype. Climbing test was performed as described. Bar graph represents the number 
of flies that successfully climbed above the 6-cm mark in 10 seconds. (C-D) 
Quantification of the climbing ability of flies of the indicated genotype. Flies were 
treated as indicated for 48 hours with DMSO or different FK506 concentrations.  
 
Figure 5: Schematic representation of the pathway regulating Parkin translocation 
and mitophagy. Mitochondrial membrane potential drives PINK1 import into healthy 
mitochondria through the TOM and TIM complexes. Once on the IMM, PINK1 gets 
cleaved by MPP and PARL and eventually degraded by the ubiquitin-proteasome 
system. In this scenario, CaN is not active and Parkin is kept in the cytosol (left panel). 
Mitochondria depolarization is followed by cytosolic Ca2+ rise, which in turn activates 
CaN. CaN dephosphorylates Parkin which then translocates to depolarized 
mitochondria. Here, PINK1 is stabilized on the OMM where it phosphorylates Parkin 
and Ubiquitin. Phospho-Parkin undergoes a closed-to-open conformational change, 
binds to phospho-ubiquitin, and becomes fully active. In this context, Parkin 
ubiquitinates its targets on the outer mitochondrial membrane and leads to 
mitochondrial autophagy (right panel) 
 
Suppl. Fig. 1: Parkin translocation is Ca2+/CaN-dependent. (A) Wildtype MEFs 
transfected with mCherry-Parkin and mito-YFP. Cells were treated with 40 M BAPTA 
for 30 min or with 40 M BAPTA for 30 min prior to 3 hours CCCP treatment as 
indicated. The panels on the right show enlarged views of the boxed areas. (B) 
Wildtype MEFs transfected with mCherry-Parkin and mito-YFP. Cells were pretreated 
with 0.6 M FK506 for 30 min before imaging or before 3 hours CCCP treatment, as 
indicated. The panels on the right show enlarged views of the boxed areas. 
 
Suppl. Fig. 2: In wildtype MEFs, Parkin S65E behaves as wildtype Parkin. (A) Wildtype 
MEFs were cotransfected with mito-YFP plus mCherry-Parkin or mCherry-Parkin S65E 
and Ub S65E. When indicated, cells were treated with CCCP. mCherry-Parkin 
colocalization with mitochondria were scored as in Fig. 1 C. (B) Wildtype MEFs were 
cotransfected with mito-YFP plus mCherry-Parkin or mCherry-Parkin S65E together 
with Ub S65E, CnB and CnAH151Q. When indicated, cells were treated with CCCP. 
mCherry-Parkin colocalization with mitochondria were scored as in Fig. 1 C. 
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Suppl. Fig. 3: In PINK1 -/- MEFs Parkin translocation is regulated by CaN. (A) Western 
blot analysis of PINK1-/- levels in wildtype and PINK1 knock out (KO) MEFs. In the first 
lane, PINK1 is detectable as two bands, with a molecular weight of 63 kDa and 52 kDa. 
In the third lane a positive control was loaded. (B) PINK1 -/- MEFs transfected with 
mito-YFP and mCherry-Parkin plus empty vector or CnB and CnAH151Q as indicated. 
mCherry-Parkin colocalization with mitochondria were scored as in Fig. 1 C. (C) PINK1 -
/- MEFs transfected with mCherry-Parkin plus empty vector or CnB and CnAH151Q as 
indicated, were treated with 10 M CCCP at different time points and lysed. Lysates 
were separated by SDS–PAGE and immunoblotted using the indicated antibodies. 
Ratio between the densitometric levels of ATP5 and those of PMP70 in MEFs 
transfected as indicated on the upper panel. (D) PINK1 -/- MEFs transfected with mito-
YFP and mCherry-Parkin or plus mCherry-Parkin S65E together with Ub S65E, CnB and 
CnA as indicated. mCherry-Parkin colocalization with mitochondria were scored as in 
Fig. 1 C. 
 
Suppl. Fig. 4: Target sites of CaN on Parkin. (A) Motif Scan and NetPhos 2.0 indicate 
Threonine 410 and Serine 407 as evolutionary conserved residues, which are likely to 
be phosphorylated. (B) Wildtype MEFs transfected with mito-YFP and mCherry-Parkin 
or Parkin phospho-mutant on Threonine 410 (Thr410Asp) and Serine 407 (Ser407Asp). 
mCherry-Parkin colocalization with mitochondria were scored as in Fig. 1 C. (C) 
Immunoprecipitation was performed in order to isolate and sequence Parkin through 
mass spectrometry. Western blot on top shows Parkin isolated from Flag-Parkin 
overexpressing MEFs. In the bottom, Silver Stain (SilverQuest™ Silver Staining Kit, 
Invitrogen) was performed, following the manufacturer’s instruction. 
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5.   Conclusions 
The molecular events which are responsible for neurodegeneration in 
Parkinson’s disease are still mostly unclear. Recently, progresses in molecular research 
on genes linked to the disease provided new insights into its pathogenesis, thus 
facilitating the understanding of the molecular mechanism underlying PD. Loss of 
function mutations in the Parkin gene (PARK2) are linked to the majority of Autosomal-
Recessive Juvenile-Parkinsonism (AR-JP)1. Parkin is an E3 Ubiquitin-ligase with an 
important neuroprotective role. Recent works have linked Parkin to the mitochondrial 
quality control pathway, nevertheless its role in neuron maintenance is still unknown2. 
Parkin translocates to unfunctional, uncoupled mitochondria, leading ton their 
elimination via autophagy3-5. Its role in PD could be linked to the accumulation of 
dysfunctional mitochondria, which fail to be eliminated as consequence of PD-related 
Parkin mutations. The aim of this thesis is to understand which molecular signals 
influence Parkin translocation and Parkin-dependent mitophagy. 
Consistent with previous studies6, we found that in MEFs Parkin was mostly 
located in the cytosol and was accumulating to mitochondria upon 3 hours of CCCP 
treatment (Fig. 1A-B). CCCP is a mitochondrial uncoupler commonly used to induce 
Parkin translocation to mitochondria. CCCP also induces microtubule depolymerization 
and increase in cytoplasmic Ca2+ concentration. Since Ca2+ regulates many processes in 
the cell, including protein trafficking and localization, we adressed whether Parkin 
translocation could be influenced by Ca2+. Indeed, we found that treatment with Ca2+ 
chelator BAPTA prior to CCCP treatment, impaired Parkin translocation (Suppl. 1A), 
suggesting that Ca2+ is required for Parkin recruitment to mitochondria. 
Sustained cytoplasmic Ca2+ concentration activates CaN, a Ca2+ dependent 
protein phosphatase which activity has been reported to regulate mitochondrial 
translocation of profission protein Drp17. With that in mind, we addressed whether 
this could also be the case for Parkin translocation to. Indeed, both chemical and 
genetic inhibition of CaN prevented Parkin recruitment to mitochondria upon CCCP 
treatment (Suppl. 1B, Fig. 1C-D). Moreover, expression of a constitutive active mutant 
of CaN triggered Parkin translocation per se, independently of CCCP intoxication (Fig. 
3A-B) or PINK1 (Fig. 3D-E). This evidence suggests that CaN activity is necessary and 
sufficient to induce Parkin recruitment downstream PINK1 (Fig. 2A-B). 
 The role of PINK1 in Parkin activation and translocation is still unclear. It has 
been shown that they act within the same genetic pathway, with PINK1 upstream of 
Parkin, but it is still unclear if PINK1 is sufficient for Parkin translocation8. Recent 
works, demonstrated that Parkin and Ubiquitin are PINK1 substrates and their 
interaction is necessary for Parkin ubiquitin ligase activity on its mitochondrial targets9-
11. We demonstrated that PINK1 mediated phosphorylation of Parkin and Ubiquitin is 
necessary but not sufficient to trigger Parkin translocation. Indeed, in cells expressing 
phospho-mimetic Ubiquitin, phospho-mimetic Parkin is not constitutively expressed on 
mitochondria (Fig. Suppl. 2A), indicating that PINK1-dependent phosphorylation of 
Parkin and Ubiquitin might not be sufficient for Parkin recruitment. On the other 
hands, we showed that expression of a constitutive active form of CaN is sufficient to 
induce Parkin translocation, independently of CCCP intoxication or PINK1 (Fig. 3D-E). 
 71 
 
Based on this, we hypothesized that either a pharmacological or a genetic approach 
that enhance CaN activity would be beneficial in ameliorating PINK1 knock out 
phenotype by bypassing PINK1 loss and activating Parkin dependent mitochondria 
quality control.  
 As previously reported, Parkin overexpression in PINK1 mutant (knock out) 
background suppress PINK1 mutant phenotype in vivo. Likewise, enhancement of CaN 
activity would rescue PINK1 mutant phenotype in vivo, by enhancing Parkin 
recruitment and activity downstream PINK1. Indeed, we found that PINK1 mutant 
(knock out) climbing ability was rescued upon expression of CaN constitutive active 
mutant (Fig. 4B).  
 Thus, our results indicate that CaN plays a fundamental, indispensable role in 
the control of Parkin translocation and Parkin-dependent mitophagy in vitro and that 
its activation has a physiological impact in an in vivo PINK1 model of PD.  
 By exploring the role of CaN in Parkin translocation and stress induced 
mitophagy and in vivo in a PINK1 model of PD, this work ultimately identified a novel 
druggable target and has the potential to widen up medical intervention for the 
treatment of PD. 
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Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy:  
A Potential Therapeutic Intervention for Parkinson’s Disease	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Abstract: Parkinson’s Disease (PD) related genes PINK1, a protein kinase [1], and Parkin, an E3 
ubiquitin ligase [2], operate within the same pathway [3-5], which controls, via specific elimination of 
dysfunctional mitochondria, the quality of the organelle network [6]. Parkin translocates to impaired 
mitochondria and drives their elimination via autophagy, a process known as mitophagy [6]. PINK1 
regulates Parkin translocation through a not yet completely understood mechanism [7, 8]. 
Mitochondrial outer membrane proteins Mitofusin (MFN), VDAC, Fis1 and TOM20 were found to 
be targets for Parkin mediated ubiquitination [9-11]. By adding ubiquitin molecules to its targets expressed on 
mitochondria, Parkin tags and selects dysfunctional mitochondria for clearance, contributing to maintain a functional and 
healthy mitochondrial network. Abnormal accumulation of misfolded proteins and unfunctional mitochondria is a 
characteristic hallmark of PD pathology. Therefore a therapeutic approach to enhance clearance of misfolded proteins and 
potentiate the ubiquitin-proteosome system (UPS) could be instrumental to ameliorate the progression of the disease. 
Recently, much effort has been put to identify specific de-ubiquitinating enzymes (DUBs) that oppose Parkin in the 
ubiquitination of its targets. Similar to other post-translational modifications, such as phosphorylation and acetylation, 
ubiquitination is also a reversible modification, mediated by a large family of DUBs [12]. DUBs inhibitors or activators 
can affect cellular response to stimuli that induce mitophagy via ubiquitination of mitochondrial outer membrane proteins 
MFN, VDAC, Fis1 and TOM20. In this respect, the identification of a Parkin-opposing DUB in the regulation of 
mitophagy, might be instrumental to develop specific isopeptidase inhibitors or activators that can modulate the 
fundamental biological process of mitochondria clearance and impact on cell survival. 
Keywords: Drosophila, DUB, mitofusin, mitophagy, parkin, parkinson’s disease, PINK1, ubiquitination.	  
THE NUMBERS OF PD	  
 Parkinson’s disease (PD) is the second most common 
neurodegenerative disease for which there is no cure. It is 
characterized by selective loss of dopaminergic neurons (DA) 
in the substantia nigra (SN) pars compacta and specific 
hallmark include accumulation of aggregates and unfolded 
proteins in the form of Lewy bodies. PD is a movement 
disorders with patients developing resting tremors, bradikinesia, 
muscle rigidity, postural instability and gait problems. It 
affects 1-2% of the population over the age of 65 and this 
percentage increases by approximately 4% in those older that 
85 years [13]. Life expectancy has risen in developed countries 
from about 47 at the beginning of the last century to about 80 
today and it is likely to increase even more, thanks to 
improving medical care and intervention. However, with the 
increased life expectancy worldwide, an increasing number of 
people will develop PD, which will socially and economically 
impact public healthcare and the future of modern society. 
 Nowadays, most of the treatment strategies for PD are 
based on the administration of dopamine, to compensate the  
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lack of dopamine release from DA neurons [14]. However, 
these treatment strategies can alleviate the symptoms of the 
disease, but they can not stop or slow down the neuronal 
degeneration. 
FAMILIAR FORMS OF PD AND THEIR GENETICS	  
 Although most PD cases are sporadic and the exact cause 
for the disease onset is unknown, a small percentage of PD 
cases is genetically linked and shows an earlier manifestation 
[15]. Since the phenotypes of both sporadic and familiar 
cases are indistinguishable at the level of DA degeneration, 
the genetic cases, although rare, can provide the basis for a 
better understanding of the molecular pathways underling 
the disease and be instrumental to tackle the disease and 
potentially find a cure [16]. 
 After the identification of SNCA gene, encoding for α-
synuclein, that causes familiar forms of PD, many other 
genes have been discovered, which cause inherited PD and 
account for 10% of PD cases. Until now, several loci 
responsible genes for PD have been identified, and for six of 
them, the corresponding genes have been characterized. Four 
loci (Park1/4, Park3, Park5 and Park8) have been associated 
with autosomal dominant forms of PD, whereas Park2, 
Park6, Park7 and Park9 have been associated with autosomal 
recessive forms. Although no corresponding gene is known 
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for loci Park3 and Park9, the other loci have been associated 
to α-synuclein gene (Park1/4), Parkin (Park2), UCHL1 
(Park5), PINK1 (Park6), DJ1 (Park7) and LRRK2 (Park8), 
respectively [17]. 
Dominant Genes 
 Park1/4, one of the most common inherited forms of PD, 
is linked to parkinsonism caused by missense mutations and 
amplifications of α-synuclein and has been associated with 
autosomal dominant forms of PD [18]. This protein is 
expressed throughout the brain and is involved in learning, 
synaptic plasticity, vesicle dynamics and dopamine 
synthesis. The wild type protein is a potent inhibitor of 
phospholipase D2, which is involved in signal transduction, 
membrane vesicle trafficking and cytoskeletal dynamics. 
Considering how neurons rely on vesicular trafficking for 
their survival, functional α-synuclein is crucial for neuronal 
survival. Interestingly, due to its hydrophobic central region, 
this protein has naturally a high propensity to aggregate that 
is accentuated in mutants. Mutant forms of these proteins 
easily aggregate in neuronal cells in vitro and in vivo, 
initially forming an intermediate annular structure, and 
ultimately forming insoluble polymers or fibrils, which are 
the main constituents of the Lewy bodies, one of the most 
common histological hallmarks of PD. 
 Park8 has been identified as the leucine rich repeat kinase 
2 gene (LRRK2). This is the most common form of inherited 
PD and the clinical features are similar to those of sporadic 
PD, except for the earlier onset age [19]. Until now, 20 
missense or nonsense mutations have been reported. This 
gene encodes for an extremely large protein of 250 kDa, 
containing many different functional domains and it is highly 
expressed in the brain. It was reported to interact with Parkin 
[20], but it also genetically interacts with PINK1 and DJ-1 
[21]. The G2019S mutation in the LRRK2 gene has been 
reported a number of times and appears to be one of the most 
common LRRK2 related mutations, accounting for 3–7% 
familial PD and 1–1.6% of so-called ‘sporadic PD’. 
Mutations in this gene inhibit an endogenous peroxidase 
promoting dysregulation of mitochondrial function and 
oxidative damage. 
Recessive Genes 
 Recessive form of parkinsonism is known to be caused 
by mutations in parkin (Park2), PINK1 (Park6) and DJ-1 
(Park7) genes. These are all relatively rare loss-of-function 
mutations that result in an early age of onset and slow 
disease progression. 
 DJ-1 mutations were firstly found in an Italian and a 
Dutch family and linked to autosomal-recessive forms of 
PD. After that, only one other mutation in a Uruguayan 
family has been identified [22]. DJ-I is almost ubiquitously 
expressed in organs, and it is present in synaptic terminals, 
mitochondria and membranous organelles [23]. The normal 
function of DJ-1 and its role in dopamine cell degeneration is 
unknown, but this protein is linked to oxidative stress 
response and mitochondrial function [24]. It has also 
reported that this gene has a role as tumor suppressor [25]. 
DJ-I protein was detected around Lewy bodies, but not as 
part of these. Several evidences suggested that DJ-I function 
as a dimer and analysis of the pathogenic Lys166Pro 
mutation showed that the dimer is less stable and an ectopic 
expression of this mutant is rapidly degraded [26]. 
 Park6 gene was identified as PINK1 (PTEN induced 
kinase 1), a serine/threonine protein kinase that contains a 
Mitochondria Targeting Sequence (MTS) and localizes to 
mitochondria [27]. Mutations in this gene are much less 
common than mutations in the DJ1 or parkin gene. This 
protein is ubiquitously expressed and contains a serine/ 
threonine kinase domain. Its function is to regulate 
mitochondrial dynamics and respiratory functions [28]. 
Interestingly, mitochondrial shape and dynamic is affected in 
PINK1 lacking cells, although literature does not always agree 
on the effect of PINK1 downregulation or overexpression 
upon mitochondria shape. Mutations in PINK1 have differential 
effects on protein stability, localization and kinase activity 
[29]. PINK1 associated cases of PD show a broad phenotypic 
spectrum, spanning from an early manifestation with atypical 
symptoms to late manifestation with the typical clinical PD 
symptoms. 
 Mutations in the parkin gene (Park2) are the most 
common among the three recessive forms of parkinsonism, 
and this gene was the first associated with recessive form of 
PD [30]. The gene codifies for an E3 ubiquitin ligase that is 
normally expressed in the cytoplasm, but translocates to 
mitochondria upon specific stimulation. More than 40 
mutations have been identified, but only a weak correlation 
between clinical manifestation and type of mutation has been 
pointed out [31]. Of note, mutations in Parkin are not 
typically associated with the formation of Lewy bodies and 
α-synuclein aggregates. 
PARKINSON’S DISEASE AND MITOCHONDRIA 
DYSFUNCTION 
 Most of the proteins encoded by Parkinson’s related 
genes, are linked to mitochondria and they have a role in 
protecting against some form of mitochondrial dysfunction 
and oxidative stress [32]. Some of them, like PINK1, are 
expressed on mitochondria and actively regulates mitochondria 
activity and fitness [1]. Others, like Parkin, are targeted to 
mitochondria upon specific stimulation, and select a subset 
of dysfunctional mitochondria for degradation [6]. DJ1 
localizes to mitochondria during oxidative stress [33].  
α-synuclein affects mitochondria function by interacting 
with mitochondria and enhancing mitochondria susceptibility 
to toxins, like rotenone, that interfere with electron transport 
chain creating build-up of electrons in the matrix and 
formation of reactive oxygen species (ROS) [34, 35]. 
 Indeed, mitochondrial dysfunction is strongly implicated 
in the etiology of the disease and impaired mitochondria are 
found in animal and cellular models of PD. Body of 
evidences suggests that mitochondria dysfunction and 
subsequent oxidative stress causes the onset of PD. 
Fission to Segregate; Fusion to Mitigate 
 Mitochondria are double membrane-bound organelles, 
which are responsible for multiple cellular events, including 
energy conversion [36, 37], Calcium (Ca2+) signaling [38] 
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and amplification of programmed cells death cascade [39]. 
The most intriguing thing about mitochondria is that they are 
extremely dynamic and they frequently divide (mitochondria 
fission) and fuse (mitochondria fusion), changing size and 
shape and subcellular location [40]. Intuitively, mitochondria 
undergo division to populate new cells with new organelles; 
mitochondria fusion is on the other hands required to 
preserve the mitochondria network and allow intermixing of 
mitochondria matrix content (including mitochondria DNA) 
to preserve mitochondria function [41]. 
 Mitochondria shape and localization are not random and 
directly correlated to mitochondria activity and fitness. In 
this respect, regulation of mitochondria fission and fusion 
events is required to respond to changes in metabolism. This 
is supported by the observations that mitochondria elongate 
in times of nutrient deprivation [42] or to boost oxidative 
phosphorylation. 
 Mitochondria fission and fusion is particularly important 
under stressful conditions: fusion between damaged 
mitochondria blends oxidative stress into the mitochondrial 
network and functionally compensate for potential damage 
[43]; fission is required to facilitate the removal of 
dysfunctional, damaged mitochondria. A pivotal study 
demonstrated how mitochondria fission often generates an 
asymmetric division where one daughter exhibits higher 
membrane potential and has better probability to undergoes 
fusion, while the other has lower membrane potential, does 
not fuse and it is more likely to be eliminated via mitophagy 
[41]. This work suggested that fission followed by selective 
fusion segregates dysfunctional mitochondria for degradation. 
In this respect, impairment of the fission machinery inhibits 
mitophagy. 
 Core components of the fission and fusion machinery are 
pro-fusion members dynamin related GTPases optic atrophy 
1 (Opa1) and Mitofusin (Mfn), and pro-fission members 
dynamin like protein 1 (Drp1) and Fis1 [44]. Mitochondria 
fusion is achieved upon the coordinated activity of Mfn and 
Opa1 [45]. Mfn is a transmembrane GTPase embedded in 
the outer mitochondrial membrane, which is required on 
adjacent organelles to mediate the fusion of outer 
mitochondrial membrane. Opa1 is expressed on the inner 
mitochondrial membrane and regulates inner membrane 
fusion [46]. Mfn and Opa1 are eclectic proteins that have 
broader functions, despite their involvement in mitochondria 
fusion. For example, in mammals, while Mfn1 participates in 
the mitochondrial fusion reaction, in coordination with 
Opa1, Mfn2 forms complexes that are capable of tethering 
mitochondria to endoplasmic reticulum (ER), a structural 
feature essential for lipid synthesis, mitochondrial energy 
metabolism, Calcium (Ca2+) transfer between the organelles 
and Ca2+ dependent cell death [47]. Opa1 also has genetically 
distinguishable functions in mitochondria fusion and 
mitochondria cristae remodeling [48, 49], an ultrastuctural 
feature that allows the intramitochondrial redistribution of 
cytochrome c that is contained inside the mitochondrial 
cristae pockets. Opa1 functions as a molecular staple that 
keeps the mitochondria cristae junctions tight and its activity 
is required in the control of cristae junctions size upon 
induction of apoptosis [48]. 
 To oppose fusion, Drp1, MFF (mitochondrial fission 
factor) and Fis1 have been found to be key components of 
the mammalian mitochondrial fission machinery. The large 
GTPase Drp1 is a dynamin-related protein that is expressed 
in the cytosol. A fraction of this protein is localized in spots 
on mitochondria, and a subset of these spots mark future 
fission sites in coordination with the endoplasmic reticulum. 
Upon induction of mitochondria fission, intermolecular 
oligomerization of Drp1 into ring-like structures occurs at 
membrane constriction sites [50]. Fis1 and MFF operate as 
Drp1 receptor on mitochondria outer membrane [51-53].	  
Pathogenesis of the Disease: The Mitochondrial 
Hypothesis 
 The earliest hypothesis of PD pathogenesis was based on 
the finding that chemical inhibition of mitochondrial 
Complex I could reproduce Parkinsonism [54]. Indeed it 
results in selective dopaminergic neuron loss and it is  
widely used to create PD animal models. For instance, 
mitochondrial toxin rotenone that inhibits electron transfer 
from Complex I to ubiquinone, causes Parkinsonism [55]. 
Also, injection of MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine), causes PD [56]: the product of 
metabolized MPTP, MPP+, inhibits Complex I of the 
electron transport chain and results in electron build up. The 
inhibition of Complex I has two major consequences: 
depletion of ATP and the generation of free radicals, with 
subsequent ROS formation that is toxic for the cell. 
 Supporting the hypothesis of a network of pathways 
converging to mitochondrial dysfunction, clear evidence of 
oxidative stress in postmortem PD brain and a reduction of 
Complex I activity has been described in organs of 
idiopathic PD patients [54]. Moreover, a primary role of 
mitochondrial respiratory chain impairment and consequent 
oxidative stress has also emerged from the study of rare 
familial forms of PD. PINK1 deficiency or disease-related 
PINK1 mutations, affects Complex I activity resulting in 
mitochondria depolarization and increased susceptibility to 
apoptotic stimuli [57]. General impaired respiration has also 
been observed in PINK1 deficient cells as a consequence of 
impaired delivery of respiratory chain substrates due to ROS 
dependent inhibition of glucose transporter [58]. Recently, a 
direct interaction between PINK1 and Complex I activity 
was described by Morais and co. workers, who showed that 
PINK1 dependent phosphorylation of Complex I on Serine-
250 is a prerequisite for ubiquitinone reduction, thus 
unrevealing the biochemical link between PINK1 
dysfunction and impaired respiration [59]. 
 Of note, Parkin mutant fibroblasts from PD patients have 
also shown to have lower mitochondrial Complex I activity 
and ATP production, which was more markedly impaired 
when cells were forced to rely on oxidative phosphorylation 
rather than glycolysis to generate their ATP. These results 
are consistent with those seen in PINK1 deficient models 
and suggest that there might be a common pathway 
mediating recessive parkinsonism in humans as has been 
suggested from studies in Drosophila [60]. 
 Interestingly, abnormalities in mitochondria shape, 
ultrastructure and subcellular localization, have been 
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described in models of both PINK1 and Parkin deficient 
cells [9, 60, 61] and enlarged and swollen mitochondria have 
been found in postmortem tissues from biopsy of PD 
patients. However, it is still not clear whether mitochondria 
structure abnormalities are a consequence of respiratory 
chain impairment, perhaps to compensate for electron leak 
and decreased ATP synthesis, or directly contribute to the 
etiology of the disease and precede respiration impairment. 
Of note, deficits in Complex I driven respiration and specific 
Complex I activity impairment are observed before any 
mitochondrial morphology alteration manifests, suggesting 
that mitochondria morphology abnormalities are a 
consequence of respiration defects [57]. Considering that 
mitochondria respond to metabolism change by modulating 
their shape and dynamics, it is plausible that to compensate 
PINK1/Parkin respiratory defects and impaired ATP 
production, mitochondria elongate to boost oxidative 
phosphorylation. This might at least partially explain why 
enlarged and hyperfused mitochondria are found in cellular 
and animal models of PINK1/Parkin deficiency. 
PINK1 AND PARKIN AND THE MITOCHONDRIA 
QUALITY CONTROL PATHWAY: A HATE-LOVE 
RELATIONSHIP 
 In 2006, by using the Drosophila Melanogaster fruit fly 
model system, three independent groups showed that PD 
related genes PINK1 and Parkin operate within the same 
pathway, with PINK1 functioning upstream of Parkin [3-5]. 
These works highlighted the fruit fly as an extremely 
powerful model system to gain insight into PD etiology. A 
number of fly models have been developed (such as PINK1, 
Parkin and OMI mutant flies), which show dopaminergic 
neuronal loss, mitochondrial dysfunction and locomotor 
deficits. In 2008, by using a fruit fly-based genetic interaction 
screening, Poole et al. showed a strong genetic interaction 
between PINK1/Parkin pathway and mitochondrial fission 
and fusion machinery. In particular, in flies, loss of function 
mutations of pro-fission protein Drp1 is lethal in a PINK1 or 
Parkin mutant background. Furthermore, PINK1 and Parkin 
mutant phenotypes, such as muscle degeneration, locomotor 
deficits and mitochondrial morphology alterations, are 
suppressed by increased Drp1 gene dosage or decreased pro- 
fusion Mitofusin gene dosage [62]. This finding highlighted 
for the first time a potential role for mitochondrial dynamics 
in the PINK1/Parkin pathway and suggested that PINK1/ 
Parkin pathway might promote mitochondria fission (or 
inhibit mitochondria fusion). 
 Recently, new insights have emerged into the function of 
the PINK1/Parkin pathway. Upon prolonged mitochondrial 
intoxication, using CCCP, Parkin is selectively recruited to 
impaired mitochondria and promotes their elimination via 
autophagy, a process known as mitophagy [6]. Further, 
PINK1 is required for Parkin translocation through a yet not 
fully understood mechanism [8]. Extended studies to 
elucidate the potential molecular mechanisms of this 
pathway showed that in several cell model systems, upon 
mitochondria intoxication by CCCP, Parkin is recruited to 
impaired mitochondria where it selectively ubiquitinates pro 
fusion protein Mfn [9, 10]. Lack of Parkin (or PINK1, which 
acts upstream Parkin in a linear pathway) results in impaired 
Mfn ubiquitination and increased Mfn steady state levels in 
several in vitro cellular systems and in vivo. This finding 
provided a biochemical explanation for the in vivo genetic 
interaction observations that show how decreased pro- fusion 
Mitofusin gene dosage in flies could ameliorate PINK1 or 
Parkin mutant phenotype. 
 Extensive studies in recent years allowed the dissection 
of this pathway and further details of the molecular 
mechanism of action of PINK/Parkin in mitochondria quality 
control have emerged. In healthy mitochondria, PINK1 is 
sequentially imported to mitochondria through the TOM and 
TIM complexes, and then it is released to span the inner 
mitochondrial membrane [63]. It has been shown that the 
proteases PARL and MPP [64] are responsible for its 
cleavage and subsequent degradation in a proteasome 
dependent manner [45]. However, upon CCCP induced 
mitochondria depolarization, PINK1 fails to be cleaved, it is 
exposed on the outer mitochondrial membrane, where it 
drives the recruitment of Parkin [8]. Recent works suggest 
that PINK1 both phosphorylates Parkin [65], Ubiquitin [66] 
and Mfn [67]. PINK1-dependent phosphorylation of Parkin 
regulates Parkin E3 ubiquitin ligase activity [65], although 
phosphomimetic Parkin mutation does not bypass PINK1 
requirement for Parkin recruitment. However, PINK1 
dependent phosphorylation of Ubiquitin is a Parkin activator 
and, in combination with PINK1-dependent phosphorylation 
of Parkin, is sufficient to fully activate Parkin E3 activity 
[66]. PINK1-dependent phosphorylation of Mfn is required 
for Parkin translocation. In particular, phospho-Mfn works 
as a molecular tag for the recruitment of Parkin that, once on 
mitochondria, ubiquitinates its targets [67]. In 2013 the 
complete repertoire of Parkin targets (Parkin-dependent 
ubiquitylome) have been published, which includes Mfn, 
VDAC, TOM20, Fis1, the authophagy adaptor p62 and Miro 
[11]. Parkin dependent ubiquitination of Miro (a GTPase that 
senses Ca2+ and binds mitochondria to the cytoskeleton via 
Milton) results in proteasome dependent degradation of Miro 
and consequent disruption of mitochondrion mobility [68]. 
Also, Mfn ubiquitination has followed by chaperone-mediated 
extraction of the protein from the outer mitochondrial 
membrane and its degradation [10]. As a result of Parkin-
dependent ubiquitination of its targets on the outer 
mitochondrial membrane, mitochondria both loose their 
ability to fuse and to move along the microtubules of the 
cytoskeleton. They are therefore isolated from the 
mitochondrial network and targeted for degradation via 
Parkin dependent recruitment of cytosolic factors, including 
p62, that are required for the activation of mitophagy. 
 Recently a new pathway in the regulation of mitochondria 
quality control has been described, that accounts for the 
formation of mitochondria-derived vesicles (MDVs) that 
bud off mitochondria. Depending on the cargoes, emerging 
MDVs promote the degradation of their contents by either 
fusing to a subpopulation of peroxisomes [69] or lysosomes 
[70]. The latter is independent of autophagy, and it is 
induced by oxidative stress. Latest works describe a role for 
Parkin/PINK1 in the biogenesis of these vesicles, suggesting 
an additional role for these two proteins in the control of 
damaged mitochondrial proteins degradation [71]. These 
data characterize a novel vesicles-based highway that direct 
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damaged mitochondrial proteins to lysosomes. This 
pathway is distinct from canonical mitophagy and it is 
primarily activated upon oxidative stress. Thus, PINK1 and 
Parkin promote mitochondrial quality control via at least 
two distinct pathways, either by tagging the entire organelle 
for autophagy-dependent degradation, or by shuttling 
specific cargoes to lysosome in an LC3/ATG-independent 
manner. The existence of an autophagy-independent 
pathway in the activation of mitochondria quality control is 
indeed supported by in vivo evidences [72]. 
UBIQUITINATION AND DE-UBIQUITINATION: A 
REVERSIBLE MODIFICATION THAT REGULATES 
SIGNALING PATHWAYS 
 Ubiquitination has recently emerged as a powerful tool to 
modulate proteins activity, via regulation of their subcellular 
localization and ability to interact with other proteins to form 
signaling complexes. E1 (ubiquitin-activating), E2 (ubiquitin-
conjugating) and E3 (ubiquitin-ligase) enzymes can regulate 
the activity of proteins, through conjugating Ubiquitin (Ub) 
monomers. This event is called “ubiquitination” and consists 
in the formation of an isopeptide bond between the carboxyl 
group of the Ub C-terminus and the free amine group of a 
lysine side-chain of a target protein. In some cases, “linear 
ubiquitination” can also occur, that means the E1/E2/E3 
cascade promotes the formation of a bond between Ub and 
the first methionine of a target, without the formation of a 
chain. However, Ub itself contain seven lysine residues, thus 
allowing ubiquitin chains formation [73]. Ub can form 
polyubiquitin chains of eight different linkages that mediate 
distinct biological functions [74]. Thus, the biological 
outcome of ubiquitin linkage can be modulated, depending 
on the ubiquitin chain that is formed. The best-characterized 
type of Ub conjugation is the Lys48 linked Ub chain that 
typically leads to degradation of the target by the 
proteasome. In contrast, chains linked via one of the other 
six lysines in Ub can function as regulatory signal in a 
variety of cellular pathways, including trafficking, signaling 
and autophagy. In this context, a common regulatory 
mechanism for many E3 ligases is the ability to self-catalyze 
their own ubiquitination, by a so-called “auto-ubiquitination” 
process.	  
 Similar to other post-translational modifications, such as 
phosphorylation and acetylation, ubiquitination is also a 
reversible modification, mediated by a large family of 
deubiquitinating enzymes (DUBs). Interestingly, a large set 
of DUBs has opposite role of the E1/E2/E3 activity. Most 
DUBs recognize and remove ubiquitin from conjugated 
proteins and/or shorten ubiquitin chains, although some 
DUBs can be cross-reactive for some Ubs. Clearly, this class 
of enzymes not only can regulate E1/E2/E3 ubiquitinated 
targets, but also auto-ubiquitinating proteins. Therefore, 
DUBs have been found to play an important role in the 
regulation of multiple processes, such as regulation of 
receptor trafficking, cell cycle progression, regulation of cell 
migration, regulation of intracellular signaling and 
transcriptional control [12]. Two different DUB enzyme 
mechanisms have been described: metalloproteases, 
classified as the JAMN/MPN+ domain superfamily, and the 
Cys-proteases. The Cys-proteases DUBs are further divided 
into four subclasses: the USP (ubiquitin-specific protease) 
superfamily, the OUT (ovarian tumour) superfamily, the 
UCH (ubiquitin C-terminal hydrolase) superfamily, and the 
Machado-Joseph disease domain superfamily (MJDs) [75]. 
Accumulating evidences indicate that DUBs mutations are 
involved with human diseases development.	  
 Recent works identified DUBs interacting with and 
regulating proteins associated with familial forms of PD, -
synucleinαsuch as [76] and Parkin [77-84]. In more detail, 
ataxin-3, USP8, USP15 and USP30 have been found to have 
a role in modulating Parkin auto-ubiquitination and Parkin-
mediated mitophagy.	  
 The MJDs superfamily member ataxin-3 is the first DUB 
reported to have a role in Parkin deubiquitination and 
stability. This enzyme, which mutations cause MJD, has 
been found to deubiquitinate Parkin, but no evidences 
indicated a role of wild-type ataxin-3 in Parkin stability 
regulation. However, the MJF-associated form of ataxin-3 
promotes Parkin degradation in a proteasome-independent 
manner [78, 85]. Moreover, ataxin-3 resulted to be unable to 
hydrolyze preassembled Ub-conjugates on Parkin. Ataxin-3 
acts through an unusual mechanism, stabilizing the interaction 
between Parkin and E2 that now cannot dissociate. When 
ataxin-3 is present, it can also interact with E2-Ub complex 
and redirect the Ub transfer from E2 onto itself, rather than 
onto Parkin [77]. Patients with MJD can exhibit symptoms 
similar to those with PD and show neurodegeneration in 
many of the same brain region. The interaction between 
ataxin-3 and Parkin could, at least partially, explain the 
similarities between these diseases.	  
 Although ataxin-3 came out as a regulator of Parkin 
stability and turnover, its role on Parkin-mediated mitophagy 
was not investigated. Furthermore, as E3s could be regulated 
by multiple DUBs, the same research group performed an 
RNAi-screen in U2OS cells to identify other enzymes that 
could be involved in Parkin deubiquitination and Parkin-
dependent mitophagy [79]. They report that Usp8, which 
was known to be associated with endosomal trafficking, is 
necessary for Parkin recruitment to mitochondria and 
mitophagy. Knock-down of Usp8 delayed but not abolished 
Parkin translocation to depolarized mitochondria, upon CCCP 
treatment. Counterintuitively, Parkin steady-state levels were 
increasing in Usp8 RNAi conditions, advocating the 
hypothesis that Usp8 specifically acts on Parkin by functional 
ubiquitination rather than degradative ubiquitination.  
Of interest, they found that Usp8 specifically removes  
K6-linked Ub conjugates, which in turns promotes Parkin 
recruitment to mitochondria [80]. Therefore, by impinging 
on the transcriptional levels of a Parkin-specific DUB, the 
authors showed how mitophagy could be inhibited.	  
 Another research group used a different approach to 
reveal Parkin interacting protein. Tandem affinity purification 
coupled to mass spectrometry identified Usp11 and Usp15 as 
DUBs binding Parkin [84]. Further experiments, confirmed 
an interaction between Usp15 and overexpressed Parkin. 
Usp15 has an opposite role on mitophagy compared to Usp8, 
since Usp15 knockdown enhanced mitochondria elimination 
in SH-SY5Y cells. Moreover, RNAi-mediated knockdown of 
this DUB rescued mitophagy defects in fibroblasts both from 
6    Current Neuropharmacology, 2016, Vol. 14, No. 0 Nardin et al. 
PARK2 and PINK1 mutant PD patients. However, Usp15 
does not act on Parkin protein itself, nor prevents Parkin 
translocation to impaired mitochondria. The targets of Usp15 
are the Parkin-ubiquitinated proteins on mitochondria. 
Usp15 impairs mitophagy through deubiquitinating Parkin 
targets on depolarized mitochondria and in this respect, it 
counteracts Parkin ubiquitination activity over Parkin 
targets. These data were also confirmed in vivo in 
Drosophila, where silencing of Usp15 homolog rescued 
parkin mutant phenotype, thus showing a genetic interaction 
between the two genes [84].	  
 Usp30 came out as a DUB inhibiting mitophagy during a 
human cDNA library screening in a mitochondrial degradation 
assay. Although more than 100 DUBs were tested, only two 
DUBs were able to robustly block mitophagy (USP30 and 
DUBA2) [83]. However, only Usp30 was reported to be 
localized in the outer mitochondrial membrane. Co-
expression of Usp30 did not alter Parkin expression levels or 
its translocation to depolarized mitochondria, nevertheless it 
was able to reduce CCCP-induced recruitment of autophagy 
markers and ubiquitin signal on GFP-Parkin positive 
mitochondria. The genuine target of Usp30 deubiquitinating 
activity was found to be TOM20. Thus, Usp30 overexpression 
opposes Parkin ubiquitination of TOM20, blocking mitophagy. 
On the other hands, Usp30 downregulation enhances 
mitochondrial degradation in neurons via stabilization of 
ubiquitinated forms of TOM20, which work as mitophagy 
signal. Fruit fly in vivo models of Parkinson disease showed 
that knockdown of Usp30 was able to rescue defective 
mitophagy caused by Parkin mutation. Moreover, it 
improves mitochondrial integrity in Parkin- or PINK1-
deficient flies and protects flies against paraquat toxicity in 
vivo. Parkin synthesizes Lys 6, Lys 11 and Lys 63 Ub chains 
on depolarized mitochondria. Usp30 opposes the induction 
of mitophagy through preferentially hydrolyzing Lys 6- and 
Lys 11-linked Ub chains on Parkin target TOM20 [82]. Lys 
6- and Lys 11-linked Ub chains are fundamental mitophagy 
signals, since other DUBs targeted to mitochondria which 
are able to specifically hydrolyze these Ub chains are 
blocking mitochondrial degradation 
 All these studies, suggest a potential role for DUBs in 
modulating mitochondrial quality control and impact on cell 
survival. Specific DUBs inhibition or enhancement could, 
for instance, compensate for PINK1 or Parkin loss-of-
function mutations in PD patients. 
DUBs AS THERAPEUTIC TARGETS	  
 Due to their involvement in the regulation of important 
signaling pathways, DUBs are emerging as attractive 
druggable candidates [86]. Clinical trials for specific 
inhibitors of the ubiquitin-proteasome system have already 
been approved in cancer therapy for the treatment of multiple 
myeloma [87-89]. Moreover, high-throughput screening of 
small chemical libraries identified non selective DUBs 
inhibitors as potent inducers of apoptosis in various cancer 
cells. For example, G5, a small molecule inhibitor of DUBs, 
was recently identified as a strong inhibitor of NLRP3 
signaling pathway, thus affecting the NLRP3-dependent 
inflammatory response [90]. 
 Recently, a number of reports identified additional 
syntetic small molecule as effective DUB inhibitors. 
Chemically diverse molecules have been reported to inhibit 
one or more of the UCH and USP family members. 
However, drug discovery against the ubiquitin system is still 
emerging and effective compounds are relatively limited. 
Often, these compounds target more than one DUB and the 
most promising chemicals showing selective inhibitions still 
have not been tested for all full length human DUBs. Here, 
we report the most promising inhibitors for DUBs of the 
USP superfamily, which hopefully, in the next future, could 
be used as therapy for different pathologies, including PD. 
For detailed information about the biochemical mechanism 
of action and other available inhibitors for DUBs, the reader 
is referred to excellent previews [91, 92].	  
 Usp7 is a deubiquitinase first identified as associated 
with a herpes-virus, and it facilitates lytic growth. It has also 
been shown as indirect regulator of p53, FOXO4 and PTEN 
proteins, able to destabilize and compromise the effectiveness 
of these tumor suppressor proteins [93]. Therefore, Usp7 can 
be considered as an oncogenic pro-survival protein. Since it 
was discovered, Usp7 antagonists have been deeply studied, 
as its inhibition could block tumor progression. At now, an 
high-throughput screening (HTS) identified HBX 19,818 and 
the related HBX 28,258 as inhibitors for Usp7 [94]. Using 
the same method, but in a parallel study, P5091 came out as 
selective antagonist of this DUB. These molecules were 
tested in multiple cell lines, thus proving their ability to 
stabilize p53, to inhibit tumor growth and to promote 
apoptosis in tumor cell lines. In vivo studies confirmed the 
effect of P22077, an optimized derivative of P5091, in 
several orthotopic neuroblastoma xenograft models [95].	  
 Some DUBs have been found to have a role in DNA 
damage response, this is the case of Usp1. When it is 
associated to the co-factor UAF1 (USP1-associated factor 1), 
Usp1 deubiquitinates different targets involved in cell 
damage response and related to different pathologies. Usp1 
deubiquitinates FANCD2 and FANCI in the Falconi anemia 
pathway, promoting DNA repair. This DUB participate in a 
similar process also in the translesion synthesis pathway, 
where deubiquitinates PCNA (proliferating cell nuclear 
antigen) in order to prevent low-fidelity polymerases 
recruitment and thereby preserve DNA integrity [96]. 
Through deubiquitinating inhibitors of DNA binding 
transcription factors, Usp1 has been found to maintain stem-
cell characteristics in osteosarcoma cells [97]. An HTS using 
USP1/UAF1 complex identified different inhibitors for this 
deubiquitinating enzyme complex [98], and pimozide 
resulted to be the more efficient chemical against it. 
However, other DUBs resulted to be inhibited by this same 
compound, thus, the effects seen by using it in cells could 
not be imputed to the specific inhibition of USP1/UAF1 
complex. However, other two independent HTS revealed 
other molecules that could be used as Usp1 inhibitors: 
ML323, and the two analogues SJB2-043 and SJB3-019A 
[99, 100]. This compounds resulted to be more selective for 
Usp1, interfering with the protein in the different pathways 
in which it controls DNA integrity maintenance. Different 
studies validated the potential therapeutic efficacy of Usp1 
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inhibition in different pathologies, such as leukemia and 
other cancers. 
 Usp14 and UCHL5 are two deubiquitinating enzymes 
found to be associated with the proteasome. These two 
proteins antagonize proteasomal degradation of substrate, by 
hydrolyzing poly-Ub chains from the substrate distal end, a 
process called trimming. Usp14 deletion is embryonic lethal 
in mice, since this enzyme is important in general homeostasis. 
Recently, IU1 has been reported as Usp14 inhibitor, 
confirming its role in Ub chain trimming. Inhibition of 
Usp14 has beneficial effects on cell viability, promoting 
proteasomal degradation of damaged proteins. On the other 
hand, overexpression of Usp14 is associated with cancer 
progression [101]. Moreover, in vivo and in vitro evidences 
showed the efficiency of inhibiting Usp14 and UCHL5 in 
tumor models, using b-AP15 [102]. 
 Besides some exceptions, most of these inhibitor 
molecules are poorly characterized in terms of structure and 
mechanism of action. Further biochemical studies together 
with proteomic tools could better explain the features of 
these molecules, thus allowing to better understand their 
mechanism of action. Nevertheless, more DUBs inhibitors 
are under development, with the aim to discover new 
therapies for different human diseases.	  
AUREA MEDIOCRITAS: THE DESIRABLE MIDDLE 
BETWEEN TWO EXTREMES 
 In recent years, much effort has been put in order to 
identify specific DUBs that oppose Parkin in the 
ubiquitination of its targets. The identification of a Parkin-
opposing DUB, counteracting Parkin activity in the 
regulation of mitophagy, might be instrumental to develop 
specific isopeptidase inhibitors or activators that can 
modulate the fundamental biological process of mitophagy 
and impact on cell survival.	  
 Since one of the hallmark of PD consists of accumulation 
of misfolded proteins and unfunctional mitochondria as a 
result of impaired mitophagy, chemical or genetic 
intervention that suppress Parkin-opposing specific DUB, 
can potentially be used to eliminate these toxic compounds 
and improve viability (Fig. 1).	  
 Overall, the enhancement of proteasome activity may 
offer a strategy to reduce the levels of aberrant proteins in 
cells and in the whole organism under stress. 
 Of note, interference with the proteasome machinery has 
already been proved to be effective in cancer therapy and 
recently, high throughput screening resulted in the discovery 
of highly specific synthetic small molecules that target 
selective components of the proteasome machinery via 
enhancement or suppression of ubiquitin-conjugating 
enzymes and DUBs.	  
 In vivo evidences suggest that suppression of specific 
DUBs is sufficient to promote mitophagy in the absence of 
Parkin or PINK1, via stabilization of the ubiquitinated forms 
of Parkin substrates. Suppression or enhancement of specific 
DUB activity might therefore be instrumental for the 
activation of mitochondria clearance pathway downstream 
 
Fig. (1). Counteracting Parkin. The cartoon illustrates the rational behind the potential therapeutic advantages of identifying DUBs that 
oppose Parkin in the ubiquitination of its target. In vivo evidences suggest that suppression of specific DUBs is sufficient to promote 
mitophagy in the absence of Parkin or PINK1, via stabilization of the ubiquitinated forms of Parkin substrates. Therefore, suppression of 
specific DUB activity might be instrumental for the activation of mitochondria clearance pathway downstream PINK1/Parkin and can offer a 
therapeutic approach to ameliorate PD phenotype. 
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PINK1/Parkin and can potentially be beneficial in 
ameliorating phenotypic deficits in PD. 
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DUBMitochondria are double membrane-bounded organelles residing in the cytoplasm of almost all eukaryotic cells,
which convert energy from the disposal of organic substrates into an electrochemical gradient that is in turn con-
verted into ATP. However, the ion gradient that is generated through the oxidation of nutrients, may lead to the
production of reactive oxygen species (ROS),which can generate free radicals, damaging cells and contributing to
disease. Originally described as static structures, to date they are considered extremely plastic and dynamic or-
ganelles. In this respect, mitochondrial dynamics is crucial to prevent potential damage that is generated by
ROS. For instance, mitochondria elongate to dilute oxidized proteins into the mitochondrial network, and they
fragment to allow selective elimination of dysfunctionalmitochondria viamitophagy. Accordingly,mitochondrial
dynamics perturbationmay compromise the selective elimination of damaged proteins and dysfunctional organ-
elles and lead to the development of different diseases including neurodegenerative diseases.
In recent years the fruitﬂyDrosophilamelanogaster has proved to be a valuablemodel system to evaluate the con-
sequences of mitochondria quality control dysfunction in vivo, particularly with respect to PINK1/Parkin depen-
dent dysregulation of mitophagy in the onset of Parkinson's Disease (PD). The current challenge is to be able to
use ﬂy based genetic strategies to gain further insights intomolecularmechanisms underlying disease in order to
develop new therapeutic strategies.
This article is part of a Special Issue entitled: Role of mitochondria in physiological and pathophysiological func-
tions in the central nervous system.
© 2015 Elsevier Inc. All rights reserved.1. Mitochondria: from structure to function.
The termMitochondria comes from the composed Greekwordmitos
(ﬁlament) and chondrion (granule) and was coined in 1898 by German
doctor Karl Benda to describe ﬁlamentous-type organelles, which were
ﬁrst observed in the 1850s by Swiss physiologist Albert Von Kölliker. Be-
tween 1850 and 1880, several scientists independently observed in dif-
ferent cell types the presence of these organelles,which vary in number,
size and subcellular localization (Ernster and Schatz, 1981).
With the advent of advanced biochemistry-based techniques, light
was shed on their physiological function. Several researchers indepen-
dently hypothesized the presence of mitochondria resident enzymatic
complexes that were responsible for processing oxygen. In the second
half of the twentieth century, Serrano et al. reported the puriﬁcation
and properties of a proton-translocating adenosine triphosphatase
complex, which was isolated from mitochondria of bovine heartamillo, IRCCS, Lido di Venezia,
om).
l.,Mitochondrial dynamics an
.11.002(Serrano et al., 1976). Two years later, the so-called theory of
chemiosmosis was proposed, according to which the ﬂow of hydrogen
ions through an enzyme complex present in the mitochondria, would
provide the potential energy that is required for ATP synthesis. The
transformation of potential energy into metabolic energy in the form
of ATP involved the oxidation of oxygen (Boyer et al., 1977; Mitchell,
1977). This theory earned the British scientist Peter Mitchell the Nobel
Prize for chemistry in 1978. About twenty years later, scientists Paul
Boyer, John Walker and Jens Skou independently showed that the pas-
sage of protons through the ATP synthase, which acts as a mechanical
force, causes the rotation of a part of this protein, catalyzing the forma-
tion of ATP via phosphorylation of a molecule of ADP (Groth and
Walker, 1996). This discovery earned them the Nobel Prize for Chemis-
try in 1997.
Thanks to the development of the electron microscope in 1931, it
was possible to analyze themicroscopic structure of themitochondrion
and characterize the intimate structure of the mitochondrion at a reso-
lution of several orders of magnitude higher than that of the optical mi-
croscope. This organelle consists of a double layer of lipid membrane,
which allows distinguishing ﬁve distinct compartments: the outer mi-
tochondrial membrane (OMM), intermembrane space (IMS) (betweendmitophagy in Parkinson's disease: Aﬂy point of view, Neurobiol. Dis.
2 S. Von Stockum et al. / Neurobiology of Disease xxx (2015) xxx–xxxthe outer membrane and the inner one), the inner mitochondrial mem-
brane (IMM), the cristae (compartments that are formed by invagina-
tion of the inner mitochondrial membrane) and the matrix (the space
surrounded by the IMM). The OMM contains channel proteins, called
Porins, which allow the free diffusion of small metabolites. In this re-
spect, the outer membrane envelopes the organelle, separating the
IMS from the cytoplasm, yet its content is metabolically similar to the
cytoplasm. Molecules that are larger that 5 kDa contain a speciﬁc mito-
chondrial targeting signal and they are actively transported across the
OMM into the IMS by a subset of proteins called translocases that,
upon ATP hydrolysis, actively import speciﬁc metabolites intended to
be part of the IMS (or the matrix).
The OMMhas originally been considered amere containment enclo-
sure of the mitochondrion. However, recent works attributed to the
OMM characteristics of physiological and signaling importance. For in-
stance, points of close contact were observed between the OMM and
thenearby endoplasmic reticulum (ER) calledMAMs (mitochondria-as-
sociated ER-membranes) (Naon and Scorrano, 2014), which have
proved to play strategically in the propagation of cellular signals, includ-
ing those that control lipid metabolism, calcium homeostasis and cell
death (Ernster and Schatz, 1981; Rizzuto et al., 2000; McBride et al.,
2006). In particular, mitochondria largely contribute to calcium
(Ca2+) homeostasis at the MAMs. Although they require Ca2+ for the
operation of mitochondrial resident enzymatic complexes, mitochon-
dria are relatively inefﬁcient Ca2+ up-taker. Nevertheless, they can up-
take Ca2+ via the mitochondrial Ca2+ uniporter (MCU), a newly
identiﬁed Ca2+ transporter (De Stefani et al., 2011) that, despite its
low Ca2+ afﬁnity, imports Ca2+ at the MAMs, where high content
Ca2+ microdomains are forming. Of note, aberrations in ER-
mitochondria juxtaposition have been described in cellular models of
different neurodegenerative diseases, including Alzheimer's,
Huntington's and Parkinson's disease (Area-Gomez et al., 2012; Cali
et al., 2013a; Cali et al., 2011; Cali et al., 2013b; Costa and Scorrano,
2012). Although the exact cause for neuronal loss is not clear, it is plau-
sible that the neurodegeneration observedmight be caused bymalfunc-
tion of the synaptic nerve transmission, which depends on proper
communication between mitochondria and ER at the MAMs.
The IMM contains the enzymatic complexes that are responsible for
the transformation of energy that comes from the processing of the or-
ganic substrates into electrochemical gradient, which is then converted
into metabolic energy (ATP), through the ATP synthase. The electro-
chemical gradient is generated through the oxidation of nutrients, via
the operation of a chain of enzymes, which resides within the IMM
and the IMS. The energy released by the passage of the electrons
through the protein complexes of the enzymatic chain, is used to ac-
tively pump protons out of the mitochondrial matrix, into the inter-
membrane space, creating a proton gradient. The energy stored in
form of the proton gradient (potential energy) is then used to produce
ATP (metabolic energy), thanks to the exergonic passage of the protons
through the ATP synthase. The IMM has a structure similar to the
plasma membrane of bacteria and, unlike the OMM, does not contain
Porin channels. It is therefore completely impermeable to any molecule
present outside. One particular molecule must then be actively
transported into the mitochondrial matrix via protein translocases.
The IMM forms numerous invaginations, which folds back into pockets,
called cristae (Frey and Mannella, 2000; Mannella et al., 2001). The
main function of such invaginations is to extend the surface for the re-
spiratory complexes so that mitochondria respiratory capacity can be
greatly ampliﬁed. Cristae size and shape can change dependingon intra-
cellular signaling. For example, cristae remodeling occurs upon activa-
tion of programmed cell death: cristae junctions become wider to
release cytochrome c (Frezza et al., 2006), which in turn activates cyste-
ine proteases Caspases, themain executers of programmed cell death. In
addition, respiratory chain complexes assemble into quaternary struc-
ture, called supercomplexes, which formation and stability depend on
cristae shape (Cogliati et al., 2013). Accordingly, the efﬁciency ofPlease cite this article as: Von Stockum, S., et al.,Mitochondrial dynamics an
(2015), http://dx.doi.org/10.1016/j.nbd.2015.11.002mitochondrial respiration in response to changes in cell metabolism or
upon stress, depends on cristae shape. Interestingly, the proteins that
control cristae architecture at the IMM and ER-mitochondria juxtaposi-
tion at the MAMs do cooperate to respond to changes in metabolism
(Sood et al., 2014), which suggests a previously uncharacterized inter
organelle coordinated process.
All these evidences clearly suggest how the dynamic orchestration of
intra and inter compartments interaction is an absolute requirement for
the modulation of mitochondrial activity.
2. The master regulators of mitochondrial dynamics
Originally described as static structures, mitochondria are now
widely considered extremely plastic and dynamic organelles. Indeed,
eukaryotic cells maintain the overall shape of their mitochondria by
balancing the opposing processes of mitochondrial ﬁssion and fusion.
Mitochondria shape and dynamic is not random and tightly correlates
to mitochondria functions, which include, beyond energy conversion,
the biosynthesis of amino acids and steroids, the beta-oxidation of
fatty acids, modulation of Ca2+ signaling and ampliﬁcation of apoptosis
(Ernster and Schatz, 1981; Rizzuto et al., 2000;McBride et al., 2006).Mi-
tochondrial shape is regulated by a set of proteins that respond to cellu-
lar cues such as phosphorylation or ubiquitination. Mitochondria
shaping proteins have pleiotropic functions, participating in apoptosis,
tethering of mitochondria to other organelles, calcium signaling and
regulation of autophagy. The players in mitochondrial network remod-
eling are dynamin-related proteins, large GTPases that participate in fu-
sion, ﬁssion and tubulation of membranes (McNiven et al., 2000). The
dynamin-related GTPases Optic Athropy 1 (OPA1) and Mitofusins
(MFNs) have been identiﬁed as themain regulator of mitochondrial fu-
sion, while the Dynamin Like Protein (DRP1) and FIS1 are responsible
for mitochondrial ﬁssion. MFNs are responsible for the fusion of the
OMM. Inmammals there are twoMFNs, MFN 1 and 2, displaying a sim-
ilar structure with a terminal GTPase domain, two hydrophobic heptad
repeats (HR) and two transmembrane domains that insert them on the
OMM. Despite their high homology, they exhibit distinct functions
(Eura et al., 2003; Koshiba et al., 2004). They both form homo- and het-
erodimers, and force OMM to fuse upon conformational changes led by
GTP hydrolysis (Chen et al., 2003). Both MFN1 and MFN2 are required
for mitochondrial fusion (Koshiba et al., 2004). However, while the
main role of MFN1 is to control mitochondria tethering in trans and, to
promote fusion in cooperation with OPA1(Cipolat et al., 2004; de Brito
and Scorrano, 2008), the role of MFN2 is more elusive. MFN2 levels cor-
relate with oxidative metabolism of skeletal muscle (Bach et al., 2003)
and the proliferative ability of vascular smooth muscle cells by seques-
tering the protooncogene Ras (Chen et al., 2004). Moreover, MFN2
forms complexes that enable the tether between mitochondria and ER
at the MAMs, impinging on lipid transfer and synthesis, mitochondria
energy metabolism, Ca2+ transfer between the two organelles and
Ca2+ dependent cell death (de Brito and Scorrano, 2008). The direct
role of MFN2 in the formation of ER-mitochondria molecular bridges
originally described by De Brito et al.(de Brito and Scorrano, 2008) has
been recently challenged by an electron microscopy study that indicate
increased ER-mitochondria interaction in MFN2 deﬁcient cells (Cosson
et al., 2012). However, in this study the authors arbitrary deﬁned sites
of tethering as those regions of ER-mitochondria distance of 10 or less
nm. Remarkably, a parallel study that also used electron microscopy to
measure the contacts and did not introduce any arbitrary tie, produced
the opposite result that MFN2 removal results in decreased sarcoplas-
mic reticulum-mitochondria juxstaposition (Chen et al., 2012). Another
recent study, which took advantage of both electron and confocal based
microscopy techniques agreed with Cosson et al. conclusions, that
MFN2 ablation increases ER-mitochondria tethering (Filadi et al.,
2015). However in this case the analysis of the confocal images was
based on selection of an arbitrary plane section and not on a three di-
mensions volume rendering reconstruction of Z stack acquired images.dmitophagy in Parkinson's disease: Aﬂy point of view, Neurobiol. Dis.
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sis is prone tomisinterpretation as it misses the interactions that do not
develop in the analyzed section. Of note, several independent works
showed that Ca2+ (Chen et al., 2012; Sugiura et al., 2013) and lipid
transfer (Area-Gomez et al., 2012; Hailey et al., 2010; Hamasaki et al.,
2013; Wasilewski et al., 2012), both functional counterparts of ER-
mitochondria physical interaction, is diminished in cells lacking MFN2.
Certainly both schools acknowledge the involvement of MFN2 in the
regulation of ER-mitochondrial interaction and controversial results
might depend on lack of deﬁnitive deﬁnition of ER-mitochondrial func-
tional tethering distance.
The other protein involved in mitochondrial fusion, OPA1, is an-
chored on the IMM and most of the protein is exposed to the IMS
(Olichon et al., 2002). In humans there are 8 splice variants of OPA1,
while inmice there are only four (Akepati et al., 2008). Its activity is reg-
ulated by proteolitic cleavage (Ehses et al., 2009) and both long and
short forms are needed for fusion (Song et al., 2007). OPA1 is not only
involved in mitochondria IMM fusion in a MFN1-dependent manner,
but it also plays a role in controlling cell death by regulating the size
of mitochondria cristae junctions. Heterocomplexes between proteo-
lytic processed or unprocessed OPA1 regulate the width of the cristae
junctions, thus affecting the release of cytochrome c (Frezza et al.,
2006; Ishihara et al., 2006).
On the other side, DRP1, MFF (Mitochondrial Fission Factor), FIS1,
MiD49 and MiD51 regulate mitochondrial ﬁssion. The large GTPase
DRP1 is a dynamin-related protein which has a role in both mitochon-
dria and peroxisomes ﬁssion (Schrader, 2006). DRP1 has mainly a cyto-
solic localization and it translocates to mitochondria in response to
Ca2+-dependent cellular signals. Cytosolic Ca2+ rise, associated with
mitochondrial depolarization, leads to Calcineurin activation and de-
phosphorylation of DRP1 on Ser637 and concomitant translocation of
DRP1 to mitochondria (Cereghetti et al., 2008), where it is stabilized
by sumoylation (Harder et al., 2004). Once on mitochondria, DRP1
oligomerizes and interacts with its putative interactors on the OMM
(Fis1, MFF, MiD49 and MiD51)(Loson et al., 2013), forming a ring-
shaped structure, which constricts around the mitochondrial tubular
structure, inducing mitochondrial ﬁssion (Loson et al., 2013; Mears
et al., 2011). Protein Kinase A (PKA)-dependent phosphorylation of
DRP1 on Ser637 prevents DRP1 translocation thus allowing unopposed
fusion (Cribbs and Strack, 2007; Chang and Blackstone, 2007). PKA ac-
tivity is dependent on cellular levels of cyclic AMP (cAMP), thus cAMP
seems to have an important role inmitochondrial shape remodeling, al-
though the relationship betweenmitochondrialmorphology and bioen-
ergetics is muchmore complex. Furthermore, DRP1 can be activated by
a phosphorylation at Ser600 by calmodulin-dependent kinase 1(Han
et al., 2008) (CaMKIα) or at Ser616 by Cyclin-Dependent Kinase 1
(CDK1) (Taguchi et al., 2007), meaning that the regulation of this pro-
tein and, consequently, of mitochondrial morphology is tightly regu-
lated by many different Ca2+-dependent proteins.
FIS1 is a membrane protein homogenously distributed in the OMM
via a transmembrane domain located at the C-terminal region, and a
small portion of region facing the IMS. The cytoplasmic region contains
six alpha helices, four of which (a2–a5) form two tetratricopeptide re-
peat (TPR)-like domains that allow protein–protein interaction
(Suzuki et al., 2003). FIS1 overexpression results in mitochondrial ﬁs-
sion, but since it does not possess enzymatic activity, its role is probably
restricted to anchoring effector proteins to mitochondria. Accordingly,
mitochondrial fragmentation by FIS1 overexpression can be blocked
by expression of dominant negative mutants of DRP1 (James et al.,
2003). Evidences suggest that FIS1 acts as an interactor for DRP1 in
the OMM (Yoon et al., 2003); however, FIS1 does not seem to be abso-
lutely required for bindingDRP1 tomitochondria, since downregulation
of FIS1 only partially blocks DRP1 recruitment to the organelles (Lee
et al., 2004). MFF is an integral protein of the OMM that has been re-
ported to participate in mitochondrial ﬁssion, by recruiting DRP1 tomi-
tochondria in a FIS1- independentmanner, acting as a putative adaptor.Please cite this article as: Von Stockum, S., et al.,Mitochondrial dynamics an
(2015), http://dx.doi.org/10.1016/j.nbd.2015.11.002Although Fis1 was the ﬁrst proposed DRP1 receptor to be identiﬁed on
the OMM, MFF appears to have a more important role in recruiting
DRP1 andpromotingmitochondrialﬁssion (Otera et al., 2010). Recently,
two novel OMM resident proteins, MiD49 and MiD51, have been found
to be able to promote ﬁssion in the absence of FIS1 andMFF, thus oper-
ating as bona ﬁdeDRP1 receptors (Loson et al., 2013). Indeed, FIS1, MFF,
MiD49 and MiD51 can each recruit DRP1 and promote mitochondrial
ﬁssion independently pointing to a potential activation of each of
themdependingon the cell type or speciﬁc physiological conditions. Re-
cent works, also suggest that mitochondrial ﬁssion events predomi-
nantly occur at the contact sites between mitochondria and ER.
Interestingly, DRP1 andMFF have been found to localize at these contact
sites (Friedman et al., 2011), suggesting an important role for the ER in
the regulation of mitochondrial dynamics.
3. Est modus in rebus: the mitochondria quality control
Although oxidative phosphorylation is a vital part of metabolism, it
produces ROS such as superoxide and hydrogen peroxide, which lead
to propagation of free radicals, that may oxidize mitochondrial own
lipids, proteins and DNA (Scherz-Shouval and Elazar, 2011), damaging
cells and contributing to disease and senescence. Therefore, mitochon-
dria are set at a central point of the equilibrium between health and dis-
ease. In this respect, the adaptation of energy supply to energy demand
is central to cellular vital bioenergetic homeostasis and is critically reg-
ulated by dynamics and turnover of the mitochondrial population. The
balance between biogenesis and degradation of mitochondria is tightly
controlled by two major catabolic processes in the cytosol. The
ubiquitin–proteasome system is able to proteolytically degrade mito-
chondrial outer membrane proteins, whereas the autophagy–
lysosome pathway can eliminate mitochondria as whole organelles in
a process termed mitophagy. Importantly, mitophagy can be employed
by cells to selectively degrade dysfunctional mitochondria in order to
maintain a healthymitochondrial network and to controlmitochondrial
components, products and by-products, a mechanism called mitochon-
drial quality control (QC). To serve as QC, mitophagy needs specialized
molecules that sense dysfunctional mitochondria and mark them for
autophagic degradation. Several studies have lined out the importance
of Parkin, an E3 ubiquitin ligase and a PD-related gene, and the serine/
threonine protein kinase PINK1, also a PD-related gene, as key players
in this process (Ziviani et al., 2010; Narendra and Youle, 2011). In
healthy cells Parkin resides in the cytosol whereas the precursor of
PINK1 is continuously imported into the intermembrane space of mito-
chondria via the translocase of outer mitochondrial membrane (TOM)
complex. Insidemitochondria the full length form of PINK1 is processed
by the mitochondrial proteases mitochondrial processing peptidase
(MPP), AFG3-like AAA ATPase 2 (AFG3L2) and presenilin-associated
rhomboid-like protein (PARL). The short form of PINK1 is then released
into the cytosol and subsequently degraded by the proteasome (Deas
et al., 2011; Jin et al., 2010; Yamano and Youle, 2013) (Fig. 1, left
panel). When cellular stress conditions lead to loss of mitochondrial
membrane potential, which in experimental models of cancer cell
lines, Drosophila cells, mouse embryonic ﬁbroblasts and primary neu-
rons is artiﬁcially induced by treatment with the uncoupler CCCP
(Ziviani et al., 2010; Narendra et al., 2012; Youle and Narendra, 2011;
Narendra et al., 2008), PINK1 cleavage fails and it accumulates on the
outer mitochondrial membrane (OMM). Once stabilized on the OMM,
PINK1 ﬁrst autophosphorylates (Okatsu et al., 2012) and subsequently
phosphorylates ubiquitin (Koyano et al., 2014), MFN (Chen and Dorn,
2013) and Parkin (Sha et al., 2010), thus inducing Parkin recruitment
to mitochondria and activation of its ubiquitin E3 ligase activity (Fig.
1, right panel). In this scenario phosphorylatedMFNwas shown to func-
tion as a tag to induce Parkin translocation from the cytosol to themito-
chondria (Chen and Dorn, 2013). The Parkin-dependent K48-mediated
polyubiquitination of several target proteins on the OMM, such asMFN,
the voltage-dependent anion channel VDAC, the kinesin anchor proteindmitophagy in Parkinson's disease: Aﬂy point of view, Neurobiol. Dis.
Fig. 1. The Pink/Parkin pathway in mitophagy. In healthy mitochondria (left panel), PINK1 is targeted to the outer mitochondrial membrane (OMM) owing to its mitochondrial target
sequencing (MTS). It is then imported into the inner mitochondrial membrane (IMM) through the TOM/TIM complex and cleaved by the TIM-associated mitochondrial processing pep-
tidase (MPP). MPP-cleaved PINK1 is thereafter further processed by the presenilin associated rhomboid-like protease (PARL), and it rapidly undergoes proteasome-dependent degrada-
tion. In depolarizedmitochondria (right panel), TIM-mediated import of mitochondria is impaired, and PINK1 accumulates on theOMM. TheOMM-accumulation of PINK1will lead to the
selective recruitment of Parkin, via PINK1-dependent phosphorylation of ubiquitin and Parkin. PINK1-dependent phosphorylation of both Parkin and ubiquitin is sufﬁcient to fully activate
Parkin E3 ubiquitin activity,which results into ubiquitination of Parkin targets on theOMM(among themMFN, TOM20, VDAC and Fis1). Ultimately, ubiquitinated proteins serve to recruit
essential adaptors such as p62, HDAC6 or p97, which will tether the phagophore membrane and induce mitophagy.
4 S. Von Stockum et al. / Neurobiology of Disease xxx (2015) xxx–xxxMiro, and the autophagy adaptor p62(Ziviani et al., 2010; Sarraf et al.,
2013) induces their proteasomal degradation and recruitment of the
autophagic machinery, resulting in mitophagy (Ziviani et al., 2010;
Geisler et al., 2010; Kim et al., 2008; Matsuda et al., 2010; Narendra
et al., 2010a). Several studies have shown that Parkin also catalyzes
other forms of ubiquitination that regulate subcellular localization and
protein-protein interactions, rather than proteasomal degradation
(Mukhopadhyay and Riezman, 2007). It was hypothesized that the pre-
vention ofmitochondrial fusion through degradation ofMFN on the one
hand and the arrest of mitochondrial motility via degradation of the
GTPase Miro linking mitochondria to the cytoskeleton for kinesin-
mediated transport on the other hand help to “quarantine” unhealthy
mitochondria, thus facilitating their autophagic engulfment (Wang
et al., 2011).
Another way for mitochondria to get rid of damaged and oxidized
proteins, is the Drp1-independent budding of mitochondria-derived
vesicles (MDVs) which can be targeted either to lysosomes or peroxi-
somes (Neuspiel et al., 2008; Soubannier et al., 2012a; McLelland
et al., 2014). This process is cargo-selective and can be induced by oxida-
tive stress,mitochondrial damage and speciﬁc nutrients. The vesicle fate
is primarily determined by its cargo. MDVs containing the outer mem-
brane mitochondria-anchored protein ligase MAPL were shown to be
targeted to peroxisomes (Neuspiel et al., 2008) whereasMDVs carrying
TOM20 or pyruvate dehydrogenase fuse with lysosomes (Soubannier
et al., 2012a). Delivery to the lysosomes is independent of ATG5 and
LC3 and mitochondrial depolarization, indicating that vesicle delivery
is a complementary process to mitophagy. Since the formation ofPlease cite this article as: Von Stockum, S., et al.,Mitochondrial dynamics an
(2015), http://dx.doi.org/10.1016/j.nbd.2015.11.002MDVs occurs in the presence of actively respiring mitochondria it was
hypothesized that this pathway is an early response to oxidative
stress, whereas mitophagy is rather induced by late-stage mitochon-
drial damage. Interestingly, a speciﬁc sub-type of MDVs targeted to
the lysosomes is regulated by PINK1 and Parkin. Ectopic expression
of wildtype Parkin but not PD-associated mutant Parkin in Hela
cells promotes the biogenesis of MDVs (McLelland et al., 2014).
Parkin was shown to colocalize with MDVs in a PINK1-dependent
manner, and to stimulate their formation in response to antimycin
A, an inhibitor of respiratory chain complex III potently increasing
ROS levels. These ﬁndings implicate that PINK1 and Parkin have a du-
plicate function in mitochondrial QC and operate even at early stages
in order to salvage mitochondria by selectively extracting damaged
components. Only when this ﬁrst step of QC fails, mitochondria are
targeted for mitophagy.
Recently, AMBRA1, an upstream autophagy regulator and Parkin
interactor was identiﬁed as another central player in mitophagy.
AMBRA1 was shown to enhance Parkin-mediated mitophagy through
binding of the autophagosome adaptor LC3. In normal conditions
AMBRA1 is present at the mitochondria where it binds to and is
inhibited by the pro-apoptotic protein Bcl-2 (Strappazzon et al., 2011).
Upon induction of mitophagy, AMBRA1 binds to LC3 through a LIR
(LC3 interacting region) motif, thereby regulating both Parkin-
dependent and -independent mitochondrial clearance. Mitochondrial
AMBRA1 was shown to control arrangement of the mitochondrial net-
work around the nucleus and to cause mitochondrial depolarization.
Authors hypothesized that AMBRA1 might facilitate mitochondrialdmitophagy in Parkinson's disease: Aﬂy point of view, Neurobiol. Dis.
5S. Von Stockum et al. / Neurobiology of Disease xxx (2015) xxx–xxxclearance by bringing damagedmitochondria onto autophagosomes via
its interaction with LC3.
4. Faber est suae quisque fortunae: consequences of impaired mito-
chondrial clearance.
Dysregulation of the QC pathway leads to the accumulation of dam-
aged mitochondria, resulting in increased oxidative stress, decreased
mitochondrial Ca2+ buffering capacity and loss of ATP, all factors partic-
ularly harmful in postmitotic cells such as neurons. Several studies in-
deed have shown that mutations in the PINK1 and Parkin genes Park6
and Park2 are linked to hereditary forms of early-onset familial
Parkinson's disease (PD), suggesting that PINK1/Parkin- mediated
mitophagy is critical for themaintenance of normalmitochondrial func-
tion in cells (Youle and Narendra, 2011).
PD is one of themost common neurodegenerative disorders, charac-
terized by the gradual degeneration of multiple neuron types including
dopaminergic neurons in the substantia nigra of the mid brain. This
causes several motor impairments such as muscle rigidity, resting
tremor, bradykinesia and postural instability as well as non-motor
symptoms including dementia, and psychiatric problems, such as de-
pression and anxiety. A pathologic hallmark of the disease is the forma-
tion of Lewy bodies, protein aggregates composed of α-synuclein,
ubiquitin and other proteins. Most cases of PD are sporadic with no
known cause. However, a small percentage of genetically-linked PD
cases caused by mutations in genes including α-synuclein
(Polymeropoulos et al., 1997), Parkin (Kitada et al., 1998), PINK1
(Valente et al., 2004), LRRK2(Paisan-Ruiz et al., 2004) and UCHL
(Ragland et al., 2009) have been identiﬁed and these manifest indistin-
guishable dopaminergic neuron loss and similar clinical symptoms
compared to sporadic cases. Therefore the knowledge gained from stud-
ies of inherited PDwill likely elucidate diseasemechanisms for sporadic
PD as well. At the moment there is no cure that can stop disease pro-
gression and most treatment approaches are based on dopamine re-
placement. Nevertheless, this can only ameliorate some motor
symptoms but not the non-motor symptoms and does often cause un-
wanted side effects. Thus, there is an urgent need for developing thera-
pies that target the disease from its origin in the underlying alterations
of cellular pathways.
Several studies demonstrated a clear link between mitochondrial
dysfunction and the onset of PD. Indeed, exposure to mitochondrial
toxins, such as rotenone, paraquat and MPTP causing oxidative stress
and dysfunctional mitochondria results in loss of dopaminergic neurons
and PD-like symptoms (Langston et al., 1983; Bove et al., 2005). Fur-
thermore, most of the proteins related to PD are directly or indirectly
linked to mitochondria and contribute to the QC pathway.
5. The fruit ﬂy as a valuable tool to model human diseases
Studying PD in human subjects is constrained by technical and eth-
ical issues. Furthermore, theworkwith human cells can only partially be
related to the tissue, organ or whole-body level. Thus, it is essential to
develop suitable animal models for studying new therapeutic strategies
targeting the actual pathogenic mechanisms. Thesemodels open up the
possibility to address cellular processes in the context of functional neu-
ronal circuits and can be used to conﬁrm data on molecular pathways
obtained in cell lines. Although themouse is a highly validmodel organ-
ism due to easy genetic manipulation and a genome that is very similar
to humans, in some cases it fails to reproduce human disease pathology
(Dawson et al., 2010). Embryonic knockout mice both for PINK1 and
Parkin do neither display loss of dopaminergic neurons nor have any be-
havioral alterations and are thus considered a poor PD model, which at
the very best can be employed to model only the early impairments
caused by pathogenic mutations. As a consequence these KO mice can-
not be used to develop neuroprotective strategies and to test promising
drugs since there is no neurodegenerative phenotype to recover from.Please cite this article as: Von Stockum, S., et al.,Mitochondrial dynamics an
(2015), http://dx.doi.org/10.1016/j.nbd.2015.11.002However, recently adult conditional parkin KO mice model were ana-
lyzed and showed a progressive loss of dopaminergic neurons (Shin
et al., 2011), demonstrating that this PD-like phenotype is probably
lost in embryonic KO mice through compensatory effects during
development.
Among various model organisms, the fruit ﬂy Drosophila
melanogaster has emerged as an especially effective model to study PD
pathology. As soon as it became obvious that most of the genes impli-
cated in human diseases have at least one ﬂy homolog (Reiter et al.,
2001), Drosophila became a powerful tool to elucidate the molecular
and cellular mechanisms that underlie these disorders. Compared to
higher organisms Drosophila offers some attractive features; these are
especially suited for studying complex biological processes. Drosophila
is ideally tractable at the genetic, biochemical, molecular and physiolog-
ical levels. First of all the ﬂies can be easily maintained in large numbers
in stocks and populations without specialized instrumentation. Dro-
sophila has a short life-cycle resulting in the production of a large num-
ber of progeny over a short, 10-day generation period (St Johnston,
2002). For the purpose of genetic screens, Drosophila provides two ben-
eﬁts in that its genome is comprised of only 4 pairs of chromosomes, as
opposed to 16 in the yeast strain Saccharomyces cerevisiae, or 23 in
humans, thus simplifying genetic inheritance. The second advantage is
that mutants can be created quite easily by molecular techniques
using P-element transposons for loss-of-function studies (Adams and
Sekelsky, 2002; Rubin and Spradling, 1982), tissue-speciﬁc downregu-
lation or overexpression of proteins by the bipartite transcription acti-
vation system UAS-GAL4 (Brand and Perrimon, 1993) or site-speciﬁc
gene integration via speciﬁc donor plasmids (Venken et al., 2011). Fur-
thermore, the use of X-rays and other mutagenic agents makes it possi-
ble to generate large collections of mutant stocks (St Johnston, 2002).
Another possibility is the screen of chemical compounds in the already
established diseasemodel in order to pick out those that ameliorate the
phenotype. This approach was successfully used in ﬂy models of adult-
onset, age-related neurodegeneration and led to the complete rescue of
disease-related phenotypes (Chang et al., 2008). Several key features of
Drosophila, such as the compound eye, provide unique methods for
studyingmutational effects by simple visual observation of the resulting
phenotype (St Johnston, 2002).
Thus, Drosophila provides an excellent model organism through the
compromise between simple cultivation, genetics and phenotypic scor-
ing, while key cellular processes are evolutionary conserved.
6. What Drosophila taught us about PD
A suitable model organism to study PD should have homologs to the
disease-related genes and should possess neurobiological cellular pro-
cesses (such as synapse formation and neuronal communication) and
neurobiological bases of behavior (such as sensory perception, aspects
of learning and memory formation) that are similar to those found in
humans. All of these criteria are fulﬁlled by Drosophila. The ﬂy genome
encodes homologs of PINK1 and Parkin, and its adult brain shows clus-
ters of dopaminergic neurons, which degenerate upon treatment with
rotenone (Nassel and Elekes, 1992), as shown in mammals. Indeed,
the ﬁrst in vivo results, showing that PINK1 and Parkin operate within
the samepathway came from studies inmutant ﬂies. Parkin loss of func-
tion ﬂies display reduced lifespan, male sterility and severe defects in
ﬂight and climbing abilities. Importantly, they show dramatic mito-
chondrial alterations (Greene et al., 2003) and indirect ﬂightmuscle de-
generation (Whitworth et al., 2005). Aged Parkin mutant ﬂies have
decreased levels of tyrosine hydroxylase, a marker of dopaminergic
neurons, and further investigation showed loss of a subset of the latter.
Drosophila PINK1 mutants exhibit male sterility, slower climbing speed
and defects in ﬂight ability (Clark et al., 2006; Park et al., 2006). Similar
to ﬂies lacking Parkin, they display strikingmitochondrial abnormalities
such as disrupted cristae resulting in reduced ATP levels and mtDNA
subsequently leading to apoptosis in ﬂight muscles. The number ofdmitophagy in Parkinson's disease: Aﬂy point of view, Neurobiol. Dis.
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here, PINK1 and Parkin Drosophila mutants share marked phenotypic
similarities. Transgenic expression of Parkin suppresses PINK1 loss of
function phenotypes, whereas transgenic expression of PINK1 cannot
compensate for Parkin loss (Clark et al., 2006; Park et al., 2006). Further-
more, doublemutants for both genes display identical phenotypes to ei-
ther single mutant. Thus, work in Drosophila provided ﬁrst in vivo
evidences that PINK1 and Parkin function in a common pathway with
PINK1 acting upstream of Parkin (Deng et al., 2008; Narendra et al.,
2010b; Poole et al., 2008; Vives-Bauza et al., 2010). Further Drosophila
in vivo studies have identiﬁed upstream and downstream regulators of
the PINK1/Parkin pathway. Assays including ectopic expression in the
Drosophila eye, genetic interaction using double mutants and epistasis
experiments revealed that the mitochondrial protease HtrA2/Omi acts
downstream of PINK1, independently of Parkin (Whitworth et al.,
2008; Tain et al., 2009a). HtrA2mutant ﬂies are viable but exhibit mild
mitochondrial defects, loss of ﬂight and climbing ability, male infertility,
and sensitivity to oxidative stress and mitochondrial toxins, a pheno-
type similar to other PD Drosophila models. PINK1:HtrA2 double mu-
tants display an identical phenotype to PINK1 mutants alone,
suggesting they act in a common pathway, whereas Parkin:HtrA2 dou-
ble mutants display a stronger phenotype than either mutant alone,
suggesting HtrA2 acts in a parallel pathway to Parkin (Tain et al.,
2009a). Another mitochondrial protease rhomboid 7 was shown to act
upstream of PINK1 and Parkin and to be required for cleaving the pre-
cursor forms of PINK1 and Omi (Whitworth et al., 2008). Rhomboid 7
is the Drosophila homolog of PARL, which promotes cleavage of verte-
brate Omi (Chao et al., 2008).
Besides mapping components of the PINK1/Parkin pathway, Dro-
sophila served also to identify genetic modiﬁers of PINK1 and Parkin.
Overexpression of the translation inhibitor Thor, the Drosophila homo-
log ofmammalian EIF4E-BP1, was shown to suppress PD-related impair-
ments such as dopaminergic neuron loss, locomotor deﬁcits andmuscle
degeneration in vivo (Tain et al., 2009b). Furthermore, PINK1 and Parkin
Drosophilamutant phenotypes could be pharmacologically rescued by
the treatment with the TOR inhibitor rapamycin that activates 4E-BP
in vivo. Mitochondrial alterations could be ameliorated by rapamycin
in PARK2-deﬁcient human cells as well (Tain et al., 2009b). Thus, phar-
macologicmodulation of 4E-BP activitymay represent a therapeutic ap-
proach for PD.
Importantly, the expression of human PINK1 or Parkin in Drosophila
abolishes phenotypical alterations of PINK1 or Parkin loss of function
ﬂies, underlining functional conservation of the PINK1/Parkin-
pathway between both species. This is supported by the fact that PD pa-
tient ﬁbroblasts also show alterations inmitochondrialmorphology and
mitochondrial respirationwith lowered complex I activity and ATP pro-
duction (Mortiboys et al., 2008) as well as by the ﬁnding that neurons
derived from pluripotent stem cells of PD patients display impaired
Parkin translocation (Seibler et al., 2011).
Drosophila has also been a key player in demonstrating that PINK1
and Parkin promote mitophagy in vivo under normal physiological con-
ditions. This has long been unclear, since all insights in the PINK1/Parkin
mitophagy pathway have been gained based on toxin-treated cell
models and PINK1 or Parkin overexpression conditions that are far
from physiological. A proteomic in vivo approach in Drosophila was
used to compare the rates ofmitochondrial protein turnover inwildtype
compared to Parkin or PINK1mutant ﬂies (Vincow et al., 2013). Parkin
null mutants showed a signiﬁcantly decreased mitochondrial protein
turnover, similar to but less severe than in autophagy-deﬁcient Atg7
mutants. This ﬁnding demonstrated that the PINK1/Parkin pathway in-
duces mitophagy in vivo. Surprisingly, the nonmitophagic turnover of
several mitochondrial respiratory chain (RC) subunits showed greater
impairment in Parkin and PINK1 mutant ﬂies than in Atg7 mutants,
thus describing an additional role of the PINK1/Parkinpathway in regu-
lating RC proteins. Loss of PINK1 and/or Parkin activity has already been
shown to cause RC impairments, particularly in complex I (MortiboysPlease cite this article as: Von Stockum, S., et al.,Mitochondrial dynamics an
(2015), http://dx.doi.org/10.1016/j.nbd.2015.11.002et al., 2008;Morais et al., 2009; Amoet al., 2011) and thiswas associated
to pathogenesis of PD (Zhu and Chu, 2010). Thus, impairment of RC
turnover andwith this accumulation of damaged proteins, as previously
shown in PINK1 and Parkinmutant ﬂies (Pimenta de Castro et al., 2012)
could account for the respiratory deﬁcits found in both familial and spo-
radic PD patients. PINK1 was shown to regulate complex I activity by
phosphorylating its NDUFA10/ND42 subunit. An RNAi based screen in
Drosophila cells for genes that regulate the PINK1/Parkin pathway iden-
tiﬁed the complex I subunit ND42(Pogson et al., 2014). PINK1 mutant
ﬂies display lowered complex I activity (Morais et al., 2009), as observed
in PD patient ﬁbroblasts (Mortiboys et al., 2008). Overexpression of
ND42 in PINK1mutantﬂies restores complex I activity and is able to par-
tially rescue ﬂight and climbing ability. The same could not be observed
in Parkin mutant ﬂies. These results indicate that the in vivo rescue is
due to restoring complex I activity rather than promoting mitophagy
and support the hypothesis that PINK1 modulates complex I indepen-
dently of its role with Parkin in mitophagy.
Interestingly, defects in mitochondrial morphology, cell death,
muscle degeneration and locomotor deﬁcits in PINK1 and Parkin loss
of function Drosophila models can be suppressed by simultaneous
overexpression of DRP1 or downregulation of Marf, ﬂy homolog of
mammalian mitofusins (Deng et al., 2008; Poole et al., 2008). This is
consistent with results obtained in MFN1/MFN2 KO mouse embryonic
ﬁbroblasts, where increased Parkin translocation to depolarization-
induced fragmented mitochondria could be observed (Narendra
et al., 2008). On the other hand phosphorylated MFN2 was shown to
be a molecular tag for Parkin translocation (Chen and Dorn, 2013), al-
though Parkin translocation is not completely abolished in MFN RNAi
knockdown cells (Ziviani et al., 2010). These ﬁndings might seem con-
tradictory at ﬁrst sight but can be explained by the fact that MFNs have
pleiotropic functions ranging from the regulation of mitochondrial fu-
sion (Chan, 2006), oxidative metabolism (Bach et al., 2003) and cell
proliferation (Chen et al., 2004) to mitochondria-ER tethering, imping-
ing on lipid transfer and Ca2+ homeostasis (de Brito and Scorrano,
2008). Thus, alterations of MFNs transcript levels or post-
translational modiﬁcations do probably not affect only one of these
functions and the physiological outcomemight depend on the complex
interplay of all of them and possibly correlates to a speciﬁc cell type/
model organism or cellular circumstances. In this respect, lack of
good mammalian models might be limiting our understanding of path-
ophysiology of potential MFN-dependent degeneration in the context
of PD. For instance, it is possible that functional abnormalities induced
by MFN2 ablation or mutations in mammals are compensated by
MFN1, therefore limiting insights into the functional role of MFN2
in vivo at the physiological level. In this respect, the fruit ﬂy is an
ideal in vivo model system to address this question as
D. melanogaster only possesses an ubiquitous MFN-christened Mito-
chondrial assembly regulatory factor called Marf.
In addition, not all of the PINK1 deﬁciency-related phenotypes can
be rescued by the increase of ﬁssion or the decrease of fusion and
might not be the result of impaired mitophagy but depend on a more
general role of PINK1 in controlling mitochondrial ﬁtness and health
as e.g. by phosphorylation of complex I. Indeed, genetic or pharmaco-
logical interventions that improvemitochondrial respiratory chain elec-
tron transport (Vos et al., 2012) or restore proton motive force (Vilain
et al., 2012), or enhance mitochondria biogenesis (Tuﬁ et al., 2014), or
provide mitochondrial substrates downstream Complex I (Gandhi
et al., 2009), proved to efﬁciently rescue PINK1 related dysfunctions
and PINK1 mutant phenotype both in vitro and in vivo.
Furthermore, alterations in assembly of the electron transport chain
complexes can be rescued as well by increasing Drp1 gene dosage (Liu
et al., 2011) and heterozygosity of Drp1 in a PINK1 or Parkin mutant
background is lethal. In cultured Drosophila cells, Parkin was shown
to induce MFN ubiquitination and proteasomal degradation (Ziviani
et al., 2010), whereas loss of either PINK1 or Parkin resulted in MFN ac-
cumulation. These data all support the hypothesis that the PINK1/dmitophagy in Parkinson's disease: Aﬂy point of view, Neurobiol. Dis.
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drial fusion providing a novel therapeutic strategy through gene
dosage-dependent manipulation of mitochondrial dynamics.
7. Drosophila in the validation of new therapeutic targets —
deubiquitinating enzymes as Parkin antagonists.
One recently emerging approach is focused on the search for
Parkin-antagonizing deubiquitinating enzymes (DUBs), catalyzing the
removal of ubiquitin from substrates. Alteration of expression level or
activity of these DUBs could lead to an attractive new therapeutic strat-
egy for PD. This becomes particularly important with regard to the ﬁnd-
ing that ubiquitin, besides tagging proteins for proteasomal
degradation, can function as a signalingmolecule modulating the activ-
ity of its target andmodifying its subcellular localization or ability to in-
teract with other proteins. The human proteome contains ﬁve
subclasses of DUBs among which the largest group is named
ubiquitin-speciﬁc protease family (USP). Recent works showed that
three members of this family USP8, USP15 and USP30, which were
identiﬁed by RNAi screen in U2OS cells (Durcan et al., 2014), tandem
afﬁnity puriﬁcation and mass spectrometry (Cornelissen et al., 2014)
or a human cDNA library screen (Bingol et al., 2014), modulate auto-
ubiquitination of Parkin and Parkin-mediated mitophagy (Fig. 2). Also
in this ﬁeld Drosophila proved to be a perfectly suitable in vivo tool to
validate data on molecular pathways obtained in cell lines. The Dro-
sophila genome encodes around 40 DUBs. Among these, CG8334 dis-
plays the highest sequence homology to human USP15. Knockdown
of CG8334 in a Parkin RNAi background rescued Parkin-related mutant
phenotypes such as the accumulation of mitochondrial clumps in indi-
rect ﬂight muscles, vacuolization of ﬂight muscle cells, alterations of
mitochondrial cristae, decreased mitochondrial membrane potential
and climbing ability (Cornelissen et al., 2014). These were the ﬁrst
in vivo results demonstrating that indeed Parkin and USP15 have antag-
onizing effects on mitochondrial morphology and mitophagy,
conﬁrming data previously obtained in cell models. More in detail,
USP15 was shown to inhibit CCCP-induced mitophagy in Parkin-
transfected Hela cells depending on its DUB activity and RNAi-
mediated silencing of USP15 enhanced Parkin-mediated mitophagy in
the same model as well as in human dopaminergic neuronal SH-SY5Y
cells and primary ﬁbroblasts from healthy human subjects
(Cornelissen et al., 2014). Furthermore, USP15 KD was able to rescue
the mitophagy defect of Parkin and PINK1 mutant PD patient ﬁbro-
blasts. Interestingly, authors were able to demonstrate that theFig. 2. DUBs role in mitochondria quality control. By impacting on the ubiquitination levels
mitophagy. USP15 deubiquitinates different Parkin targets on mitochondria, and knockdown o
phenotypes. USP30 targets TOM20, another Parkin putative substrate. USP30 downregulation p
lation of the ﬂy USP30 (CG3016) in Drosophila Parkin or PINK1 mutant backgrounds rescue PIN
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(2015), http://dx.doi.org/10.1016/j.nbd.2015.11.002Parkin-opposing effect of USP15 indeed was due to its direct role in
deubiquitinating Parkin targets on the outer mitochondrial membrane
and that USP15 KD lead to the accumulation of ubiquitinated Parkin
substrates such as MFN2 after depolarization (Fig. 2).
Another studydemonstrated that USP30has a similar function in an-
tagonizing Parkin-induced mitophagy via deubiquination. USP30 was
identiﬁed in a human cDNA library screening as the only candidate
that robustly blocked mitophagy and at the same time is localized on
the OMM (Bingol et al., 2014). Overexpression of USP30 in dopaminer-
gic SH-SY5Y cells reduced CCCP-induced recruitment of autophagic
markers and mitochondrial ubiquitination. A mass spectrometry ap-
proach identiﬁed 41 proteins that are oppositely regulated by Parkin
and USP30, among these the mitochondrial protein TOM20 whose
ubiquitination was shown to be a mitophagy-promoting signal. Strik-
ingly, downregulation of the ﬂy USP30 (CG3016) in Drosophila Parkin
or PINK1 mutant backgrounds could rescue mitochondrial abnormali-
ties and ameliorate climbing ability as well as dopamine depletion in
the brain. As a model of PD, ﬂies were treated with the mitochondrial
toxin paraquat inducing dopamine depletion and resulting in reduced
climbing performance. RNAi-mediated knockdown of USP30 speciﬁ-
cally in dopaminergic neurons via the dopamine decarboxylase driver
completely rescued the paraquat-induced behavioral deﬁcit and
prevented dopamine depletion in ﬂy heads. These results demonstrate
that the beneﬁcial effect of USP30 silencing after mitochondrial damage
is occurring in dopaminergic neurons and provide further in vivo evi-
dence that the regulation of DUBs is a promising therapeutic strategy
for PD (Fig. 2).
8. Conclusions
By converting the energy that is trapped in the electrochemical gra-
dient, mitochondria are undoubtedly considered the cell power plant
and indispensable to the life of all eukaryotic cells. Nevertheless, they
also actively participate in the pathways leading to cell death. In this re-
spect, mitochondria are at the intriguing, yet not fully characterized, in-
tersection point between life and death and a better understanding of
their functions andmalfunctionswould be instrumental to gain insights
in human pathologies. Not surprisingly, mutations in genes that affect
mitochondrial functions have been linked to the onset of multifactorial
human pathologies like cancer, Alzheimer's and Parkinson's diseases
and diabetes. With respect to neurodegenerative diseases, and particu-
larly to PD, ROS formation and oxidative stress resulting from oxidative
phosphorylation-dependent redox reactions, has been clearly linked toof Parkin targets, USP15 and USP30 affect Parkin translocation and Parkin-dependent
f USP15 ﬂy homolog CG8334, in a Parkin RNAi background rescues Parkin-related mutant
romotes mitophagy via its effect on TOM20 ubiquitinated levels. Accordingly, downregu-
K1 and Parkin mutants abnormalities.
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Fig. 3. Fly-based in vivo screening. The identiﬁcation of speciﬁc DUB/DUBs that counteract Parkin activity in the ubiquitination of mitophagy substrates is emerging as one of the most
promising approaches to promote mitophagy in PINK1/Parkin deﬁcient system. In this respect, the fruit ﬂy has proved to be a valuable model system to dissect functional defects under-
lying PD pathogenesis in vivo and screen for the effect of both genetic or chemical inhibition of speciﬁc Parkin-opposing DUBs in vivo, which might ameliorate PINK1/Parkin mutant
abnormalities.
8 S. Von Stockum et al. / Neurobiology of Disease xxx (2015) xxx–xxxPD onset (Youdim and Lavie, 1994; Yoshikawa, 1993). ROSmay oxidize
mitochondrial lipids and proteins and induce DNA damage: cells need
to promptly respond in order to avoid cell demise. One possibility to ef-
ﬁciently handle damaged components is viamitochondrial complemen-
tation, where damaged components are diluted into the mitochondria
network upon mitochondrial fusion and subsequently degraded (Ono
et al., 2001;Nakada et al., 2001). Degradation of damagedmitochondrial
components can occur upon formation of mitochondria-derived vesi-
cles that engulf and shuttle selected cargoes to the lysosome in a LC3/
ATG-independent manner (Soubannier et al., 2012a; Soubannier et al.,
2012b). However,when damage accumulates above a certain threshold,
it is safer for the cell to eliminate the entire organelle via mitophagy
(McLelland et al., 2014; Parone et al., 2008; Twig et al., 2008). In this re-
spect, mitochondrial asymmetric division is a pre-requisite to segregate
debris and promote mitophagy of selected dysfunctional mitochondria
via PINK1/Parkin (Youle and Narendra, 2011; McLelland et al., 2014).
The fruit ﬂy Drosophila has provided key insights in revealing alter-
ation of the PINK1/Parkin mitophagy pathway and it has proved to be
a valuable tool to dissect functional defects underlying PD pathogenesis
in vivo. In contrast to embryonic mice KOmodels, Drosophila PINK1 and
parkin mutants display key PD-related phenotypes such as dopaminer-
gic neuron loss andmotor impairments and at the same time reproduce
molecular pathways characterized in patientﬁbroblasts, such as impair-
ment in mitochondrial bioenergetics. Also, the ﬂy relative low cost of
maintenance, its rapid life cycle and the small size, makes it the perfect
model system for in vivo high-throughput screening of chemical librar-
ies like those of small compounds that might impact mitophagy and be
beneﬁcial in ameliorating PINK1/Parkin mutant phenotype (Fig. 3).Please cite this article as: Von Stockum, S., et al.,Mitochondrial dynamics an
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8.  Abbreviations 
ADP: Adenosine diphosphate 
AKAP1: A kinase anchor protein 1 
Ala: Alanine 
APAF1: apoptotic protease-activating factor 1 
Asp: Aspartatic Acid 
ATP: Adenosine Tri-Phosphate 
BAK: Bcl-2 homologous antagonist/killer 
BAPTA: 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
BAX: BCL (B Cell Lymphoma)-Associated X 
Bcl-2: B-cell lymphoma 2 
Bcl-xL: B-cell lymphoma-extra large 
BH3: Bcl-2 homology 3 
BID: BH3 interacting domain death agonist 
Ca2+: Calcium 
CaN: calcineurin 
CCCP: carbonyl cyanide m-chlorophenyl hydrazine 
CD95: cluster of differentiation 95 
CJs: cristae junctions 
CM: cristae membrane 
CnA: catalytic subunit of Calcineurin 
CnB: regulatory subunit of Calcineurin 
CO2: Carbon dioxide 
DA: dopamine 
DMEM: Dulbecco's modified Eagle medium 
DNA: Deoxyribonucleic acid 
Drp1: dynamin-related protein 1 
DUBs: deubiquitinating enzymes 
EDTA: ethilendiammintetracetic acid 
ER: endoplasmatic reticulum 
FBS: Fetal Bovine Serum 
Fis1: fission protein 1 
FK506: tacrolimus 
GTPase: GTP-binding proteins 
H2O2: hydrogen peroxide 
His: histidine 
Hrs: hours 
HtrA2: high temperature requirement A2 protease 
ICS: intercrystal space 
IMM: inner mitochondrial membrane 
IMS: intermembrane space 
KDa: kiloDalton 
LB: Lewy bodies 
LC3: light chain 3 
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L-DOPA: L-3,4-dihydroxyphenylalanine 
L-OPA1: long OPA1 form 
LRRK2: leucine-rich repeat kinase 2 
L-strand: light strand 
MAMs: mitochondria-associated-membranes 
MAO-B: Monoamine Oxidase B 
MAPK: mitogen-activated protein kinase 
MCU: mitochondrial Ca2+ uniporter 
MEFs: mouse embryonic fibroblasts 
Mff: mitochondrial fission factor 
MFN1: Mitofusin 1 
MFN2: Mitofusin 2 
Mg2+: Magnesium 
MIRO: mitochondrial Rho GTPases 
Mito-YFP: mitochondrial yellow fluorescent protein 
MPP: mitochondrial processing peptidase 
MPTP: mitochondrial permeability transition pore 
MtDNA: mitochondrial DNA 
MTS: mitochondrial targeting sequence 
NAD+: nicotinamide adenine dinucleotide 
NADH: reduced Nicotinamide adenine dinucleotide 
NADPH: reduced Nicotinamide adenine dinucleotide phosphate 
nM: nanoMolar 
O2: Oxygen 
OMA1: overlapping activity with m-AAA protease 
OMM: outer mitochondrial membrane 
OPA1: Optic Atrophy 1 
OriH: origin of heavy-strand replication 
OriL: origin of light-strand replication 
PARL: presenilin-associated rhomboid-like protease 
PBS: phosphate saline buffer 
PD: Parkinson’s disease 
PIC: protease inhibitor 
PINK1: (PTEN)-induced putative kinase 1 
PKA: protein kinase A 
PP2A: Protein phosphatase 2 
RaM: rapid mode of Ca2+ uptake 
RBR: ring-between-ring fingers 
REP: repressor element of Parkin 
RIPA: radioimmunoprecipitation assay 
RNAi: RNA interference 
ROS: reactive oxygen species 
rpm: revolutions per minute 
RT: room temperature 
s: second 
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Ser: Serine 
SMAC: second mitochondria-derived activator of caspases 
SNc: substantia nigra pars compacta 
SNCA: synuclein alpha 
SOD: superoxide dismutase 
S-OPA1: short OPA1 form 
Squassh: Segmentation and QUAntification of Subcellular Shapes 
tBID: truncated BH3 interacting domain death agonist 
TCA: tricarboxylic acid cycle 
TFAM: transcription factor A of mitochondria 
Thr: Threonine 
TIM: translocase of the inner membrane 
TK: tyrosine kinase 
TNFR1: tumour necrosis factor receptor 1 
TOM: translocase of the OMM 
Ub: ubiquitin 
UBL: ubiquitin-like 
UPD: unique Parkin domain 
USP: Ubiquitin-specific protease 
VDAC1: Voltage-Dependent Anion Channel 1 
ΔCnA: constitutively active mutant of Calcineurin 
ΔCnAH151Q: dominant negative mutant of Calcineurin 
μM: microMolarPINK1: PTEN-induced putative kinase 1 
 
